Use of depressants is likely to be more dangerous when:
- combined with alcohol or other drugs, particularly
- driving or operating heavy machinery
- judgement or motor coordination is required
- a person is alone (in case medical assistance is required).
Use of any drug always carries some risk, however, if you choose to take it, always try a small test amount first.4 For example, the chemical composition of GHB/GBL is highly variable. It’s very easy to take too much GHB - the difference between the amount needed to get high and the amount that causes an overdose can be hard to judge.
If drinking alcohol, stay hydrated and have something to eat before and while drinking.
Tolerance and dependence
People who use depressants regularly, can develop a dependence and tolerance to them. Tolerance means they need to take larger amounts of depressants to get the same effect.
People who are psychologically dependent may feel an urge to use them when in specific surroundings or socialising with friends. With physical dependence, a person’s body adapts to the depressants and gets used to functioning with them.
People who depend on depressants may find that using the drug becomes more important than other activities in their life. Cravings can make it difficult to stop using depressants.
Reducing harm
Use of depressants is likely to be more dangerous when:
- combined with alcohol or other drugs, particularly
- driving or operating heavy machinery
- judgement or motor coordination is required
- a person is alone (in case medical assistance is required).
Use of any drug always carries some risk. But, if you choose to take it, always try a small test amount first.4 For example, the chemical composition of GHB/GBL is highly variable. It’s very easy to take too much GHB - the difference between the amount needed to get ‘high’ and the amount that causes an overdose can be hard to judge.
If drinking alcohol, stay hydrated and have something to eat before and while drinking.
Withdrawal
Giving up depressants after using them for a long time is challenging because the body has to get used to functioning without them.
The severity of withdrawal symptoms will depend on the type of depressant, but generally withdrawal symptoms should settle down in about 5-7 days.
Withdrawal symptoms vary from person to person, but generally the withdrawal from depressants may include:
- cold or flu-like symptoms
- headache
- sweating
- aches and pains
- difficulty sleeping
- nausea
- mood swings7
Getting help
If your use of depressants is affecting your health, family, relationships, work, school, financial or other life situations, or you’re concerned about a loved one, you can find help and support.
- Call DrugInfo on 1300 85 85 84 or email to speak to a real person and your questions answered as well as advice on practical ‘next steps’. It’s confidential too.
- Help and Support Services search
Find a service in your local area from our list. Simply add your location or postcode and filter by service type to quickly discover help near you.
NameCentral Nervous System DepressantsAccession NumberDBCAT000399Description
A very loosely defined group of drugs that tend to reduce the activity of the central nervous system. The major groups included here are ethyl alcohol, anesthetics, hypnotics and sedatives, narcotics, and tranquilizing agents (antipsychotics and antianxiety agents).
DrugsSodium oxybate | A central nervous system depressant used to treat cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy. |
Lorazepam | A short-acting benzodiazepine commonly used to treat panic disorders, severe anxiety, and seizures. |
Tramadol | A centrally-acting opioid agonist and SNRI (serotonin/norepinephrine reuptake inhibitor) used for the management of moderate to severe pain in adults. |
Reserpine | For the treatment of hypertension |
Pregabalin | An anticonvulsant drug used to treat neuropathic pain conditions and fibromyalgia, and for the treatment of partial onset seizures in combination with other anticonvulsants. |
Temazepam | A short-acting benzodiazepine commonly used to treat panic disorders, severe anxiety, and insomnia. |
Butabarbital | A barbiturate drug used as a sedative and hypnotic. |
Ziprasidone | An atypical antipsychotic used to manage schizophrenia, bipolar mania, and agitation in patients with schizophrenia. |
Morphine | An opioid agonist used for the relief of moderate to severe acute and chronic pain. |
Pentobarbital | A barbiturate drug used to induce sleep, cause sedation, and control certain types of seizures. |
Codeine | An opioid analgesic used to treat moderate to severe pain when the use of an opioid is indicated. |
Hydromorphone | An opioid analgesic used to treat moderate to severe pain when the use of an opioid is indicated. |
Methadone | An opioid analgesic indicated for management of severe pain that is not responsive to alternative treatments. Also used to aid in detoxification and maintenance treatment of opioid addiction. |
Olanzapine | An antipsychotic drug used in the management of schizophrenia, bipolar 1 disorder, and agitation associated with these disorders. |
Clozapine | An antipsychotic drug used in treatment resistant schizophrenia and to decrease suicide risk in schizophrenic patients. |
Meprobamate | An anxiolytic drug used for the short-term management of anxiety symptoms. |
Eszopiclone | A sedative-hypnotic used in the treatment of insomnia, improving both the latency phase and the maintenance phase of sleep. |
Alprazolam | A triazolobenzodiazepine with intermediate onset commonly used to treat panic disorders and generalized anxiety in addition to anxiety associated with depression. |
Loxapine | A antipsychotic used for the treatment of schizophrenia. |
Secobarbital | A barbiturate used for the short-term treatment of insomnia. |
Promazine | A phenothiazine used to manage schizophrenia. |
Zolpidem | A sedative hypnotic used for the short-term treatment of insomnia to improve sleep latency. |
Prochlorperazine | A phenothiazine derivative used in the treatment of schizophrenia and anxiety and to relieve severe nausea and vomiting. |
Droperidol | A butyrophenone derivative and dopamine antagonist used to prevent and treat postoperative nausea and vomiting. |
Meperidine | An opioid agonist with analgesic and sedative properties used to manage severe pain. |
Methohexital | An anesthetic used to induce deep sedation. |
Chlordiazepoxide | A benzodiazepine used to treat the withdrawal symptoms of acute alcoholism, to treat preoperative anxiety, and to treat anxiety over a short term period. |
Chlorpromazine | A phenothiazine antipsychotic used to treat nausea, vomiting, preoperative anxiety, schizophrenia, bipolar disorder, and severe behavioral problems in children. |
Oxycodone | An opioid used in the management of moderate to severe pain. |
Haloperidol | An antipsychotic agent used to treat schizophrenia and other psychoses, as well as symptoms of agitation, irritability, and delirium. |
Carbamazepine | An anticonvulsant used to treat various types of seizures and pain resulting from trigeminal neuralgia. |
Butorphanol | An opioid agonist-antagonist used to treat moderate to severe pain. |
Fluphenazine | A phenothiazine used to treat patients requiring long-term neuroleptic therapy. |
Clorazepic acid | A benzodiazepine used to treat anxiety, partial seizures, and alcohol withdrawal. |
Pentazocine | An analgesic used to treat moderate to severe pain. |
Thioridazine | A phenothiazine antipsychotic used to treat schizophrenia and generalized anxiety disorder. |
Midazolam | A short-acting injectable benzodiazepine with rapid onset that is commonly used in seizures, anesthesia and anxiety disorders. |
Flurazepam | A long-acting benzodiazepine with a rapid onset of action that is commonly used to treat insomnia. |
Sufentanil | An opioid used to induce and maintain anesthesia, to act as an analgesic in labor and delivery, and to treat severe, acute pain. |
Risperidone | A second-generation antipsychotic medication used to treat a number of mental health disorders including schizophrenia, bipolar mania, psychosis, or as an adjunct in severe depression. |
Isoflurane | An inhaled general anesthetic used in surgery. |
Alfentanil | An opioid agonist used to induce and maintain anesthesia, as well as an analgesic. |
Fentanyl | An opioid analgesic used in anesthesia, for breakthrough cancer pain, or round the clock pain management. |
Propofol | A medication used in general anesthesia and for sedation. |
Diazepam | A long-acting benzodiazepine with rapid onset commonly used to treat panic disorders, severe anxiety, alcohol withdrawal, and seizures. |
Trifluoperazine | A phenothiazine used to treat depression, anxiety, and agitation. |
Oxazepam | An intermediate-acting benzodiazepine with slow onset commonly used to treat panic disorders, severe anxiety, alcohol withdrawals, and insomnia. |
Nalbuphine | An opioid agonist-antagonist used to treat pain, for pre and postoperative analgesia, and for analgesia in labor and delivery. |
Perphenazine | A phenothiazine used to treat schizophrenia as well as nausea and vomiting. |
Levorphanol | An opioid analgesic used to treat moderate to severe pain. |
Flupentixol | A thioxanthene neuroleptic used to treat schizophrenia and depression. |
Triazolam | A benzodiazepine used for short term treatment of insomnia. |
Remifentanil | An opioid analgesic used in anesthesia. |
Buprenorphine | A partial opioid agonist used for management of severe pain that is not responsive to alternative treatments. Also used for maintenance treatment of opioid addiction. |
Cyclobenzaprine | A skeletal muscle relaxant that works on the brainstem to treat muscle spasms of local origin. |
Hydrocodone | An opioid agonist used as an analgesic and antitussive agent. |
Zaleplon | A sedative used for short term treatment of insomnia in adults. |
Gabapentin | An anticonvulsant medication used in the management of peripheral neuropathic pains, postherpetic neuralgia, and partial-onset seizures. |
Diphenhydramine | A H1 receptor antihistamine used in the treatment of seasonal allergies, and various allergic reactions including sneezing, runny nose, itchy/watery eyes, itching of nose or throat, pruritus, urticaria, insect bites/stings, and allergic rashes. |
Diphenoxylate | An antidiarrheal medication used with atropine to manage diarrhea. |
Pimozide | An antipsychotic used to manage debilitating motor and phonic tics in patients with Tourette's Disorder. |
Phenobarbital | A long-lasting barbiturate and anticonvulsant used in the treatment of all types of seizures, except for absent seizures. |
Desflurane | A general inhalation anesthetic for inpatient and outpatient surgery in adults. |
Oxymorphone | An opioid analgesic used in the management of moderate-to-severe pain and for analgesic therapies. |
Zopiclone | A nonbenzodiazepine hypnotic used for the short-term management of insomnia. |
Estazolam | A benzodiazepine used for the short-term management of insomnia. |
Ketamine | A rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant. |
Quetiapine | A psychotropic agent used for the management of bipolar disorder, schizophrenia, and major depressive disorder. |
Sevoflurane | A inhalation anaesthetic agent used for induction and maintenance of general anesthesia during surgical procedures. |
Aripiprazole | An atypical antipsychotic used in the treatment of a wide variety of mood and psychotic disorders, such as schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's syndrome. |
Paliperidone | An atypical antipsychotic used in the treatment of schizophrenia and other schizoaffective or delusional disorders. |
Amobarbital | A barbiturate derivative used for the induction of sedation during procedures, short-term management of insomnia, and acute management of refractory tonic-clonic seizures. |
Methotrimeprazine | A phenothiazine used in the management of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder. |
gamma-Hydroxybutyric acid | Used as a general anesthetic, to treat conditions such as insomnia, clinical depression, narcolepsy, and alcoholism, and to improve athletic performance. |
Dihydrocodeine | An opioid analgesic agent used for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. |
Bromazepam | A short-acting benzodiazepine with intermediate onset commonly used to treat panic disorders and severe anxiety. |
Quazepam | A long -acting benzodiazepine used to manage insomnia. |
Nitrazepam | A long-acting benzodiazepine with intermediate onset commonly used to treat panic disorders, severe anxiety, insomnia, and seizures. |
Thiothixene | An antipsychotic indicated for the management of schizophrenia. |
Zuclopenthixol | An antipsychotic indicated for the management of schizophrenia. The acuphase formulation is indicated for initial treatment of acute psychosis or exacerbation of psychosis, while the depot formulation is best for maintenance. |
Asenapine | An atypical antipsychotic used to treat patients with bipolar I disorder and patients with schizophrenia. |
Nitrous oxide | An inhalatory gas used as an adjunct to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in certain neonates with hypoxic respiratory failure. |
Lurasidone | An atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar I disorder. |
Paraldehyde | A central nervous system depressant previously used to control convulsions due to various clinical causes, including tetanus, status epilepticus, and convulsive drugs. |
Baclofen | A GABA-ergic agonist used to manage severe spasticity of cerebral or spinal origin in adult and pediatric patients. |
Butalbital | A barbiturate drug used for symptomatic treatment of tension-type headache in various combinations with acetaminophen, aspirin, caffeine, and codeine. |
Phenytoin | An anticonvulsant drug used in the prophylaxis and control of various types of seizures. |
Topiramate | An anticonvulsant drug used in the control of epilepsy and in the prophylaxis and treatment of migraines. |
Clemastine | An antihistamine with sedative and anticholinergic effects used to treat the symptoms of allergic rhinitis. |
Amitriptyline | A tricyclic antidepressant indicated in the treatment of depressive illness, either endogenous or psychotic, and to relieve depression associated anxiety. |
Tolcapone | A catechol-O-methyltransferase (COMT) inhibitor used as adjunct therapy in the symptomatic management of idiopathic Parkinson's disease. |
Cetirizine | A selective Histamine-1 antagonist drug used in allergic rhinitis and chronic urticaria. |
Protriptyline | A tricyclic antidepressant that is indicated in the treatment of depression only under close clinical supervision. |
Clobazam | A benzodiazepine used as adjunct treatment in seizures associated with Lennox-Gastaut syndrome. |
Chlorzoxazone | A drug with muscle relaxant properties that is used as an adjunct to physical therapy and analgesics to treat stiffness and pain caused by a variety of musculoskeletal conditions. |
Doxylamine | An antihistamine used to treat insomnia and allergy symptoms and is used with pyridoxine in the treatment of nausea and vomiting in pregnancy. |
Mirtazapine | A tetracyclic antidepressant used in the treatment of major depression and is used off-label as a drug for insomnia and to increase appetite. |
Carisoprodol | A centrally acting muscle relaxant used to relieve the discomfort associated with various musculoskeletal conditions. |
Dexbrompheniramine | An antihistamine used to treat allergy symptoms including upper respiratory tract symptoms. |
Methocarbamol | A CNS depressant indicated with rest, physical therapy and other treatments to control the discomfort associated with various acute musculoskeletal conditions. |
Triprolidine | A sedating antihistamine combined with pseudoephedrine and guaifenesin in various types of cold and allergy medications to relieve allergy symptoms, hay fever and common cold symptoms, and to aid in sleep. |
Cyproheptadine | A combined serotonin and histamine antagonist used in the treatment of allergic symptoms, for appetite stimulation, and off-label in the treatment of serotonin syndrome. |
Imipramine | A tricyclic antidepressant indicated for the treatment of depression and to reduce childhood enuresis. |
Brimonidine | An alpha-2 adrenergic agonist used to treat glaucoma and ocular hypertension, as well as facial erythema in rosacea. |
Entacapone | A selective reversible catechol-O-methyltransferase inhibitor for the treatment of Parkinson's disease. |
Nortriptyline | A tricyclic antidepressant used in the treatment of depression. |
Amoxapine | A tricyclic antidepressant used in the treatment of neurotic or reactive depressive disorders and endogenous or psychotic depression. |
Lamotrigine | A phenyltriazine antiepileptic used to treat some types of epilepsy and bipolar I disorder. |
Hydroxyzine | An antihistamine used to treat anxiety and tension associated with psychoneuroses, as well as allergic conditions such as pruritus and chronic urticaria. |
Clonidine | An alpha-2 adrenergic agonist used to treat hypertension and severe cancer pain, among other conditions, and to treat withdrawal symptoms from various substances. It is also used to aid in the diagnosis of pheochromocytoma and to prevent migraines. |
Fluticasone propionate | A glucocorticoid used to treat asthma, inflammatory pruritic dermatoses, and nonallergic rhinitis. |
Ethosuximide | An anticonvulsant used to treat petit mal seizures. |
Efavirenz | A non-nucleoside reverse transcriptase inhibitor used to treat HIV infection or prevent the spread of HIV. |
Metaxalone | A muscle relaxant used to treat muscle pain or spasm. |
Tizanidine | An alpha-2 adrenergic agonist used for the short-term treatment of muscle spasticity. |
Trimipramine | A tricyclic antidepressant used to treat depression. |
Meclizine | A histamine H1 antagonist used to treat nausea, vomiting, and dizziness associated with motion sickness. |
Scopolamine | A belladonna alkaloid with anticholinergic effects indicated for the treatment of nausea and vomiting associated with motion sickness and postoperative nausea and vomiting (PONV). |
Carbinoxamine | A first generation antihistamine used to treat allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, allergic reactions, and mild allergic reactions. |
Ethotoin | A hydantoin antiepileptic used to control tonic-clonic and complex partial seizures. |
Olopatadine | A histamine H1 antagonist used to treat allergic conjunctivitis and rhinitis. |
Clidinium | A synthetic anticholinergic used to treat peptic ulcer disease, colicky abdominal pain, diverticulitis, and IBS. |
Primidone | An antiepileptic used to treat grand mal, psychomotor, and focal epileptic seizures. |
Brompheniramine | A histamine H1 antagonist used to treat coughs, upper respiratory symptoms, and nasal congestion associated with allergies and the common cold. |
Tiagabine | An antiepileptic used to treat partial seizures. |
Zonisamide | A sulfonamide anticonvulsant used to treat partial seizures. |
Maprotiline | A tetracyclic antidepressant used to treat depressive illness, major depressive disorder, bipolar disorder, and anxiety associated with depression. |
Felbamate | An anticonvulsant used to treat severe epilepsy. |
Desloratadine | A second generation tricyclic antihistamine used to treat seasonal and non seasonal allergic rhinitis, pruritus, and urticaria. |
Azelastine | A histamine H1-receptor antagonist used intranasally to treat allergic and vasomotor rhinitis and in an ophthalmic solution to treat allergic conjunctivitis. |
Dimenhydrinate | A medication used to prevent and treat nausea, vomiting, vertigo, and motion sickness. |
Guanfacine | An alpha-2A adrenergic receptor agonist used to treat ADHD. |
Thalidomide | A medication used to treat cancers, particularly newly diagnosed multiple myeloma, and erythema nodosum leprosum. |
Clonazepam | A long-acting benzodiazepine with intermediate onset commonly used to treat panic disorders, severe anxiety, and seizures. |
Promethazine | A first-generation antihistamine used for the treatment of allergic conditions, nausea and vomiting, and motion sickness. |
Vigabatrin | An irreversible GABA transaminase inhibitor used as an adjunct therapy to treat refractory complex partial seizures in patients ≥2 years unresponsive to alternatives. May also be used as monotherapy to treat infantile spasms in infants 1 month to 2 years. |
Levocabastine | A selective histamine H1 receptor antagonist indicated for the management of seasonal allergic conjunctivitis symptoms. |
Chlorpheniramine | A histamine-H1 receptor antagonist indicated for the management of symptoms associated with upper respiratory allergies. |
Doxepin | A psychotropic agent used for the treatment of depression, anxiety, manic-depressive disorder, and insomnia. |
Desipramine | A tricyclic antidepressant used in the treatment of depression. |
Orphenadrine | A muscarinic antagonist used as an adjunct for the symptomatic relief of musculoskeletal pain and discomfort. |
Cyclizine | An antihistamine and antiemetic drug used for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness, and vertigo. |
Levetiracetam | A novel anticonvulsant agent used as an adjunct medication to manage partial onset, myoclonic, and generalized tonic-clonic seizures in patients with epilepsy. |
Dantrolene | A direct-acting skeletal muscle relaxant used for the treatment of management of the fulminant hypermetabolism of skeletal muscle leading to malignant hyperthermia crisis. |
Levodopa | A dopamine precursor used in the management of Parkinson's disease, often in combination with carbidopa, as well as other conditions associated with parkinsonism. |
Clomipramine | A tricyclic antidepressant used in the treatment of obsessive-compulsive disorder and disorders with an obsessive-compulsive component, such as depression, schizophrenia, and Tourette’s disorder. |
Fosphenytoin | An antiepileptic agent used for the management of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. |
Difenoxin | An antidiarrheal agent used as an adjunct for the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. |
Pipotiazine | An antipsychotic indicated for the management of chronic, non-agitated schizophrenic patients. |
Flunarizine | A selective calcium-entry blocker used as migraine prophylaxis in patients with severe and frequent episodes who have not responded adequately to more common treatments. |
Flibanserin | A 5-HT receptor modulator used for the treatment of selected premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). |
Iloperidone | An atypical antipsychotic agent used for the acute treatment of schizophrenia in adults. |
Ezogabine | An antiepileptic agent used as an adjuvant treatment of partial-onset seizures. |
Methsuximide | A succinimide anticonvulsant that increases the seizure threshold. Primarily used for childhood absence seizures. Functions by suppressing paroxysmal spike-and-wave patterns associated with lapses of consciousness in absence seizures. |
Pizotifen | A serotonin and tryptamine antagonist indicated for migraine prophylaxis. |
Tapentadol | An opioid used to manage severe pain that has not responded to non-opioid medications, and for which opioid analgesic therapy is appropriate. |
Levocetirizine | An H1-receptor antagonist used to treat symptoms associated with chronic allergic rhinitis and uncomplicated cases of chronic idiopathic urticaria. |
Ziconotide | An N-type calcium channel antagonist used to manage patients with severe chronic pain who cannot tolerate, or who have not responded adequately to other treatments such as intrathecal morphine and systemic analgesics. |
Gabapentin enacarbil | A gabapentin prodrug used to treat Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN). |
Perampanel | A non-competitive AMPA glutamate receptor antagonist used to treat partial-onset seizures with or without secondarily generalized seizures, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy. |
Pomalidomide | A thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma. |
Stiripentol | An antiepileptic agent used in combination with other anticonvulsants to treat seizures associated with Dravet syndrome. |
Brexpiprazole | A serotonin–dopamine activity modulator used in the treatment of major depressive disorder as an adjunct and schizophrenia. |
Fluvoxamine | A selective serotonin-reuptake inhibitor used to treat obsessive-compulsive disorder. |
Ethchlorvynol | A sedative hypnotic agent used for the short-term management of insomnia. |
Enflurane | A halogenated inhalational anesthetic agent used for the induction and maintenance of anesthesia and for analgesia during labor and delivery. |
Etomidate | A short-acting intravenous anesthetic indicated for the induction of anesthesia and supplementation of subpotent anesthesia during short operative procedures. |
Dapiprazole | Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations. |
Valproic acid | An anticonvulsant used to control complex partial seizures and both simple and complex absence seizures. |
Sulpiride | A selective D2 dopamine receptor antagonist indicated to treat chronic and acute schizophrenia. |
Remoxipride | An discontinued atypical antipsychotic selective for dopamine D2 receptors. |
Nabilone | A synthetic delta-9-THC used in the treatment of anorexia and weight loss in HIV patients as well as nausea and vomiting in cancer chemotherapy. |
Triflupromazine | Used mainly in the management of psychoses. Also used to control nausea and vomiting. |
Thiopental | A barbiturate used to induce general anesthesia, treat convulsions, and reduce intracranial pressure. |
Dexmedetomidine | An alpha-2 agonist used for sedation during various procedures. |
Dyclonine | An topical anesthetic used prior to examination to suppress the gag reflex or for pain relief from canker sores and fever blisters. |
Dextropropoxyphene | An opioid analgesic used to treat mild to moderate pain. |
Magnesium sulfate | A drug used to treat convulsions during pregnancy, nephritis in children, magnesium deficiency, and tetany. |
Trazodone | A serotonin uptake inhibitor used to treat major depressive disorder. |
Procaine | A local anesthetic used for anesthesia, peripheral nerve block, and spinal nerve block. |
Tranylcypromine | A monoamine oxidase inhibitor used to treat major depressive disorder. |
Halazepam | Used to relieve anxiety, nervousness, and tension associated with anxiety disorders. |
Methylphenobarbital | For the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy. |
Ethanol | For therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical... |
Ondansetron | A serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting in cancer chemotherapy and postoperatively. |
Mesoridazine | A phenothiazine antipsychotic used to treat schizophrenia, organic brain disorders, alcoholism, and psychoneuroses. |
Methoxyflurane | For use in the induction and maintenance of general anesthesia |
Melatonin | An endogenous hormone produced by the pineal gland that regulates sleep-wake cycles and when provided exogenously has beneficial effects on sleep-onset latency; available as an over-the-counter supplement. |
Thiamylal | Used for the production of complete anaesthesia of short duration, for the induction of general anaesthesia, and for inducing a hypnotic state. |
Halothane | A general inhalation anesthetic used for the induction and maintenance of general anesthesia. |
Chlormezanone | Used in the management of anxiety and in the treatment of muscle spasm. |
Dezocine | Indicated in the treatment of moderate to severe pain. |
Levacetylmethadol | For the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients. |
Chlorprothixene | A thioxanthene antipsychotic. |
Butobarbital | For the treatment of insomnia. |
Hexobarbital | For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful... |
Lithium cation | A drug used for the management of bipolar disorder and other psychiatric conditions. |
Methadyl acetate | Used mainly in the treatment of narcotic dependence. |
Glutethimide | For the treatment of insomnia. |
Dihydroetorphine | Not Available |
Diamorphine | An opioid analgesic agent used in the relief of severe pain associated with surgical procedures, myocardial infarction or pain in the terminally ill and for the relief of dyspnea in acute pulmonary edema. |
Fencamfamin | For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy. |
Ethylmorphine | An opioid analgesic and antitussive agent used to reduce coughs caused by colds and lung infections in combination with codeine. |
Barbital | A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice... |
Dextromoramide | An opioid analgesic structurally related to methadone and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070) |
Carfentanil | Carfentanil is similar (but more potent) to the opioid analgesic fentanyl. It is used as a tranquilizer for large animals. |
Flunitrazepam | A benzodiazepine used to manage anxiety disorders and insomnia. |
Ethyl loflazepate | Not Available |
Drotebanol | Not Available |
Alphacetylmethadol | A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. [PubChem] |
Chloral hydrate | A mild hypnotic used for experimental purposes that was previously used for the treatment of insomnia. |
Dihydromorphine | Dihydromorphine is an opioid analgesic used for moderate to severe pain relief. |
Fludiazepam | Used for the short-term treatment of anxiety disorders. |
Oxprenolol | A non-selective beta-adrenergic antagonist used to treat hypertension, angina pectoris, arrhythmias, and anxiety. |
Ketazolam | A long-acting benzodiazepine used to manage anxiety and insomnia. |
Prazepam | A benzodiazepine used to manage more severe forms of anxiety disorders. |
Acepromazine | Acepromazine was first used in humans in the 1950s as an antipsychotic agent. It is now rarely used in humans. Acepromazine is frequently used in animals as a sedative and... |
Aceprometazine | Aceprometazine is often used in combination with meprobamate for the treatment of sleep disorders. |
Molindone | An antipsychotic used to treat schizophrenia. |
7-Nitroindazole | Not Available |
Methapyrilene | Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979. |
Urethane | Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963. |
Methaqualone | For the treatment of insomnia, and as a sedative and muscle relaxant. |
Fluspirilene | An antipsychotic agent used in the treatment of schizophrenia. |
Osanetant | Potential therapy for schizophrenia, depression and visceral pain. |
Tetrodotoxin | For the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence. |
Sertindole | An atypical antipsychotic indicated in the treatment of schizophrenia. |
Amisulpride | A dopamine D2 receptor antagonist used in the treatment of acute and chronic schizophrenia, and in the prevention and treatment of postoperative nausea and vomiting in adults. |
Clomethiazole | Investigated for use/treatment in strokes. |
Deramciclane | Investigated for use/treatment in anxiety disorders. |
Adipiplon | Investigated for use/treatment in insomnia and sleep disorders. |
Agomelatine | Agomelatine is indicated to treat major depressive episodes in adults. |
Fospropofol | A sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. |
Ketobemidone | For the treatment of all types of severe pain, such as postoperative, cancer, kidney stones and fractures. |
Benzyl alcohol | An antiparasitic agent used for the topical treatment of head lice infestation in patients 6 months of age and older. |
DPDPE | A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond. |
Perospirone | For the treatment of schizophrenia and acute cases of bipolar mania. |
Amperozide | Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily... |
Etifoxine | A benzoxazine class drug primarily used as an anxiolytic, but that also possesses neuroprotective, neuroplastic, and anti-inflammatory properties; these effects are thought to arise due to modulation of GABAergic neurotransmission and neurosteroid synthesis. |
Brotizolam | A benzodiazepine analogue with sedative-hypnotic properties used for short-term treatment of severe or debilitating insomnia. |
Vortioxetine | A serotonin modulating antidepressant indicated for the treatment of major depressive disorder (MDD). |
Etizolam | A thienodiazepine derivative used to treat anxiety and insomnia. |
Lofentanil | Lofentanil is an analog of fentanyl and is one of the most potent opioids available today. It displays most similarity to carfentanil (4-carbomethoxyfentanyl) and is considered to be slightly more... |
Melperone | An atypical butyrophenone antipsychotic used to treat sleep disorders, confusion, and psychomotor dysfunction associated with geriatric, psychiatric, and alcohol-dependent patients. |
Zotepine | Zotepine, like other atypical antipsychotics, is considered as the first-line treatment in newly diagnosed schizophrenia. It is usually thought to be an option of choice for managing acute schizophrenic episodes... |
Pipamperone | Treatment of chronic psychoses and states of aggressiveness of various origins . |
Opium | A medication used to treat moderate to severe pain. |
Alfaxalone | Alfaxalone, also known as alphaxalone or alphaxolone, is a neuroactive steroid and general anaesthetic. It is used in veterinary practice under the trade name Alfaxan, and is licensed for use... |
Azaperone | Azaperone is a pyridinylpiperazine and butyrophenone agent that is capable of eliciting neuroleptic sedative and antiemetic effects. It is subsequently employed predominantly as a veterinary tranquilizer and mainly for pigs... |
Doramectin | Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in... |
Medetomidine | Medetomidine is a synthetic compound used as a surgical anesthetic and analgesic. It is normally found as its hydrochloride salt, medetomidine hydrochloride. Medetomidine is an intravenously available alpha-2 adrenergic agonist.... |
Xylazine | A non-opioid and clonidine analog with analgesic and muscle relaxant properties used as a tranquilizer used in veterinary medicine. |
Romifidine | Romifidine is a veterinary drug utilized as a sedative primarily in large animals, most frequently horses. It is also used less commonly in a wide variety of other animal species.... |
Tiletamine | This drug is a dissociative anesthetic agent that falls under the drug category of NMDA receptor antagonists. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt... |
Tricaine | Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish. It is also the only anesthetic licensed in the United States for use in fin... |
Zolazepam | Zolazepam is a pyrazolodiazepinone derivative used as an anaesthetic in veterinary medicine. Zolazepam is typically used in combination with the NMDA antagonist tiletamine or the α2 adrenoceptor agonist xylazine. It... |
Detomidine | Used as a large animal sedative, primarily in horses. |
Normethadone | An opioid antitussive used to treat a cough associated with inflamed mucosa. |
Brexanolone | Brexanolone is a synthetic neuroactive steroid gamma-aminobutyric acid A (GABA(a)) receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adult women [FDA Label][A176080, A176083, F4063, F4066, F4072]. |
Tetrahydropalmatine | Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity). |
Gepirone | Gepirone has been used in trials studying the treatment of Cocaine-Related Disorders. |
Ecopipam | Ecopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior. |
Eltanolone | Eltanolone is under investigation in clinical trial NCT02603926 (Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone). |
Bromperidol | A first-generation butyrophenone antipsychotic used in the treatment of schizophrenia and other psychotic manifestations. |
Piritramide | A synthetic opioid used in the treatment of severe pain. |
Raclopride | Raclopride has been used in trials studying Parkinson Disease. |
Indiplon | Indiplon has been used in trials studying the treatment of Insomnia and Depression. |
Ritanserin | Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders. |
Perazine | A phenothiazine antipsychotic used in the acute and chronic treatment of psychotic disorders. |
Tandospirone | Tandospirone has been used in trials studying the treatment of Schizophrenia. |
Benperidol | A neuroleptic butyrophenone derivative indicated in the treatment of psychoses, manic episodes, and psychomotor agitation. |
Tiapride | A dopamine D2 and D3 receptor antagonist indicated in the treatment of chorea in Huntington's disease, as well as agitation and anxiety in the elderly or with acute or chronic alcoholism. |
Alphaprodine | Not Annotated |
Propanidid | An intravenous anesthetic that has been used for rapid induction of anesthesia and for maintenance of anesthesia of short duration. (From Martindale, The Extra Pharmacopoeia, 30th ed, p918) |
Proxibarbal | Proxibarbal is a derivative of barbiturates, which has been used to treat migraines. Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing... |
Clothiapine | An atypical antipsychotic indicated in the treatment of acute psychosis, exacerbations of chronic psychosis, chronic psychosis, paranoid psychosis, and anxiety. |
Ethyl chloride | A local anesthetic. |
Sultopride | Sultopride is used in Japan, Hong Kong, and Europe to treat schizophrenia. It is of the drug class atypical antipsychotics . |
Trichloroethylene | Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. It has been sold under a variety of... |
Bromisoval | Not Annotated |
Medazepam | A long-acting benzodiazepine used for its sedative and anxiolytic properties. |
Phenibut | Not Annotated |
Meptazinol | Not Annotated |
Mebicar | Not Annotated |
Veralipride | Not Annotated |
Trifluperidol | Not Annotated |
Diethyl ether | Not Annotated |
Phenoperidine | Not Annotated |
Phenazocine | Not Annotated |
Loprazolam | Loprazolam is an imidazobenzodiazepine with anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent... |
Fluanisone | Not Annotated |
Vinyl ether | Not Annotated |
Dixyrazine | Not Annotated |
Tilidine | A synthetic opioid indicated in the treatment of severe pain. |
Penfluridol | Not Annotated |
Clopenthixol | Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. |
Lormetazepam | A benzodiazepine indicated in the treatment of anxiety and the induction of anesthesia. |
Cyclopropane | Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene. Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery... |
Nordazepam | A benzodiazepine indicated in the treatment of insomnia. |
Tryptophan | An amino acid commonly found as a component of total parenteral nutrition. |
Citalopram | A selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression. |
Reboxetine | A drug used for the acute treatment of major depression and for maintenance therapy of depression. |
Venlafaxine | A selective serotonin and norepinephrine reuptake inhibitor (SNRI) used for the treatment of major depression, generalized or social anxiety disorder, and panic disorder. |
Fluoxetine | A selective serotonin reuptake inhibitor used to treat major depressive disorder, bulimia, OCD, premenstrual dysphoric disorder, panic disorder, and bipolar I. |
Duloxetine | A serotonin norepinephrine reuptake inhibitor used to treat generalized anxiety disorder, neuropathic pain, osteoarthritis, and stress incontinence. |
Paroxetine | A selective serotonin reuptake inhibitor used to treat major depressive disorder, panic disorder, OCD, social phobia, generalized anxiety disorder, the vasomotor symptoms of menopause, and premenstrual dysphoric disorder. |
Phenelzine | A monoamine oxidase inhibitor used to treat atypical, nonendogenous, or neurotic depression. |
Sertraline | A selective serotonin reuptake inhibitor (SSRI) indicated to treat major depressive disorder, social anxiety disorder and many other psychiatric conditions. |
Nefazodone | An antidepressant used in the treatment of depression. |
Bupropion | A norepinephrine and dopamine reuptake inhibitor used in the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. |
Moclobemide | A monoamine oxidase inhibitor used in the treatment of major depressive disorder and bipolar disorder. |
Escitalopram | A selective serotonin re-uptake inhibitor used in the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and other select psychiatric disorders such as obsessive-compulsive disorder (OCD). |
Isocarboxazid | A monoamine oxidase inhibitor used to treat enduring and debilitating symptoms of depression following inadequate clinical response to other antidepressant drugs. |
Oxitriptan | A naturally occurring amino acid that is used to manage post-hypoxic myoclonus. |
Nialamide | Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine. |
Amineptine | For the treatment of depression. |
Milnacipran | A selective serotonin and norepinephrine reuptake inhibitor (SNRI) used for the treatment of fibromyalgia and a short-term treatment of major depressive disorder. |
Mianserin | A tetracyclic antidepressant with therapeutic activity similar to amitriptyline used to treat depression and anxiety. |
Vilazodone | An antidepressant agent used for the treatment of major depressive disorder that targets the 5-HT transporter and 5-HT1A receptors. |
Desvenlafaxine | An antidepressant agent and SNRI used for the treatment of major depressive disorders in adults. |
Viloxazine | A selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults in children. |
Toloxatone | For the treatment of major depressive disorder. |
Tianeptine | An atypical tricyclic antidepressant with antidepressant and anxiolytic effects primarily used to treat major depressive disorder. |
Opipramol | A medication to treat general anxiety and somatoform disorders. |
Dibenzepin | Dibenzepin is approved for use in Europe. |
Lofepramine | Not Annotated |
Iprindole | Not Annotated |
Alaproclate | Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity... |
Bifemelane | Not Annotated |
Adinazolam | For the treatment of anxiety and status epilepticus. |
Progabide | Indicated for the treatment of epilepsy. |
Sibutramine | A norepinephrine, serotonin and dopamine reuptake inhibitor indicated to assist with weight loss in obesity. |
Rolipram | A phosphodiesterase inhibitor with antidepressant properties. |
Aniracetam | A nootropic drug used to ameliorate memory and attention disturbances accompanying cerebrovascular diseases and degenerative brain disorders. |
Iproniazid | For the treatment of depression (originally intended to treat tuberculosis). |
Dextofisopam | Investigated for use/treatment in irritable bowel syndrome (IBS). |
Saredutant | Investigated for use/treatment in depression and anxiety disorders. |
Esmirtazapine | Investigated for use/treatment in insomnia and sleep disorders. |
Tofisopam | For the treatment of anxiety and alcohol withdrawal. |
Levomilnacipran | A selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD). |
Indalpine | Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse... |
Benactyzine | Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety. Benactyzine is no longer widely used in medicine, although it is still a... |
Pirlindole | For the treatment of major depression. It is being studied in the treatment of fibromyalgia pain syndrome. One study determined that the effect of pirlindole on sensorimotor performance while driving... |
Oxaprotiline | Investigated for the treatment of depression. |
Lanicemine | Lanicemine has been used in trials studying the treatment and basic science of Depression, Major Depressive Disorder, and Treatment Resistant Major Depressive Disorder. |
Orvepitant | Orvepitant has been used in trials studying the treatment of Depressive Disorder, Depressive Disorder, Major, Post-Traumatic Stress Disorder, and Posttraumatic Stress Disorder (PTSD). |
Hypericin | Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma. |
Deanol | Deanol is commonly referred to as 2-(dimethylamino)ethanol, dimethylaminoethanol (DMAE) or dimethylethanolamine (DMEA). It holds tertiary amine and primary alcohol groups as functional groups. Deanol has been used in the treatment... |
St. John's Wort | An herbal ingredient used in non-prescription therapeutic products for the short-term treatment of minor skin irritations, insomnia, depression, and anxiety. |
Nomifensine | Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA... |
Zimelidine | For the treatment of depression. |
Dimetacrine | Dimetacrine is also known as dimethacrine or acripamine. It is marketed under the names Istonil, Istonyl, Linostil, and Miroistonil. Dimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in... |
Butriptyline | Butriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline. |
Etoperidone | Etoperidone has been studied for the treatment of depression , tremors in Parkinson, extrapyramidal symptoms and male impotence . It is not certain if it was ever approved and marketed... |
Iproclozide | For the treatment of depression. |
Pivagabine | Pivagabine has been used in trials studying the treatment of Stress and Anxiety. |
Medifoxamine | Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases... |
Quinupramine | Quinupramine has been approved in France under the brand name Kinupril, as an antidepressant . |
Melitracen | A thioxanthene neuroleptic indicated in the treatment of anxiety, depression, and asthenia. |
Oxaflozane | Not Annotated |
Imipramine oxide | Not Annotated |
Dapoxetine | A selective serotonin reuptake inhibitor used in the treatment of premature ejaculation. |
Mazindol | A sympathomimetic used to treat obesity in combination with lifestyle modifications. |
Benzphetamine | A sympathomimetic used to manage exogenous obesity short term. |
Midomafetamine | Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used... |
Tenamfetamine | An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons... |
Metamfetamine | A sympathomimetic agent used in the treatment of attention deficit hyperactivity disorder (ADHD) and exogenous obesity. |
Edivoxetine | Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment.... |
Amitriptylinoxide | A tricyclic antidepressant indicated in the treatment of depressive disorders. |
Selegiline | A monoamine oxidase inhibitor used to treat major depressive disorder and Parkinson's. |
Rasagiline | An irreversible inhibitor of monoamine oxidase used for the symptomatic management of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa. |
Pargyline | For the treatment of moderate to severe hypertension. |
Hydracarbazine | Was used for the treatment of hypertension . |
Methylene blue | An oxidation-reduction agent used for the treatment of pediatric and adult patients with acquired methemoglobinemia. |
Benmoxin | For the treatment of depression. |
Mebanazine | For the treatment of depression. |
Octamoxin | For the treatment of depression. |
Pheniprazine | For the treatment of depression, schizophrenia, and angina pectoris. |
Phenoxypropazine | For the treatment of depression. |
Pivhydrazine | For the treatment of depression. |
Safrazine | For the treatment of depression. |
Caroxazone | For the treatment of depression. |
Furazolidone | A drug for the treatment of infectious diarrhea. |
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | Potent reversible inhibitor of phenylethanolamine N-methyltransferase. |
Harmaline | Not Annotated |
Brofaromine | Not Annotated |
Procarbazine | An antineoplastic agent indicated for the treatment of stage III and stage IV Hodgkin's disease in combination with other chemotherapeutic agents. |
Dronabinol | A synthetic delta-9-THC used in the treatment of anorexia and weight loss in HIV patients as well as nausea and vomiting in cancer chemotherapy. |
Bufotenine | A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a... |
4-Methoxyamphetamine | Not Available |
4-Bromo-2,5-dimethoxyamphetamine | Not Available |
Dimethyltryptamine | Some people use this compound as a psychedelic inducing agent. |
Cathinone | Cathinone is a monoamine alkaloid found in the shrub Catha edulis (Khat). Closely related to ephedrine, cathine and other amphetamines, it is probably the main contributor to the stimulant effect... |
Phencyclidine | A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to ketamine in structure and in many of its effects. Like... |
Phenethylamine | Not Available |
Lysergic acid diethylamide | Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by... |
Psilocybin | Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA. |
Nefiracetam | Nefiracetam has been used in trials studying the treatment of Alzheimer's Disease. |
Oxiracetam | Not Annotated |
Cyamemazine | Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an... |
Imagabalin | Imagabalin has been investigated in Generalized Anxiety Disorder. |
MRK-409 | MRK-409 is a GABA-A receptor agonist . |
Camazepam | Camazepam has been used in placebo controlled studies for the treatment of patients suffering from anxiety and depression. |
Cloxazolam | Used primarily as an anti-anxiety agent. Typically used short term, and may be given as a single dose of up to 100mcg/kg to reduce anxiety and tension experienced prior to... |
Clotiazepam | A thienodiazepine used to manage anxiety disorders and insomnia. |
Mebutamate | Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a... |
Captodiame | Captodiame is indicated for the treatment of anxiety. |
Benzoctamine | Benzoctamine is a drug with two main uses. It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. It can also be... |
Pinazepam | A benzodiazepine indicated in the treatment of anxiety and severe insomnia. |
Gedocarnil | Not Annotated |
Emylcamate | Not Annotated |
Fabomotizole | Not Annotated |
Mephenoxalone | A muscle relaxant indicated in the treatment of painful muscle spasms and cramps. |
Delorazepam | A benzodiazepine used to manage severe anxiety disorders and insomnia. |
Doxefazepam | Not Annotated |
Cinolazepam | A benzodiazepine used to manage severe and debilitating forms of sleep disorders of various origins in adults. |
AZD-3043 | AZD3043 has been used in trials studying the treatment and basic science of Safety, Sedation, Tolerability, and Pharmacokinetics. |
Talbutal | For use as a sedative and hypnotic. |
Propiomazine | Propiomazine is largely used for its antihistamininc sleep inducing effects in treating insomnia. |
Methyprylon | For the treatment of insomnia. |
Aprobarbital | Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. A primary treatment... |
Heptabarbital | Used mainly for sedation and hypnosis. |
Dichloralphenazone | Dichloralphenazone is a sedative composed of chloral hydrate and phenazone. It is typically found in combination products Nodolor and Midrin containing isometheptene and acetaminophen used for the relief of tension... |
Triclofos | Not Annotated |
Valnoctamide | Valnoctamide has been used in trials studying the treatment of Mania and Schizoaffective Disorder, Manic Type. |
Valerian | A plant used in some non-prescription natural health products. |
Apronalide | Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura . |
Pyrithyldione | Not Annotated |
Vinbarbital | Not Annotated |
Acetylglycinamide chloral hydrate | Not Annotated |
Allobarbital | Not Annotated |
Hexapropymate | Not Annotated |
Niaprazine | Niaprazine is a selective brain catecholamine depletor. |
Methylpentynol | Not Annotated |
Cyclobarbital | Not Annotated |
Vinylbital | Not Annotated |
Reposal | Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia. |
Carbromal | Not Annotated |
Emepronium | Not Annotated |
Trimethadione | An anticonvulsant agent indicated for the control of treatment-refractory petit mal seizures. |
Mephenytoin | A phenylhydantoin used to treat refractory partial epilepsy. |
Oxcarbazepine | An anti-epileptic used in the treatment of partial-onset seizures. |
Valpromide | A valproic acid derivative used to treat epilepsy and as adjunct therapy for psychomotor agitation, depression, and manic episodes of bipolar disorder. |
Lacosamide | An antiepileptic drug used to treat partial onset seizures in adults. |
Eslicarbazepine acetate | An anticonvulsant agent used as an adjunct to treat partial-onset seizures in patients with inadequate clinical response to conventional antiepileptic therapy. |
Sulthiame | A carbonic anhydrase inhibitor used primarily in benign focal epilepsies of childhood that may be useful as an adjunct therapy in a variety of other refractory epilepsies. |
Pheneturide | Not Annotated |
Riluzole | A glutamate antagonist used to treat amyotrophic lateral sclerosis. |
Acetazolamide | A carbonic anhydrase inhibitor used to treat edema from heart failure or medications, certain types of epilepsy, and glaucoma. |
Remacemide | Investigated for use/treatment in epilepsy, huntington's disease, and parkinson's disease. |
Tramiprosate | Investigated for use/treatment in strokes and alzheimer's disease. |
Gaboxadol | Investigated for use/treatment in sleep disorders and insomnia. |
Ifenprodil | N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer... |
Eperisone | An antispasmodic that functions through voltage-gated channel blockade, notably with little to no sedation, effective in relaxing skeletal muscles and vascular smooth muscles. |
Etiracetam | Etiracetam is under investigation in clinical trial NCT01137110 (Comparison of Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After Subarachnoid Hemorrhage (SAH)). |
Vinpocetine | A synthetic derivative of a vinca alkaloid used to treat neurological symptoms of cerebrovascular disease. |
Metharbital | Metharbital is used for the treatment of epilepsy. |
Paramethadione | Used for the control of absence (petit mal) seizures that are refractory to treatment with other medications. |
Phensuximide | For the treatment of epilepsy. |
Phenacemide | Used to control certain seizures in the treatment of epilepsy. |
Brivaracetam | An anticonvulsant used for the treatment of partial-onset seizures that functions by binding to synaptic vesicle glycoprotein 2A (SV2A) in the brain. |
Rufinamide | An antiepileptic drug used as adjunctive therapy to treat seizures associated with Lennox-Gastaut Syndrome (LGS). |
Barbexaclone | Created for the treatment for epilepsy, with the intent of creating an antiepileptic with less sedative properties than phenobarbital. |
Beclamide | Has been used in the management of epilepsy and epilepsy related behavioural disorders. It was used for generalised tonic-clonic seizures, and was not effective for absence seizures. More recently focus... |
Carisbamate | Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence. |
Neocitrullamon | Not Annotated |
Ethadione | Not Annotated |
Succinylcholine | A depolarizing skeletal muscle relaxant used adjunctly to anesthesia and for skeletal muscle relaxation during intubation, mechanical ventilation, and surgical procedures. |
Cisatracurium | A skeletal muscle relaxant used to facilitate tracheal intubation, muscle relaxation in surgery, or mechanical ventilation. |
Rocuronium | A vecuronium analog used to facilitate tracheal intubation and to relax skeletal muscles during surgery. |
Atracurium besylate | A non-depolarizing neuromuscular blocker used to facilitate endotracheal intubation and relax skeletal muscles during surgery. |
Pancuronium | A neuromuscular blocker used as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. |
Vecuronium | A nondepolarizing neuromuscular blocking agent used to relax muscles or as an adjunct in general anesthesia during surgical procedures. |
Metocurine iodide | For use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy. |
Gallamine triethiodide | A nondepolarizing nerve blocker used in addition to anesthesia to cause skeletal muscle relaxation. |
Doxacurium | A nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures. |
Tubocurarine | Tubocurarine is a non-depolarizing neuromuscular blocking agent and the first identified curare alkaloid. Curare is one of the names used to describe plant-derived poisons used by indigenous South Americans to... |
Mivacurium | A short-acting non-depolarizing neuromuscular blocking agent used to induce anesthesia during intubation and promote skeletal muscle relaxation during surgery or mechanical ventilation. |
Decamethonium | For use as a skeletal muscle relaxant |
Metocurine | Metocurine is a muscle relaxant. |
Pipecuronium | A nondepolarizing neuromuscular blocking agent used to relax muscles during anesthesia and surgical procedures. |
Rapacuronium | A nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures. |
Neosaxitoxin | Neosaxitoxin is under investigation in clinical trial NCT01786655 (Safety Study of Long-Acting Local Anesthetic). |
Atracurium | A neuromuscular blocker indicated to relax muscles during mechanical ventilation under general anesthesia or intubation. |
Gallamine | Not Annotated |
Alcuronium | A non-depolarizing skeletal muscle relaxant similar to tubocurarine. It is used as an anesthesia adjuvant. |
Pyrantel | An anthelmintic used to treat helminth infections. |
Bifeprunox | Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease. |
Acetophenazine | For the treatment of disorganized and psychotic thinking. Also used to help treat false perceptions (e.g. hallucinations or delusions.) |
Periciazine | A phenothiazine used with other medications to treat aggressiveness, impulsiveness, and hostility associated with psychiatric conditions such as schizophrenia. |
Thioproperazine | An antipsychotic indicated for the management of acute and chronic schizophrenia, including cases that are refractory to more common neuroleptics. May also be used to treat manic syndromes. |
Cariprazine | An atypical antipsychotic used to treat schizophrenia and acute manic or mixed episodes due to bipolar I disorder. |
Prothipendyl | A neuroleptic agent indicated in the treatment of restlessness and agitation in patients with underlying psychiatric conditions. |
Butaperazine | Butaperazine was approved in 1967 , and possibly discontinued in the 1980s . |
Chlorproethazine | Not Annotated |
Oxypertine | Not Annotated |
Moperone | Not Annotated |
Thiopropazate | Not Annotated |
Mosapramine | Not Annotated |
Botulinum toxin type B | A purified form of botulinum toxin type B used to block acetylcholine release in the treatment of cervical dystonia and sialorrhea. |
Botulinum toxin type A | A purified form of botulinum toxin type A used to block acetylcholine release in the treatment of chronic sialorrhea, muscle spasticity, and dystonia, as well as in cosmetic applications. |
Hexafluronium | Used as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations. |
Thiocolchicoside | A semi-synthetic colchicine derivative used as an analgesic and anti-inflammatory. |
Febarbamate | Not Annotated |
Tetrazepam | Not Annotated |
Phenprobamate | A skeletal muscle relaxant indicated in the treatment of pain caused by muscle spasms. |
Styramate | Not Annotated |
Fenyramidol | A muscle relaxant indicated in the symptomatic treatment of musculoskeletal pain and spasms. |
Mephenesin | A cresol glyceryl ether used to treat muscle spasticity in Parkinson's and Multiple Sclerosis. |
Pridinol | An atropine-like muscle relaxant indicated in the treatment of muscle pain associated with muscle tightness. |
Fazadinium bromide | Not Annotated |
Tolperisone | A muscle relaxant used to relieve spasticity after stroke in adults. |
Thiethylperazine | A drug used for the treatment of nausea and vomiting. |
Moricizine | An antiarrhythmic used to treat arrhythmias. |
Alimemazine | An antihistamine agent used to prevent and relieve allergic conditions which cause pruritus and other allergic skin conditions, including urticaria. |
BL-1020 | Investigated for use/treatment in schizophrenia and schizoaffective disorders. |
Propiopromazine | Not Annotated |
Thiazinam | Not Annotated |
Blonanserin | Used for the treatment of schizophrenia . |
Lumateperone | A novel 2nd generation antipsychotic used to manage both positive and negative symptoms in patients with schizophrenia. |
Brilaroxazine | Investigated for the treatment of schizophrenia and schizoaffective disorder. |
Cannabidivarin | Cannabidivarin does not currently have any FDA or Health Canada approved indications, however in October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett... |
Esreboxetine | Esreboxetine has been used in trials studying the treatment and basic science of Fibromyalgia. |
Lortalamine | Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been... |
Nisoxetine | Nisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. It was originally investigated as an antidepressant but has no current clinical applications aside from being a research... |
Talopram | Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed. |
Arbaclofen Placarbil | Investigated for the treatment of spasticity in multiple sclerosis, acute back spasms, and GERD. |
Donepezil | An acetylcholinesterase inhibitor used to treat the behavioral and cognitive effects of Alzheimer's Disease and other types of dementia. |
Quinine | An alkaloid used to treat uncomplicated Plasmodium falciparum malaria. |
Gantacurium | Investigated for use/treatment in anesthesia (unspecified). |
Hexamethonium | A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been... |
Etorphine | Etorphine is only available for its use in veterinary. This main usage is related to the immobilization of large mammals. |
Ramelteon | A melatonin receptor agonist used to treat insomnia. |
Tasimelteon | A melatonin receptor agonist used to treat Non- 24-Hour Sleep-Wake Disorder. |
Aripiprazole lauroxil | An antipsychotic used to treat schizophrenia in adults. |
Chlorphenesin | A phenol ether used to treat painful muscular conditions. |
Domoic Acid | Not Available |
Lithium carbonate | A medication used to treat manic episodes of bipolar disorder. |
Linezolid | An oxazolidinone antibiotic used to treat infections by susceptible strains of aerobic Gram-positive bacteria. |
Safinamide | A MAO-B inhibitor used as an add-on treatment to levodopa/carbidopa for Parkinson's disease during "off" episodes. |
Eletriptan | A triptan used for the treatment of migraines. |
Methysergide | An ergot alkaloid used for the prophylaxis of migraine and cluster headaches. |
Zolmitriptan | A member of the triptan class of 5-HT(1B/1D/1F) receptor agonist drugs used for the acute treatment of migraine with or without aura in adults. |
Palonosetron | A serotonin antagonist used in the prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting. |
Fenfluramine | Fenfluramine is a phenethylamine that is structurally similar to serotonin. Due to its ability to increase extracellular serotonin levels, modulate serotonergic and other neurologic receptors, and control neurotransmission, it is effective in treating pharmacoresistant seizures. |
Lisuride | For the management of Parkinson's Disease |
Sumatriptan | A serotonin receptor agonist used to treat migraines and cluster headaches. |
Ergotamine | An alpha-1 selective adrenergic agonist vasoconstrictor used to treat migraines with or without aura and cluster headaches. |
Dolasetron | An antinauseant and antiemetic used in chemotherapy and postoperatively. |
Granisetron | A 5HT3 antagonist used to treat nausea and vomiting in cancer therapy and postoperatively. |
Almotriptan | A 5-HT1B/1D receptor agonist used to treat migraines. |
Naratriptan | A 5-HT1B/1D receptor agonist used to treat migraines. |
Rizatriptan | A 5-HT1B/1D receptor agonist used to treat migraines. |
Pindolol | A beta adrenoceptor antagonist used to treat hypertension, edema, ventricular tachycardias, and atrial fibrillation. |
Alosetron | A 5-HT3 antagonist used to treat diarrhea-predominant IBS. |
Frovatriptan | A 5-HT1B/1D receptor agonist used to treat migraines. |
Renzapride | For the treatment of constipation-predominant irritable bowel syndrome (IBS-C). |
APD791 | For the treatment and prophylaxis of arterial thrombosis. |
Naronapride | Investigated for use/treatment in gastroesophageal reflux disease (GERD) and gastroparesis. |
Naluzotan | Investigated for use/treatment in anxiety disorders and depression. |
YKP-1358 | Investigated for use/treatment in schizophrenia and schizoaffective disorders. |
Dotarizine | A calcium antagonist used to treat and prevent migraines. |
Serotonin | For temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product. |
Ramosetron | A selective 5-HT3 antagonist used as an antiemetic for chemotherapy- and postoperative-associated nausea and vomiting. It may also possess efficacy in irritable bowel syndrome. |
Mosapride | A prokinetic 5-HT4 receptor agonist used to stimulate gastric motility. |
Tropisetron | A 5HT-3 receptor antagonist used as an antiemetic in the treatment of chemotherapy-induced nausea and vomiting. |
m-Chlorophenylpiperazine | m-Chlorophenylpiperazine has been used in trials studying the treatment of Alcoholism. |
MK-212 | MK-212 has been used in trials studying the treatment of Alcoholism. |
Sarpogrelate | Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic. |
Eplivanserin | Eplivanserin has been used in trials studying the treatment of Sleep, Insomnia, Chronic Pain, Fibromyalgia, and Primary Insomnia, among others. |
Piclozotan | Piclozotan has been investigated for the treatment of Parkinson's Disease. |
Ketanserin | Ketanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer. |
Urapidil | A combination adrenergic antagonist and serotonin agonist given orally for the treatment of essential hypertension and intravenously in hypertensive emergencies. |
Eltoprazine | Eltoprazine has been used in trials studying the treatment of Schizophrenia and Cognitive Impairment. |
Metergoline | An ergot-derivative that acts as an antagonist at certain 5-HT receptor subtypes and as an agonist at dopamine receptors. It is often used in situations where inhibition of prolactin is desirable. |
Iprazochrome | Not Annotated |
Naftidrofuryl | A peripheral vasodilator indicated in the treatment of chronic venous ulcers. |
Wortmannin | Wortmannin is a steroid metabolite of Penicillium funiculosum and Talaromyces wortmannii fungi. This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks). |
Dextromethorphan | An NMDA receptor antagonist used to treat cases of dry cough. |
Dihydroergotamine | An ergot alkaloid used in the acute treatment of migraine headache and cluster headache. |
Cabergoline | A dopamine receptor agonist used for the treatment of hyperprolactinemic conditions due to various causes. |
Rotigotine | A non-selective dopamine agonist used for the treatment of Parkinson's Disease and Restless Leg Syndrome. |
Cinitapride | A benzamide with gastroprokinetic and antiemetic properties typically used for the treatment of gastrointestinal motility disorders such as gastroesophageal reflux disease (GERD), non-ulcer dyspepsia, and delayed gastric emptying. |
5-methoxy-N,N-dimethyltryptamine | 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a tryptamine with psychedelic properties. It is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad. This drug,... |
Tetrahydrocannabivarin | THCV does not currently have any FDA, Health Canada, or EMA approved indications. |
Pergolide | A long-acting dopamine agonist that is uncommonly used for the management of Parkinson's disease, due to the risk for cardiac valvulopathy. |
Bromocriptine | A dopamine D2 receptor agonist used for the treatment of galactorrhea due to hyperprolactinemia and other prolactin-related conditions, as well as in early Parkinsonian Syndrome. |
MMDA | MMDA is a recreational drug. It has no current medical uses and is a Schedule I controlled substance in the USA at present. |
2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties. |
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine | 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was... |
Lofexidine | A centrally acting alpha2-adrenergic agonist used for the symptomatic treatment of acute opioid withdrawal syndrome to facilitate abrupt opioid discontinuation in adults. |
Felcisetrag | Felcisetrag (TD-8954) has been used in trials studying the treatment of Enteral Feeding Intolerance and Gastrointestinal Motility Disorder. |
Lorcaserin | A serotonin 2C receptor agonist used in conjunction with physical activity and calorie restriction for weight loss in obese patients with a body mass index (BMI) of 30 and above, and in overweight patients with weight-related comorbidities. |
Vabicaserin | Vabicaserin has been used in trials studying the health services research and treatment of Schizophrenia. |
Cannabidiol | An active cannabinoid used as an adjunctive treatment for the management of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome and symptomatic relief of moderate to severe neuropathic pain or other painful conditions, like cancer. |
Iferanserin | Iferanserin has been investigated for the treatment of Hemorrhoids. |
Idalopirdine | Idalopirdine has been used in trials studying the treatment of Cognition, Schizophrenia, and Alzheimer's Disease. |
Cerlapirdine | Cerlapirdine has been investigated for the treatment of Alzheimer Disease. |
Cilansetron | For the treatment of symptoms associated with irritable bowel syndrome. |
Yohimbine | An alpha-2-adrenergic blocker and sympatholytic found in supplements used to. |
PRX-08066 | Investigated for use/treatment in chronic obstructive pulmonary disease (COPD) and pulmonary hypertension. |
Epinastine | An H1 receptor antagonist used to prevent itching in allergic conjunctivitis. |
Alprenolol | For the treatment of hypertension, angina, and arrhythmia |
Alverine | A smooth muscle relaxant used to relieve abdominal pain associated with gastrointestinal conditions like heartburn, flatulence, and Irritable Bowel Syndrome. |
Penbutolol | A beta-adrenergic antagonist used for the management of mild to moderate arterial hypertension, alone or in combination with other antihypertensive agents. |
Ergoloid mesylate | A nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity. |
Ergometrine | An ergot alkaloid used for the treatment of postpartum haemorrhage and post abortion hemorrhage in patients with uterine atony. |
Tedizolid phosphate | An oxazolidinone class antibiotic that inhibits bacterial protein synthesis and is proven to be effective in the treatment of certain Gram-positive bacterial infections. |
Dexmethylphenidate | A norepinephrine-dopamine reuptake inhibitor used in the treatment of ADHD in conjunction with other therapies. |
Eslicarbazepine | An antiepileptic indicated as a monotherapy or adjunct therapy in the treatment of epilepsy. |
Ocinaplon | Investigated for use/treatment in anxiety disorders. |
Pagoclone | For the potential treatment of panic and anxiety disorders. |
Oxazepam acetate | Not Annotated |
Perphenazine enanthate | Not Annotated |
Minaprine | For the treatment of depression |
Dosulepin | A tricyclic antidepressant commonly used only in patients for whom alternative therapies are ineffective due to its toxicity potential. |
Cisapride | A medication used to treat heartburn associated with GERD. |
Apomorphine | A morphine derivative D2 dopamine agonist used to treat hypomobile "off" episodes of advanced Parkinson's disease. |
Cinazepam | Not Annotated |
1,2-Benzodiazepine | Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary... |
Bentazepam | Not Annotated |
Clorgiline | An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE. |
Seproxetine | Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an... |
S-Ethylisothiourea | S-Ethylisothiourea is a nitric oxide synthase inhibitor. |
Chlorhexadol | Chlorhexadol is a sedative and hypnotic which is regulated in the United States as a Schedule III controlled substance. It is a derivative of chloral hydrate. |
Trimethobenzamide | An antiemetic used to treat postoperative nausea and vomiting and nausea associated with gastroenteritis. |
Diethylpropion | An appetite suppressant used for the short term treatment of exogenous obesity in addition to calorie restriction. |
Suvorexant | A orexin receptor antagonist used to treat insomnia that is characterized by difficulties with sleep onset and/or sleep maintenance. |
Esketamine | A NMDA receptor antagonist used for treatment-resistant depression. |
Solriamfetol | Solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy, but is not a treatment for the underlying airway obstruction in apnea patients[FDA Label][A176534,A176744]. |
Carfentanil, C-11 | Carfentanil, C-11 is under investigation in clinical trial NCT01899170 (Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain). |
JNJ-26489112 | JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy). |
Desomorphine | Not Available |
Mepyramine | An antihistamine agent used for the symptomatic treatment of allergy, hypersensitivity reactions, and pruritic skin disorders. |
Nicomorphine | Not Annotated |
Pyrazolam | Not Annotated |
Salvinorin A | Salvinorin A has been investigated for the basic science of Pharmaceutical Preparations. |
Lithium citrate | Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment. |
Zuranolone | Not Annotated |
Mexazolam | A benzodiazepine indicated to treat anxiety with or without psychoneurotic conditions. |
Metoclopramide | An antiemetic agent and dopamine D2 antagonist used in the treatment of gastroesophageal reflux disease, prevention of nausea and vomiting, and to stimulate gastric emptying. |
Lorpiprazole | In 2016, lorpiprazole was classified in the "Chemical structure-related drug-like criteria of global approved drugs" as an antipsychotic and anxiolytic. An antipsychotic is a medication used to treat a state... |
Cenobamate | A small molecule drug indicated to treat partial onset seizures in adults. |
Lemborexant | A dual orexin antagonist indicated for the treatment of sleep-onset and/or sleep maintenance insomnia. |
Y-27632 | Y-27632 is an inhibitor of Rho-associated protein kinase. It inhibits calcium sensitization to affect smooth muscle relaxation. |
Harmine | Not Available |
Amibegron | Investigated for use/treatment in depression, irritable bowel syndrome (IBS), and obesity. |
Tegaserod | A serotonin-4 (5-HT4) receptor agonist indicated for the treatment of constipation predominant irritable bowel syndrome (IBS-C) specifically in women under the age of 65. There is currently no safety or efficacy data for use of tegaserol in men. |
Remimazolam | An ultra short-acting benzodiazepine used for the induction and maintenence of procedural sedation during short procedures. |
Lidocaine | A local anesthetic used in a wide variety of superficial and invasive procedures. |
Ropivacaine | An amide-type local anesthetic used for local or regional anesthesia during surgery and for short-term management of acute pain. |
Bupivacaine | A local anesthetic used in a wide variety of superficial and invasive procedures. |
Buspirone | An anxiolytic agent used for short-term treatment of generalized anxiety and second-line treatment of depression. |
Cinchocaine | An anesthetic used for local or regional anesthesia. |
Prilocaine | A local anesthetic used in dental procedures. |
Proparacaine | A topical anesthetic used for ophthalmic practice. |
Oxybuprocaine | A local anesthetic used in ophthalmology. |
Mepivacaine | A local anesthetic used for local or regional analgesia or anesthesia. |
Levobupivacaine | A drug used for nerve block and anesthesia. |
Benzocaine | A topical local anesthetic used for the temporary relief of pain and itching associated with minor burns, sunburn, scrapes and insect bites or minor skin irritations. |
Chloroprocaine | A local anesthetic agent indicated for intrathecal injection in adults for the production of subarachnoid block, or spinal anesthesia. |
Articaine | A local anesthetic used for inducing local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. |
Tetracaine | A local anaesthetic agent used to induce local analgesia in the eyes and skin during medical procedures. |
Pramocaine | A local anesthetic and antipruritic agent found in various topical preparations. |
Butamben | Anesthesia of mucus membranes other than the eyes. |
Phenoxyethanol | An antiseptic used as a hand disinfectant or preservative in medications. |
SUVN-502 | Investigated for use/treatment in neurologic disorders. |
Oliceridine | A biased opioid agonist indicated for the management of severe acute pain in adult patients. Through preferential activation of G-protein-coupled signalling pathways, oliceridine provides analgesic effect with a comparable or improved safety profile over conventional opioid agonists. |
Levosulpiride | indicated to treat dyspepsia, symptoms of Meniere's syndrome, and second line in the treatment of drug-induced nausea and vomiting. |
Volinanserin | Volinanserin is under investigation in clinical trial NCT00464243 (Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study). |
Lithium chloride | An injection indicated for cardiac output measurement. |
Prucalopride | A 5-HT4 receptor agonist indicated to treat adults with chronic idiopathic constipation. |
Pimavanserin | A second generation atypical antipsychotic used for the treatment of hallucinations and delusions caused by Parkinson's Disease. |
CP-96345 | Not Annotated |
Daridorexant | A dual orexin receptor antagonist used to treat insomnia in adults. |
Ecgonine | Not Available |
Methylecgonine | Not Available |
Canertinib | Investigated for use/treatment in breast cancer and lung cancer. |
Etidocaine | Etidocaine is marketed under the name Duranest. It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage... |
Propoxycaine | Propoxycaine is a local anesthetic medication. It was used beginning in the 1950s during dental procedures . It has been combined with procaine to accelerate its onset of action and... |
Butacaine | Not Annotated |
Norflurane | Norflurane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage). |
Quinisocaine | Not Annotated |
Padsevonil | Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil). |
Xenon | Not Annotated |
Dexfenfluramine | For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet |
4-Bromo-2,5-dimethoxyphenethylamine | Not Available |
Xaliproden | Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and alzheimer's disease. |
Repinotan | Investigated for use/treatment in strokes, cerebral ischemia, and depression. |
Lasmiditan | An oral 5HT1F agonist used for the acute treatment of migraine headache with or without aura. |
Norclozapine | Investigated for use/treatment in schizophrenia and schizoaffective disorders. |
Lecozotan | Lecozotan has been used in trials studying the treatment of Alzheimer Disease. |
Letibotulinumtoxina | A purified type A botulinum neurotoxin protein complex used to improve the appearance of glabellar lines. |
Passiflora incarnata flower | A herbal product indicated in the treatment of stress, nervousness, anxiety, irritability, and trouble sleeping. |
Azasetron | Not Annotated |
Hydromethylthionine mesylate | Not Annotated |
Ganaxolone | A neuroactive steroid GABA-A receptor modulator used for the treatment of seizures associated with CDKL5 deficiency disorder (CDD). |
F-15599 | Not Annotated |
Sodium oxybate | Succinate-semialdehyde dehydrogenase, mitochondrial | enzyme |
Sodium oxybate | Hydroxyacid-oxoacid transhydrogenase, mitochondrial | enzyme |
Sodium oxybate | GABA(B) Receptor | target |
Sodium oxybate | Gamma-hydroxybutyrate (GHB) receptor | target |
Sodium oxybate | NAD(P) transhydrogenase, mitochondrial | enzyme |
Lorazepam | UDP-glucuronosyltransferase 2B15 | enzyme |
Lorazepam | GABA(A) Receptor | target |
Lorazepam | Cytochrome P450 3A4 | enzyme |
Lorazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Tramadol | Mu-type opioid receptor | target |
Tramadol | Sodium-dependent noradrenaline transporter | target |
Tramadol | 5-hydroxytryptamine receptor 2C | target |
Tramadol | Kappa-type opioid receptor | target |
Tramadol | Sodium-dependent serotonin transporter | target |
Tramadol | Cytochrome P450 2D6 | enzyme |
Tramadol | Delta-type opioid receptor | target |
Tramadol | Cytochrome P450 3A4 | enzyme |
Tramadol | Cytochrome P450 2B6 | enzyme |
Tramadol | Alpha-7 nicotinic cholinergic receptor subunit | target |
Tramadol | Muscarinic acetylcholine receptor M3 | target |
Tramadol | Muscarinic acetylcholine receptor M1 | target |
Tramadol | UDP-glucuronosyltransferase 1-1 | enzyme |
Tramadol | Neurokinin 1 receptor | target |
Tramadol | Sodium channel protein type 2 subunit alpha | target |
Tramadol | Transient receptor potential cation channel subfamily V member 1 | target |
Tramadol | NMDA receptor | target |
Tramadol | Adenosine receptor A1 | target |
Tramadol | Alpha-2 adrenergic receptors | target |
Reserpine | Synaptic vesicular amine transporter | target |
Reserpine | P-glycoprotein 1 | transporter |
Reserpine | Solute carrier family 22 member 1 | transporter |
Reserpine | Bile salt export pump | transporter |
Reserpine | Canalicular multispecific organic anion transporter 1 | transporter |
Reserpine | Solute carrier family 22 member 2 | transporter |
Reserpine | Cytochrome P450 3A5 | enzyme |
Reserpine | Chromaffin granule amine transporter | target |
Reserpine | Baculoviral IAP repeat-containing protein 5 | target |
Reserpine | Solute carrier organic anion transporter family member 1B1 | transporter |
Reserpine | Solute carrier organic anion transporter family member 2B1 | transporter |
Pregabalin | Excitatory amino acid transporter 3 | transporter |
Pregabalin | Voltage-dependent calcium channel subunit alpha-2/delta-1 | target |
Pregabalin | Large neutral amino acids transporter small subunit 1 | transporter |
Temazepam | Cytochrome P450 3A4 | enzyme |
Temazepam | Cytochrome P450 2B6 | enzyme |
Temazepam | Cytochrome P450 2C9 | enzyme |
Temazepam | GABA(A) Receptor | target |
Temazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Butabarbital | Glutamate receptor 2 | target |
Butabarbital | Glutamate receptor ionotropic, kainate 2 | target |
Butabarbital | GABA(A) Receptor | target |
Butabarbital | Solute carrier family 2, facilitated glucose transporter member 1 | transporter |
Butabarbital | Neuronal Acetylcholine (nACh) Receptor Subunits | target |
Butabarbital | Glutamate receptor 1 | target |
Butabarbital | Glutamate receptor 3 | target |
Butabarbital | Glutamate receptor 4 | target |
Butabarbital | Glutamate receptor ionotropic, kainate 1 | target |
Butabarbital | Glutamate receptor ionotropic, kainate 3 | target |
Butabarbital | Glutamate receptor ionotropic, kainate 4 | target |
Butabarbital | Glutamate receptor ionotropic, kainate 5 | target |
Butabarbital | Serum albumin | carrier |
Ziprasidone | Alpha-1A adrenergic receptor | target |
Ziprasidone | Dopamine D2 receptor | target |
Ziprasidone | 5-hydroxytryptamine receptor 2C | target |
Ziprasidone | Dopamine D3 receptor | target |
Ziprasidone | 5-hydroxytryptamine receptor 1A | target |
Ziprasidone | 5-hydroxytryptamine receptor 1D | target |
Ziprasidone | Histamine H1 receptor | target |
Ziprasidone | 5-hydroxytryptamine receptor 2A | target |
Ziprasidone | Dopamine D4 receptor | target |
Ziprasidone | 5-hydroxytryptamine receptor 7 | target |
Ziprasidone | Cytochrome P450 3A4 | enzyme |
Ziprasidone | Alpha-2A adrenergic receptor | target |
Ziprasidone | Alpha-1B adrenergic receptor | target |
Ziprasidone | Alpha-2B adrenergic receptor | target |
Ziprasidone | Alpha-2C adrenergic receptor | target |
Ziprasidone | Dopamine D1 receptor | target |
Ziprasidone | Dopamine D5 receptor | target |
Ziprasidone | Muscarinic acetylcholine receptor M1 | target |
Ziprasidone | Muscarinic acetylcholine receptor M2 | target |
Ziprasidone | Muscarinic acetylcholine receptor M3 | target |
Ziprasidone | Muscarinic acetylcholine receptor M4 | target |
Ziprasidone | Muscarinic acetylcholine receptor M5 | target |
Ziprasidone | 5-hydroxytryptamine receptor 1B | target |
Ziprasidone | 5-hydroxytryptamine receptor 1E | target |
Ziprasidone | 5-hydroxytryptamine receptor 6 | target |
Ziprasidone | Aldehyde oxidase | enzyme |
Ziprasidone | Serum albumin | carrier |
Ziprasidone | P-glycoprotein 1 | transporter |
Ziprasidone | Alpha-1-acid glycoprotein 1 | carrier |
Ziprasidone | 5-hydroxytryptamine 3 receptor | target |
Ziprasidone | 5-hydroxytryptamine receptor 5A | target |
Morphine | Mu-type opioid receptor | target |
Morphine | Delta-type opioid receptor | target |
Morphine | Kappa-type opioid receptor | target |
Morphine | P-glycoprotein 1 | transporter |
Morphine | Cytochrome P450 2C8 | enzyme |
Morphine | Cytochrome P450 3A4 | enzyme |
Morphine | UDP-glucuronosyltransferase 2B7 | enzyme |
Morphine | UDP-glucuronosyltransferase 1-1 | enzyme |
Morphine | UDP-glucuronosyltransferase 1-8 | enzyme |
Morphine | UDP-glucuronosyltransferase 2B15 | enzyme |
Morphine | UDP-glucuronosyltransferase 2B4 | enzyme |
Morphine | UDP-glucuronosyltransferase 1-3 | enzyme |
Morphine | Lymphocyte antigen 96 | target |
Morphine | Serum albumin | carrier |
Pentobarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Pentobarbital | Cytochrome P450 3A4 | enzyme |
Pentobarbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Pentobarbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Pentobarbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Pentobarbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Pentobarbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Pentobarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Pentobarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Pentobarbital | Glutamate receptor 2 | target |
Pentobarbital | Glutamate receptor ionotropic, kainate 2 | target |
Pentobarbital | Cytochrome P450 2C19 | enzyme |
Pentobarbital | Cytochrome P450 2A6 | enzyme |
Pentobarbital | GABA(A) Receptor | target |
Pentobarbital | NMDA receptor | target |
Pentobarbital | Nuclear receptor subfamily 1 group I member 2 | target |
Codeine | Mu-type opioid receptor | target |
Codeine | Delta-type opioid receptor | target |
Codeine | Kappa-type opioid receptor | target |
Codeine | Cytochrome P450 2D6 | enzyme |
Codeine | Cytochrome P450 3A4 | enzyme |
Codeine | Solute carrier family 22 member 1 | transporter |
Codeine | UDP-glucuronosyltransferase 2B7 | enzyme |
Codeine | UDP-glucuronosyltransferase 2B4 | enzyme |
Hydromorphone | Mu-type opioid receptor | target |
Hydromorphone | Delta-type opioid receptor | target |
Hydromorphone | Kappa-type opioid receptor | target |
Hydromorphone | Cytochrome P450 2C9 | enzyme |
Hydromorphone | UDP-glucuronosyltransferase 1-3 | enzyme |
Hydromorphone | UDP-glucuronosyltransferase 2B7 | enzyme |
Hydromorphone | Serum albumin | carrier |
Methadone | NMDA receptor | target |
Methadone | Mu-type opioid receptor | target |
Methadone | Cytochrome P450 2B6 | enzyme |
Methadone | Cytochrome P450 3A4 | enzyme |
Methadone | Cytochrome P450 2C19 | enzyme |
Methadone | Delta-type opioid receptor | target |
Methadone | Cytochrome P450 3A7 | enzyme |
Methadone | Cytochrome P450 2D6 | enzyme |
Methadone | P-glycoprotein 1 | transporter |
Methadone | Cytochrome P450 2C8 | enzyme |
Methadone | Cytochrome P450 19A1 | enzyme |
Methadone | Cytochrome P450 1A2 | enzyme |
Methadone | Cytochrome P450 2C18 | enzyme |
Methadone | Cytochrome P450 2C9 | enzyme |
Methadone | 5-hydroxytryptamine receptor 3A | target |
Methadone | Alpha-1-acid glycoprotein 1 | carrier |
Methadone | Serum albumin | carrier |
Methadone | Neuronal acetylcholine receptor subunit alpha-7 | target |
Methadone | Neuronal acetylcholine receptor subunit alpha-3 | target |
Methadone | Neuronal acetylcholine receptor subunit alpha-4 | target |
Methadone | Neuronal acetylcholine receptor subunit beta-2 | target |
Methadone | Cytochrome P450 3A Subfamily | enzyme |
Methadone | UDP-glucuronosyltransferase 2B4 | enzyme |
Olanzapine | Dopamine D1 receptor | target |
Olanzapine | Muscarinic acetylcholine receptor M1 | target |
Olanzapine | Muscarinic acetylcholine receptor M3 | target |
Olanzapine | 5-hydroxytryptamine receptor 2A | target |
Olanzapine | Dopamine D4 receptor | target |
Olanzapine | Histamine H1 receptor | target |
Olanzapine | Muscarinic acetylcholine receptor M4 | target |
Olanzapine | Muscarinic acetylcholine receptor M2 | target |
Olanzapine | Dopamine D2 receptor | target |
Olanzapine | 5-hydroxytryptamine receptor 2C | target |
Olanzapine | Dopamine D3 receptor | target |
Olanzapine | Alpha-1B adrenergic receptor | target |
Olanzapine | Cytochrome P450 1A2 | enzyme |
Olanzapine | 5-hydroxytryptamine receptor 3A | target |
Olanzapine | 5-hydroxytryptamine receptor 6 | target |
Olanzapine | Alpha-1A adrenergic receptor | target |
Olanzapine | Dopamine D5 receptor | target |
Olanzapine | Serum albumin | carrier |
Olanzapine | Alpha-1-acid glycoprotein 1 | carrier |
Olanzapine | Dimethylaniline monooxygenase [N-oxide-forming] 3 | enzyme |
Olanzapine | Cytochrome P450 2D6 | enzyme |
Olanzapine | P-glycoprotein 1 | transporter |
Olanzapine | Cytochrome P450 2C19 | enzyme |
Olanzapine | D(1) dopamine receptor | target |
Olanzapine | Beta adrenergic receptor | target |
Olanzapine | 5-hydroxytryptamine receptor 1 | target |
Olanzapine | GABA(A) Receptor Benzodiazepine Binding Site | target |
Olanzapine | Cytochrome P450 2C9 | enzyme |
Olanzapine | UDP-glucuronosyltransferase 1-4 | enzyme |
Olanzapine | Cytochrome P450 3A4 | enzyme |
Olanzapine | Cytochrome P450 3A Subfamily | enzyme |
Clozapine | Dopamine D4 receptor | target |
Clozapine | Histamine H1 receptor | target |
Clozapine | Dopamine D2 receptor | target |
Clozapine | Neuron-specific vesicular protein calcyon | target |
Clozapine | Histamine H4 receptor | target |
Clozapine | 5-hydroxytryptamine receptor 2A | target |
Clozapine | 5-hydroxytryptamine receptor 1A | target |
Clozapine | 5-hydroxytryptamine receptor 2C | target |
Clozapine | Dopamine D1 receptor | target |
Clozapine | Cytochrome P450 1A2 | enzyme |
Clozapine | Cytochrome P450 2D6 | enzyme |
Clozapine | Dopamine D3 receptor | target |
Clozapine | Muscarinic acetylcholine receptor M1 | target |
Clozapine | Muscarinic acetylcholine receptor M2 | target |
Clozapine | Muscarinic acetylcholine receptor M3 | target |
Clozapine | Muscarinic acetylcholine receptor M4 | target |
Clozapine | Muscarinic acetylcholine receptor M5 | target |
Clozapine | 5-hydroxytryptamine receptor 1B | target |
Clozapine | 5-hydroxytryptamine receptor 1D | target |
Clozapine | 5-hydroxytryptamine receptor 1E | target |
Clozapine | 5-hydroxytryptamine receptor 3A | target |
Clozapine | 5-hydroxytryptamine receptor 6 | target |
Clozapine | 5-hydroxytryptamine receptor 7 | target |
Clozapine | Alpha-1A adrenergic receptor | target |
Clozapine | Alpha-1B adrenergic receptor | target |
Clozapine | Alpha-2A adrenergic receptor | target |
Clozapine | Alpha-2B adrenergic receptor | target |
Clozapine | Alpha-2C adrenergic receptor | target |
Clozapine | Cytochrome P450 2C9 | enzyme |
Clozapine | P-glycoprotein 1 | transporter |
Clozapine | Cytochrome P450 3A4 | enzyme |
Clozapine | Cytochrome P450 2C19 | enzyme |
Clozapine | Dimethylaniline monooxygenase [N-oxide-forming] 3 | enzyme |
Clozapine | UDP-glucuronosyltransferase 1-4 | enzyme |
Clozapine | Cytochrome P450 1A1 | enzyme |
Clozapine | Cytochrome P450 2A6 | enzyme |
Clozapine | Cytochrome P450 2C8 | enzyme |
Clozapine | Glutathione S-transferase P | target |
Meprobamate | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Meprobamate | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Meprobamate | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Meprobamate | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Meprobamate | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Meprobamate | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Meprobamate | GABA(A) Receptor | target |
Eszopiclone | Cytochrome P450 3A4 | enzyme |
Eszopiclone | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Eszopiclone | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Eszopiclone | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Eszopiclone | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Eszopiclone | Cytochrome P450 2C8 | enzyme |
Eszopiclone | GABA(A) Receptor | target |
Alprazolam | Cytochrome P450 3A4 | enzyme |
Alprazolam | Cytochrome P450 2C9 | enzyme |
Alprazolam | Cytochrome P450 3A5 | enzyme |
Alprazolam | Cytochrome P450 3A7 | enzyme |
Alprazolam | GABA(A) Receptor | target |
Alprazolam | Serum albumin | carrier |
Alprazolam | alpha1-acid glycoprotein | carrier |
Alprazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Loxapine | Dopamine D1 receptor | target |
Loxapine | Dopamine D2 receptor | target |
Loxapine | 5-hydroxytryptamine receptor 2A | target |
Loxapine | 5-hydroxytryptamine receptor 2C | target |
Loxapine | 5-hydroxytryptamine receptor 1A | target |
Loxapine | 5-hydroxytryptamine receptor 1B | target |
Loxapine | 5-hydroxytryptamine receptor 1D | target |
Loxapine | 5-hydroxytryptamine receptor 1E | target |
Loxapine | 5-hydroxytryptamine receptor 3A | target |
Loxapine | 5-hydroxytryptamine receptor 5A | target |
Loxapine | 5-hydroxytryptamine receptor 6 | target |
Loxapine | 5-hydroxytryptamine receptor 7 | target |
Loxapine | Alpha-1A adrenergic receptor | target |
Loxapine | Alpha-1B adrenergic receptor | target |
Loxapine | Alpha-2A adrenergic receptor | target |
Loxapine | Alpha-2B adrenergic receptor | target |
Loxapine | Alpha-2C adrenergic receptor | target |
Loxapine | Beta-1 adrenergic receptor | target |
Loxapine | Muscarinic acetylcholine receptor M1 | target |
Loxapine | Muscarinic acetylcholine receptor M2 | target |
Loxapine | Muscarinic acetylcholine receptor M3 | target |
Loxapine | Muscarinic acetylcholine receptor M4 | target |
Loxapine | Muscarinic acetylcholine receptor M5 | target |
Loxapine | D(1) dopamine receptor | target |
Loxapine | Dopamine D3 receptor | target |
Loxapine | Dopamine D4 receptor | target |
Loxapine | Dopamine D5 receptor | target |
Loxapine | Histamine H1 receptor | target |
Loxapine | Histamine H2 receptor | target |
Loxapine | Histamine H4 receptor | target |
Loxapine | Sodium-dependent serotonin transporter | target |
Loxapine | Sodium-dependent noradrenaline transporter | target |
Loxapine | Sodium-dependent dopamine transporter | target |
Secobarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Secobarbital | Cytochrome P450 2C8 | enzyme |
Secobarbital | Cytochrome P450 2C9 | enzyme |
Secobarbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Secobarbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Secobarbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Secobarbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Secobarbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Secobarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Secobarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Secobarbital | Glutamate receptor 2 | target |
Secobarbital | Glutamate receptor ionotropic, kainate 2 | target |
Secobarbital | Cytochrome P450 1A2 | enzyme |
Secobarbital | NMDA receptor | target |
Secobarbital | Cytochrome P450 2C19 | enzyme |
Promazine | Dopamine D2 receptor | target |
Promazine | 5-hydroxytryptamine receptor 2A | target |
Promazine | 5-hydroxytryptamine receptor 2C | target |
Promazine | Alpha-1A adrenergic receptor | target |
Promazine | Muscarinic acetylcholine receptor M1 | target |
Promazine | Histamine H1 receptor | target |
Promazine | Cytochrome P450 2C19 | enzyme |
Promazine | Cytochrome P450 1A2 | enzyme |
Promazine | Cytochrome P450 3A4 | enzyme |
Promazine | Cytochrome P450 2C9 | enzyme |
Promazine | Cytochrome P450 2D6 | enzyme |
Zolpidem | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Zolpidem | Cytochrome P450 3A4 | enzyme |
Zolpidem | Cytochrome P450 1A2 | enzyme |
Zolpidem | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Zolpidem | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Zolpidem | Cytochrome P450 2C9 | enzyme |
Zolpidem | Cytochrome P450 2C19 | enzyme |
Zolpidem | Cytochrome P450 2D6 | enzyme |
Zolpidem | Gamma-aminobutyric acid receptor subunit gamma-2 | target |
Prochlorperazine | Dopamine D2 receptor | target |
Prochlorperazine | Cytochrome P450 2D6 | enzyme |
Prochlorperazine | Histamine H1 receptor | target |
Prochlorperazine | Alpha-1 adrenergic receptors | target |
Prochlorperazine | Alpha-2 adrenergic receptors | target |
Droperidol | Dopamine D2 receptor | target |
Droperidol | Alpha-1A adrenergic receptor | target |
Meperidine | Kappa-type opioid receptor | target |
Meperidine | Cytochrome P450 2D6 | enzyme |
Meperidine | Cytochrome P450 2B6 | enzyme |
Meperidine | Glutamate receptor ionotropic, NMDA 1 | target |
Meperidine | Glutamate receptor ionotropic, NMDA 2B | target |
Meperidine | Glutamate receptor ionotropic, NMDA 2A | target |
Meperidine | Glutamate receptor ionotropic, NMDA 2C | target |
Meperidine | Glutamate receptor ionotropic, NMDA 2D | target |
Meperidine | Cytochrome P450 2C19 | enzyme |
Meperidine | Cytochrome P450 3A4 | enzyme |
Meperidine | Serum albumin | carrier |
Meperidine | Alpha-1-acid glycoprotein 1 | carrier |
Meperidine | Muscarinic acetylcholine receptor | target |
Meperidine | Mu-type opioid receptor | target |
Meperidine | Sodium-dependent dopamine transporter | target |
Meperidine | Sodium-dependent noradrenaline transporter | target |
Meperidine | Sodium-dependent serotonin transporter | target |
Meperidine | Liver carboxylesterase 1 | target |
Meperidine | Cytochrome P450 1A2 | enzyme |
Meperidine | P-glycoprotein 1 | transporter |
Methohexital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Chlordiazepoxide | GABA(A) Receptor | target |
Chlordiazepoxide | GABA(A) Receptor Benzodiazepine Binding Site | target |
Chlordiazepoxide | Cytochrome P450 3A4 | enzyme |
Chlorpromazine | Dopamine D2 receptor | target |
Chlorpromazine | 5-hydroxytryptamine receptor 2A | target |
Chlorpromazine | Cytochrome P450 2D6 | enzyme |
Chlorpromazine | Cholinesterase | enzyme |
Chlorpromazine | Cytochrome P450 1A2 | enzyme |
Chlorpromazine | Serum albumin | carrier |
Chlorpromazine | P-glycoprotein 1 | transporter |
Chlorpromazine | Dopamine D1 receptor | target |
Chlorpromazine | 5-hydroxytryptamine receptor 1A | target |
Chlorpromazine | Alpha-1A adrenergic receptor | target |
Chlorpromazine | Alpha-1B adrenergic receptor | target |
Chlorpromazine | Cytochrome P450 2E1 | enzyme |
Chlorpromazine | Cytochrome P450 3A4 | enzyme |
Chlorpromazine | Histamine H1 receptor | target |
Chlorpromazine | Potassium voltage-gated channel subfamily H member 2 | target |
Chlorpromazine | D(1) dopamine receptor | target |
Chlorpromazine | Dopamine D3 receptor | target |
Chlorpromazine | Dopamine D4 receptor | target |
Chlorpromazine | Dopamine D5 receptor | target |
Chlorpromazine | 5-hydroxytryptamine receptor 2C | target |
Chlorpromazine | 5-hydroxytryptamine 2 receptor | target |
Chlorpromazine | Alpha-1 adrenergic receptors | target |
Chlorpromazine | Alpha-2 adrenergic receptors | target |
Chlorpromazine | Muscarinic acetylcholine receptor M1 | target |
Chlorpromazine | Muscarinic acetylcholine receptor M3 | target |
Chlorpromazine | Sphingomyelin phosphodiesterase | target |
Chlorpromazine | Calmodulin | target |
Chlorpromazine | alpha1-acid glycoprotein | target |
Chlorpromazine | 5-hydroxytryptamine receptor 6 | target |
Chlorpromazine | 5-hydroxytryptamine receptor 7 | target |
Chlorpromazine | Histamine H4 receptor | target |
Chlorpromazine | Bile salt export pump | transporter |
Oxycodone | Mu-type opioid receptor | target |
Oxycodone | Kappa-type opioid receptor | target |
Oxycodone | Delta-type opioid receptor | target |
Oxycodone | Cytochrome P450 2D6 | enzyme |
Oxycodone | Cytochrome P450 3A4 | enzyme |
Oxycodone | Cytochrome P450 3A5 | enzyme |
Oxycodone | Serum albumin | carrier |
Oxycodone | alpha1-acid glycoprotein | carrier |
Haloperidol | Dopamine D2 receptor | target |
Haloperidol | Glutamate receptor ionotropic, NMDA 2B | target |
Haloperidol | Dopamine D1 receptor | target |
Haloperidol | Cytochrome P450 1A2 | enzyme |
Haloperidol | Cytochrome P450 2D6 | enzyme |
Haloperidol | 5-hydroxytryptamine receptor 2A | target |
Haloperidol | Dopamine D3 receptor | target |
Haloperidol | Cytochrome P450 3A4 | enzyme |
Haloperidol | Cytochrome P450 3A5 | enzyme |
Haloperidol | Cytochrome P450 3A7 | enzyme |
Haloperidol | P-glycoprotein 1 | transporter |
Haloperidol | Carbonyl reductase [NADPH] 1 | enzyme |
Haloperidol | UDP-glucuronosyltransferase 1-9 | enzyme |
Haloperidol | Cytochrome P450 2C19 | enzyme |
Haloperidol | Cytochrome P450 2C9 | enzyme |
Haloperidol | Melanin-concentrating hormone receptor 1 | target |
Haloperidol | Synaptic vesicular amine transporter | target |
Haloperidol | 5-hydroxytryptamine receptor 2C | target |
Haloperidol | Sigma non-opioid intracellular receptor 1 | target |
Haloperidol | Histamine H1 receptor | target |
Haloperidol | Muscarinic acetylcholine receptor M3 | target |
Haloperidol | Alpha-1A adrenergic receptor | target |
Haloperidol | Alpha-2A adrenergic receptor | target |
Haloperidol | Alpha-2B adrenergic receptor | target |
Haloperidol | Alpha-2C adrenergic receptor | target |
Haloperidol | 5-hydroxytryptamine receptor 1A | target |
Haloperidol | 5-hydroxytryptamine receptor 6 | target |
Haloperidol | 5-hydroxytryptamine receptor 7 | target |
Haloperidol | Cytochrome P450 1A1 | enzyme |
Carbamazepine | Voltage-gated sodium channel alpha subunit | target |
Carbamazepine | Cytochrome P450 2C8 | enzyme |
Carbamazepine | Cytochrome P450 2B6 | enzyme |
Carbamazepine | Cytochrome P450 3A4 | enzyme |
Carbamazepine | Cytochrome P450 1A2 | enzyme |
Carbamazepine | Cytochrome P450 2C19 | enzyme |
Carbamazepine | Cytochrome P450 2C9 | enzyme |
Carbamazepine | P-glycoprotein 1 | transporter |
Carbamazepine | Cytochrome P450 3A5 | enzyme |
Carbamazepine | UDP-glucuronosyltransferase 2B7 | enzyme |
Carbamazepine | RalA-binding protein 1 | transporter |
Carbamazepine | Canalicular multispecific organic anion transporter 1 | transporter |
Carbamazepine | Neuronal acetylcholine receptor subunit alpha-4 | target |
Carbamazepine | Nuclear receptor subfamily 1 group I member 2 | target |
Carbamazepine | UDP-glucuronosyltransferase 1-1 | enzyme |
Carbamazepine | UDP-glucuronosyltransferase 1-6 | enzyme |
Carbamazepine | UDP-glucuronosyltransferase 1-7 | enzyme |
Butorphanol | Kappa-type opioid receptor | target |
Butorphanol | Mu-type opioid receptor | target |
Butorphanol | Delta-type opioid receptor | target |
Fluphenazine | Dopamine D2 receptor | target |
Fluphenazine | Calmodulin | target |
Fluphenazine | Dopamine D1 receptor | target |
Fluphenazine | Cytochrome P450 2D6 | enzyme |
Fluphenazine | P-glycoprotein 1 | transporter |
Fluphenazine | Cytochrome P450 2E1 | enzyme |
Fluphenazine | Androgen receptor | target |
Fluphenazine | 5-hydroxytryptamine receptor 2A | target |
Fluphenazine | 5-hydroxytryptamine receptor 2C | target |
Clorazepic acid | Cytochrome P450 3A4 | enzyme |
Clorazepic acid | GABA(A) Receptor | target |
Clorazepic acid | GABA(A) Receptor Benzodiazepine Binding Site | target |
Pentazocine | Mu-type opioid receptor | target |
Pentazocine | Kappa-type opioid receptor | target |
Pentazocine | Sigma non-opioid intracellular receptor 1 | target |
Pentazocine | P-glycoprotein 1 | transporter |
Thioridazine | Alpha-1A adrenergic receptor | target |
Thioridazine | Dopamine D2 receptor | target |
Thioridazine | 5-hydroxytryptamine receptor 2A | target |
Thioridazine | Dopamine D1 receptor | target |
Thioridazine | Cytochrome P450 2C19 | enzyme |
Thioridazine | Cytochrome P450 2D6 | enzyme |
Thioridazine | Alpha-1B adrenergic receptor | target |
Thioridazine | Potassium voltage-gated channel subfamily H member 2 | target |
Thioridazine | Cytochrome P450 2E1 | enzyme |
Midazolam | Cytochrome P450 3A4 | enzyme |
Midazolam | Cytochrome P450 3A5 | enzyme |
Midazolam | UDP-glucuronosyltransferase 1-4 | enzyme |
Midazolam | Cytochrome P450 3A7 | enzyme |
Midazolam | GABA(A) Receptor | target |
Midazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Flurazepam | Cytochrome P450 3A4 | enzyme |
Flurazepam | P-glycoprotein 1 | transporter |
Flurazepam | Cytochrome P450 2E1 | enzyme |
Flurazepam | Cytochrome P450 2A6 | enzyme |
Flurazepam | Solute carrier family 22 member 2 | transporter |
Flurazepam | GABA(A) Receptor | target |
Flurazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Sufentanil | Mu-type opioid receptor | target |
Sufentanil | Delta-type opioid receptor | target |
Sufentanil | Kappa-type opioid receptor | target |
Sufentanil | Cytochrome P450 3A4 | enzyme |
Risperidone | Cytochrome P450 2D6 | enzyme |
Risperidone | Cytochrome P450 3A4 | enzyme |
Risperidone | P-glycoprotein 1 | transporter |
Risperidone | Serum albumin | carrier |
Risperidone | Alpha-1-acid glycoprotein 1 | carrier |
Risperidone | 5-hydroxytryptamine receptor 2A | target |
Risperidone | Dopamine D2 receptor | target |
Risperidone | Alpha-1B adrenergic receptor | target |
Risperidone | Alpha-2B adrenergic receptor | target |
Risperidone | Alpha-1A adrenergic receptor | target |
Risperidone | Alpha-2C adrenergic receptor | target |
Risperidone | Histamine H1 receptor | target |
Risperidone | 5-hydroxytryptamine receptor 2C | target |
Risperidone | 5-hydroxytryptamine receptor 1D | target |
Risperidone | 5-hydroxytryptamine receptor 1A | target |
Risperidone | 5-hydroxytryptamine receptor 7 | target |
Risperidone | D(2L) dopamine receptor | target |
Risperidone | Dopamine D1 receptor | target |
Isoflurane | Calcium-transporting ATPase type 2C member 1 | target |
Isoflurane | ATP synthase subunit delta, mitochondrial | target |
Isoflurane | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Isoflurane | Potassium voltage-gated channel subfamily A member 1 | target |
Isoflurane | Glutamate receptor 1 | target |
Isoflurane | Glycine receptor subunit alpha-1 | target |
Isoflurane | Calmodulin | target |
Isoflurane | Cytochrome P450 2E1 | enzyme |
Isoflurane | Serum albumin | carrier |
Isoflurane | Cytochrome P450 2B6 | enzyme |
Isoflurane | NADH-ubiquinone oxidoreductase chain 1 | enzyme |
Isoflurane | GABA(A) Receptor | target |
Isoflurane | Neuronal acetylcholine receptor subunit alpha-4 | target |
Isoflurane | Neuronal acetylcholine receptor subunit beta-2 | target |
Alfentanil | Mu-type opioid receptor | target |
Alfentanil | Cytochrome P450 3A4 | enzyme |
Alfentanil | Cytochrome P450 3A5 | enzyme |
Alfentanil | Alpha-1-acid glycoprotein 1 | carrier |
Alfentanil | Serum albumin | carrier |
Alfentanil | Cytochrome P450 3A7 | enzyme |
Alfentanil | P-glycoprotein 1 | transporter |
Fentanyl | Mu-type opioid receptor | target |
Fentanyl | Delta-type opioid receptor | target |
Fentanyl | Cytochrome P450 3A4 | enzyme |
Fentanyl | Cytochrome P450 3A7 | enzyme |
Fentanyl | P-glycoprotein 1 | transporter |
Fentanyl | Kappa-type opioid receptor | target |
Fentanyl | P-glycoprotein 1 | target |
Fentanyl | Serum albumin | carrier |
Fentanyl | alpha1-acid glycoprotein | carrier |
Propofol | Cytochrome P450 2B6 | enzyme |
Propofol | UDP-glucuronosyltransferase 1-1 | enzyme |
Propofol | UDP-glucuronosyltransferase 1-9 | enzyme |
Propofol | Gamma-aminobutyric acid receptor subunit beta-2 | target |
Propofol | Gamma-aminobutyric acid receptor subunit beta-3 | target |
Propofol | Serum albumin | carrier |
Propofol | Sodium channel protein type 4 subunit alpha | target |
Propofol | Sodium channel protein type 2 subunit alpha | target |
Propofol | Fatty-acid amide hydrolase 1 | enzyme |
Propofol | Cytochrome P450 2C9 | enzyme |
Propofol | UDP-glucuronosyltransferase 1-8 | enzyme |
Propofol | Cytochrome P450 2E1 | enzyme |
Propofol | Cytochrome P450 1B1 | enzyme |
Propofol | Cytochrome P450 1A1 | enzyme |
Propofol | Cytochrome P450 1A2 | enzyme |
Propofol | Cytochrome P450 2C18 | enzyme |
Propofol | Cytochrome P450 2C19 | enzyme |
Propofol | Cytochrome P450 2C8 | enzyme |
Propofol | UDP-glucuronosyltransferase 1-6 | enzyme |
Propofol | GABA(A) Receptor | target |
Propofol | P-glycoprotein 1 | transporter |
Diazepam | Cytochrome P450 3A4 | enzyme |
Diazepam | Serum albumin | carrier |
Diazepam | Cytochrome P450 2C9 | enzyme |
Diazepam | Cytochrome P450 2C19 | enzyme |
Diazepam | Cytochrome P450 3A5 | enzyme |
Diazepam | Cytochrome P450 3A7 | enzyme |
Diazepam | P-glycoprotein 1 | transporter |
Diazepam | Cytochrome P450 2B6 | enzyme |
Diazepam | Prostaglandin G/H synthase 1 | enzyme |
Diazepam | Cytochrome P450 2C18 | enzyme |
Diazepam | Cytochrome P450 2C8 | enzyme |
Diazepam | GABA(A) Receptor | target |
Diazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Trifluoperazine | Dopamine D2 receptor | target |
Trifluoperazine | Alpha-1A adrenergic receptor | target |
Trifluoperazine | Neuron-specific vesicular protein calcyon | target |
Trifluoperazine | Xanthine dehydrogenase/oxidase | enzyme |
Trifluoperazine | UDP-glucuronosyltransferase 1-4 | enzyme |
Trifluoperazine | Cytochrome P450 1A2 | enzyme |
Trifluoperazine | P-glycoprotein 1 | transporter |
Trifluoperazine | Calmodulin | target |
Trifluoperazine | Troponin C, slow skeletal and cardiac muscles | target |
Trifluoperazine | Protein S100-A4 | target |
Oxazepam | UDP-glucuronosyltransferase 2B15 | enzyme |
Oxazepam | UDP-glucuronosyltransferase 2B7 | enzyme |
Oxazepam | UDP-glucuronosyltransferase 1-9 | enzyme |
Oxazepam | GABA(A) Receptor | target |
Oxazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Oxazepam | Serum albumin | carrier |
Nalbuphine | Kappa-type opioid receptor | target |
Nalbuphine | Mu-type opioid receptor | target |
Nalbuphine | Delta-type opioid receptor | target |
Perphenazine | Dopamine D1 receptor | target |
Perphenazine | Dopamine D2 receptor | target |
Perphenazine | Calmodulin | target |
Perphenazine | Cytochrome P450 2D6 | enzyme |
Perphenazine | Cytochrome P450 1A2 | enzyme |
Perphenazine | Cytochrome P450 2C18 | enzyme |
Perphenazine | Cytochrome P450 2C19 | enzyme |
Perphenazine | Cytochrome P450 2C8 | enzyme |
Perphenazine | Cytochrome P450 2C9 | enzyme |
Perphenazine | Cytochrome P450 3A4 | enzyme |
Perphenazine | Serum albumin | carrier |
Levorphanol | Mu-type opioid receptor | target |
Levorphanol | Delta-type opioid receptor | target |
Levorphanol | Kappa-type opioid receptor | target |
Flupentixol | Alpha-1A adrenergic receptor | target |
Flupentixol | Dopamine D2 receptor | target |
Flupentixol | Dopamine D1 receptor | target |
Flupentixol | Aromatic-L-amino-acid decarboxylase | enzyme |
Flupentixol | 5-hydroxytryptamine receptor 2A | target |
Flupentixol | P-glycoprotein 1 | transporter |
Flupentixol | Muscarinic acetylcholine receptor M1 | target |
Flupentixol | Liver carboxylesterase 1 | enzyme |
Flupentixol | Dopamine D3 receptor | target |
Flupentixol | Dopamine D4 receptor | target |
Flupentixol | 5-hydroxytryptamine receptor 2C | target |
Triazolam | Cytochrome P450 3A4 | enzyme |
Triazolam | Cytochrome P450 3A5 | enzyme |
Triazolam | Cytochrome P450 3A7 | enzyme |
Triazolam | Cytochrome P450 2C8 | enzyme |
Triazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Triazolam | GABA(A) Receptor | target |
Remifentanil | Mu-type opioid receptor | target |
Remifentanil | Delta-type opioid receptor | target |
Remifentanil | Kappa-type opioid receptor | target |
Buprenorphine | Kappa-type opioid receptor | target |
Buprenorphine | Mu-type opioid receptor | target |
Buprenorphine | Cytochrome P450 3A4 | enzyme |
Buprenorphine | Cytochrome P450 2D6 | enzyme |
Buprenorphine | P-glycoprotein 1 | transporter |
Buprenorphine | ATP-binding cassette sub-family G member 2 | transporter |
Buprenorphine | Cytochrome P450 2C9 | enzyme |
Buprenorphine | Cytochrome P450 3A5 | enzyme |
Buprenorphine | Cytochrome P450 2C8 | enzyme |
Buprenorphine | Cytochrome P450 3A7 | enzyme |
Buprenorphine | Delta-type opioid receptor | target |
Buprenorphine | Cytochrome P450 2C18 | enzyme |
Buprenorphine | Cytochrome P450 2C19 | enzyme |
Buprenorphine | Nociceptin receptor | target |
Cyclobenzaprine | 5-hydroxytryptamine receptor 2A | target |
Cyclobenzaprine | Cytochrome P450 1A2 | enzyme |
Cyclobenzaprine | Cytochrome P450 3A4 | enzyme |
Cyclobenzaprine | Cytochrome P450 2D6 | enzyme |
Cyclobenzaprine | Serum albumin | carrier |
Cyclobenzaprine | UDP-glucuronosyltransferase 1-4 | enzyme |
Cyclobenzaprine | UDP-glucuronosyltransferase 2B10 | enzyme |
Cyclobenzaprine | 5-hydroxytryptamine receptor 2B | target |
Cyclobenzaprine | 5-hydroxytryptamine receptor 2C | target |
Cyclobenzaprine | 5-hydroxytryptamine receptor 7 | target |
Cyclobenzaprine | 5-hydroxytryptamine receptor 6 | target |
Cyclobenzaprine | Sodium-dependent serotonin transporter | target |
Cyclobenzaprine | Sodium-dependent noradrenaline transporter | target |
Cyclobenzaprine | Toll-like receptor 4 | target |
Cyclobenzaprine | Aldehyde oxidase | target |
Hydrocodone | Mu-type opioid receptor | target |
Hydrocodone | Delta-type opioid receptor | target |
Hydrocodone | Cytochrome P450 3A4 | enzyme |
Hydrocodone | Cytochrome P450 2D6 | enzyme |
Hydrocodone | Cytochrome P450 2B6 | enzyme |
Hydrocodone | Cytochrome P450 2C19 | enzyme |
Hydrocodone | Sigma non-opioid intracellular receptor 1 | target |
Zaleplon | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Zaleplon | Cytochrome P450 3A4 | enzyme |
Zaleplon | Aldehyde oxidase | enzyme |
Zaleplon | Cytochrome P450 3A5 | enzyme |
Zaleplon | Cytochrome P450 3A7 | enzyme |
Gabapentin | Adenosine receptor A1 | target |
Gabapentin | Voltage-dependent calcium channel subunit alpha-2/delta-1 | target |
Gabapentin | Voltage-dependent calcium channel subunit alpha-2/delta-2 | target |
Gabapentin | Branched-chain-amino-acid aminotransferase, cytosolic | enzyme |
Gabapentin | Large neutral amino acids transporter small subunit 1 | transporter |
Gabapentin | Voltage-dependent N-type calcium channel | target |
Gabapentin | Potassium voltage-gated channel subfamily KQT member 3 | target |
Gabapentin | Potassium voltage-gated channel subfamily KQT member 5 | target |
Diphenhydramine | Histamine H1 receptor | target |
Diphenhydramine | Cytochrome P450 2D6 | enzyme |
Diphenhydramine | Cytochrome P450 2C9 | enzyme |
Diphenhydramine | Cytochrome P450 2C19 | enzyme |
Diphenhydramine | Solute carrier family 22 member 2 | transporter |
Diphenhydramine | Solute carrier family 22 member 5 | transporter |
Diphenhydramine | Prostaglandin G/H synthase 1 | enzyme |
Diphenhydramine | Muscarinic acetylcholine receptor M2 | target |
Diphenoxylate | Mu-type opioid receptor | target |
Diphenoxylate | Delta-type opioid receptor | target |
Pimozide | Dopamine D2 receptor | target |
Pimozide | Calmodulin | target |
Pimozide | Potassium voltage-gated channel subfamily H member 2 | target |
Pimozide | Cytochrome P450 3A4 | enzyme |
Pimozide | Cytochrome P450 1A2 | enzyme |
Pimozide | Cytochrome P450 3A5 | enzyme |
Pimozide | Cytochrome P450 3A7 | enzyme |
Pimozide | P-glycoprotein 1 | transporter |
Pimozide | Dopamine D3 receptor | target |
Pimozide | Cytochrome P450 2D6 | enzyme |
Phenobarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Phenobarbital | Cytochrome P450 2C19 | enzyme |
Phenobarbital | Cytochrome P450 2C9 | enzyme |
Phenobarbital | Cytochrome P450 2B6 | enzyme |
Phenobarbital | Cytochrome P450 2C8 | enzyme |
Phenobarbital | Cytochrome P450 1A2 | enzyme |
Phenobarbital | Cytochrome P450 3A4 | enzyme |
Phenobarbital | Canalicular multispecific organic anion transporter 2 | transporter |
Phenobarbital | Bile salt export pump | transporter |
Phenobarbital | P-glycoprotein 1 | transporter |
Phenobarbital | Multidrug resistance-associated protein 1 | transporter |
Phenobarbital | Solute carrier organic anion transporter family member 2A1 | transporter |
Phenobarbital | Canalicular multispecific organic anion transporter 1 | transporter |
Phenobarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Phenobarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Phenobarbital | Glutamate receptor 2 | target |
Phenobarbital | Glutamate receptor ionotropic, kainate 2 | target |
Phenobarbital | Cytochrome P450 2A6 | enzyme |
Phenobarbital | Cytochrome P450 2E1 | enzyme |
Phenobarbital | Cytochrome P450 3A5 | enzyme |
Phenobarbital | Cytochrome P450 1A1 | enzyme |
Phenobarbital | Cytochrome P450 2C18 | enzyme |
Phenobarbital | Cytochrome P450 3A7 | enzyme |
Phenobarbital | Cytochrome P450 4B1 | enzyme |
Phenobarbital | NMDA receptor | target |
Phenobarbital | Nuclear receptor subfamily 1 group I member 2 | target |
Phenobarbital | UDP-glucuronosyltransferase 1-1 | enzyme |
Phenobarbital | UDP-glucuronosyltransferase 2B7 | enzyme |
Desflurane | NADH-ubiquinone oxidoreductase chain 1 | target |
Desflurane | Glycine receptor subunit alpha-1 | target |
Desflurane | Glutamate receptor 1 | target |
Desflurane | GABA(A) Receptor | target |
Desflurane | Potassium voltage-gated channel subfamily A member 1 | target |
Desflurane | ATP synthase subunit delta, mitochondrial | target |
Desflurane | Serum albumin | carrier |
Desflurane | Calcium transporting ATPases | target |
Desflurane | Cytochrome P450 2E1 | enzyme |
Oxymorphone | Mu-type opioid receptor | target |
Oxymorphone | Cytochrome P450 2D6 | enzyme |
Oxymorphone | Delta-type opioid receptor | target |
Oxymorphone | Cytochrome P450 3A4 | enzyme |
Zopiclone | Translocator protein | target |
Zopiclone | Cytochrome P450 2C8 | enzyme |
Zopiclone | Cytochrome P450 2C9 | enzyme |
Zopiclone | Cytochrome P450 3A4 | enzyme |
Zopiclone | Prostaglandin G/H synthase 1 | enzyme |
Zopiclone | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Zopiclone | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Zopiclone | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Zopiclone | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Estazolam | Cytochrome P450 3A4 | enzyme |
Estazolam | GABA(A) Receptor | target |
Estazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Ketamine | Glutamate receptor ionotropic, NMDA 3A | target |
Ketamine | Neurokinin 1 receptor | target |
Ketamine | Cytochrome P450 2B6 | enzyme |
Ketamine | Cytochrome P450 2C9 | enzyme |
Ketamine | Cytochrome P450 3A4 | enzyme |
Ketamine | Dopamine D2 receptor | target |
Ketamine | Prostaglandin G/H synthase 1 | enzyme |
Ketamine | Cytochrome P450 2C8 | enzyme |
Ketamine | Delta-type opioid receptor | target |
Ketamine | Sodium-dependent noradrenaline transporter | target |
Ketamine | Kappa-type opioid receptor | target |
Ketamine | Mu-type opioid receptor | target |
Ketamine | Muscarinic acetylcholine receptor | target |
Ketamine | 5-hydroxytryptamine receptor 2 | target |
Ketamine | 5-hydroxytryptamine receptor 1 | target |
Ketamine | 5-hydroxytryptamine receptor 3A | target |
Ketamine | Alpha-7 nicotinic cholinergic receptor subunit | target |
Ketamine | Cholinesterase | target |
Ketamine | Nitric oxide synthase, brain | target |
Quetiapine | 5-hydroxytryptamine receptor 2A | target |
Quetiapine | 5-hydroxytryptamine receptor 2C | target |
Quetiapine | Dopamine D2 receptor | target |
Quetiapine | 5-hydroxytryptamine receptor 1A | target |
Quetiapine | Histamine H1 receptor | target |
Quetiapine | Cytochrome P450 3A4 | enzyme |
Quetiapine | Alpha-1 adrenergic receptors | target |
Quetiapine | Alpha-2A adrenergic receptor | target |
Quetiapine | Alpha-2B adrenergic receptor | target |
Quetiapine | Alpha-2C adrenergic receptor | target |
Quetiapine | 5-hydroxytryptamine receptor 1D | target |
Quetiapine | Muscarinic acetylcholine receptor M1 | target |
Quetiapine | Muscarinic acetylcholine receptor M2 | target |
Quetiapine | Muscarinic acetylcholine receptor M3 | target |
Quetiapine | Muscarinic acetylcholine receptor M4 | target |
Quetiapine | Muscarinic acetylcholine receptor M5 | target |
Quetiapine | 5-hydroxytryptamine receptor 1B | target |
Quetiapine | 5-hydroxytryptamine receptor 1E | target |
Quetiapine | 5-hydroxytryptamine receptor 3A | target |
Quetiapine | 5-hydroxytryptamine receptor 6 | target |
Quetiapine | 5-hydroxytryptamine receptor 7 | target |
Quetiapine | Dopamine D5 receptor | target |
Quetiapine | Dopamine D1 receptor | target |
Quetiapine | Dopamine D3 receptor | target |
Quetiapine | Dopamine D4 receptor | target |
Quetiapine | Cytochrome P450 3A5 | enzyme |
Quetiapine | P-glycoprotein 1 | transporter |
Quetiapine | Cytochrome P450 2C19 | enzyme |
Quetiapine | Cytochrome P450 2D6 | enzyme |
Quetiapine | Cytochrome P450 3A7 | enzyme |
Sevoflurane | NADH-ubiquinone oxidoreductase chain 1 | target |
Sevoflurane | Glycine receptor subunit alpha-1 | target |
Sevoflurane | Glutamate receptor 1 | target |
Sevoflurane | Cytochrome P450 2E1 | enzyme |
Sevoflurane | Serum albumin | carrier |
Sevoflurane | Cytochrome P450 2A6 | enzyme |
Sevoflurane | Cytochrome P450 2B6 | enzyme |
Sevoflurane | Cytochrome P450 3A4 | enzyme |
Sevoflurane | GABA(A) Receptor | target |
Sevoflurane | Mitochondrial potassium channel | target |
Sevoflurane | Calcium transporting ATPases | target |
Aripiprazole | Dopamine D2 receptor | target |
Aripiprazole | 5-hydroxytryptamine receptor 1A | target |
Aripiprazole | 5-hydroxytryptamine receptor 2A | target |
Aripiprazole | Cytochrome P450 3A4 | enzyme |
Aripiprazole | Cytochrome P450 2D6 | enzyme |
Aripiprazole | 5-hydroxytryptamine receptor 1B | target |
Aripiprazole | 5-hydroxytryptamine receptor 1D | target |
Aripiprazole | 5-hydroxytryptamine receptor 1E | target |
Aripiprazole | Dopamine D1 receptor | target |
Aripiprazole | Dopamine D5 receptor | target |
Aripiprazole | Dopamine D3 receptor | target |
Aripiprazole | Dopamine D4 receptor | target |
Aripiprazole | 5-hydroxytryptamine receptor 2C | target |
Aripiprazole | 5-hydroxytryptamine receptor 3A | target |
Aripiprazole | 5-hydroxytryptamine receptor 6 | target |
Aripiprazole | 5-hydroxytryptamine receptor 7 | target |
Aripiprazole | Histamine H1 receptor | target |
Aripiprazole | Alpha-1A adrenergic receptor | target |
Aripiprazole | Alpha-1B adrenergic receptor | target |
Aripiprazole | Alpha-2A adrenergic receptor | target |
Aripiprazole | Alpha-2B adrenergic receptor | target |
Aripiprazole | Alpha-2C adrenergic receptor | target |
Aripiprazole | Cytochrome P450 3A5 | enzyme |
Aripiprazole | Cytochrome P450 3A7 | enzyme |
Aripiprazole | Serum albumin | carrier |
Aripiprazole | 5-hydroxytryptamine receptor 2B | target |
Aripiprazole | 5-hydroxytryptamine receptor 5A | target |
Aripiprazole | Beta-1 adrenergic receptor | target |
Aripiprazole | Beta-2 adrenergic receptor | target |
Aripiprazole | Histamine H2 receptor | target |
Aripiprazole | Histamine H3 receptor | target |
Aripiprazole | Histamine H4 receptor | target |
Aripiprazole | Muscarinic acetylcholine receptor M1 | target |
Aripiprazole | Muscarinic acetylcholine receptor M2 | target |
Aripiprazole | Muscarinic acetylcholine receptor M3 | target |
Aripiprazole | Muscarinic acetylcholine receptor M4 | target |
Aripiprazole | Muscarinic acetylcholine receptor M5 | target |
Aripiprazole | Kappa-type opioid receptor | target |
Aripiprazole | Mu-type opioid receptor | target |
Aripiprazole | Delta-type opioid receptor | target |
Aripiprazole | Glutamate (NMDA) receptor | target |
Aripiprazole | Sodium-dependent dopamine transporter | target |
Aripiprazole | Sodium-dependent serotonin transporter | target |
Paliperidone | Dopamine D2 receptor | target |
Paliperidone | 5-hydroxytryptamine receptor 2A | target |
Paliperidone | Histamine H1 receptor | target |
Paliperidone | Alpha-1A adrenergic receptor | target |
Paliperidone | Alpha-1B adrenergic receptor | target |
Paliperidone | Dopamine D3 receptor | target |
Paliperidone | Dopamine D4 receptor | target |
Paliperidone | Dopamine D1 receptor | target |
Paliperidone | Alpha-2A adrenergic receptor | target |
Paliperidone | Alpha-2B adrenergic receptor | target |
Paliperidone | Alpha-2C adrenergic receptor | target |
Paliperidone | 5-hydroxytryptamine receptor 1A | target |
Paliperidone | 5-hydroxytryptamine receptor 1D | target |
Paliperidone | 5-hydroxytryptamine receptor 2C | target |
Paliperidone | 5-hydroxytryptamine receptor 7 | target |
Paliperidone | Cytochrome P450 3A4 | enzyme |
Paliperidone | Cytochrome P450 2D6 | enzyme |
Paliperidone | Cytochrome P450 3A5 | enzyme |
Paliperidone | P-glycoprotein 1 | transporter |
Amobarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Amobarbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Amobarbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Amobarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Amobarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Amobarbital | Glutamate receptor 2 | target |
Amobarbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Amobarbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Amobarbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Amobarbital | Glutamate receptor ionotropic, kainate 2 | target |
Methotrimeprazine | Dopamine D3 receptor | target |
Methotrimeprazine | Histamine H1 receptor | target |
Methotrimeprazine | Muscarinic acetylcholine receptor M1 | target |
Methotrimeprazine | Muscarinic acetylcholine receptor M2 | target |
Methotrimeprazine | Muscarinic acetylcholine receptor M3 | target |
Methotrimeprazine | Muscarinic acetylcholine receptor M4 | target |
Methotrimeprazine | Muscarinic acetylcholine receptor M5 | target |
Methotrimeprazine | Alpha-1A adrenergic receptor | target |
Methotrimeprazine | Alpha-1B adrenergic receptor | target |
Methotrimeprazine | Alpha-1D adrenergic receptor | target |
Methotrimeprazine | Cytochrome P450 2D6 | enzyme |
Methotrimeprazine | Dopamine D2 receptor | target |
Methotrimeprazine | Dopamine D1 receptor | target |
Methotrimeprazine | Dopamine D5 receptor | target |
Methotrimeprazine | Dopamine D4 receptor | target |
Methotrimeprazine | Alpha-2A adrenergic receptor | target |
Methotrimeprazine | Alpha-2B adrenergic receptor | target |
Methotrimeprazine | Alpha-2C adrenergic receptor | target |
Methotrimeprazine | 5-hydroxytryptamine receptor 2A | target |
Methotrimeprazine | 5-hydroxytryptamine receptor 2C | target |
Methotrimeprazine | Cytochrome P450 2E1 | enzyme |
gamma-Hydroxybutyric acid | Monocarboxylate transporter 2 | transporter |
gamma-Hydroxybutyric acid | Monocarboxylate transporter 1 | transporter |
gamma-Hydroxybutyric acid | Monocarboxylate transporter 4 | transporter |
gamma-Hydroxybutyric acid | Gamma-hydroxybutyrate (GHB) receptor | target |
gamma-Hydroxybutyric acid | Gamma-aminobutyric acid receptor subunit beta-1 | target |
Dihydrocodeine | Cytochrome P450 2D6 | enzyme |
Dihydrocodeine | Cytochrome P450 3A4 | enzyme |
Bromazepam | Cytochrome P450 1A2 | enzyme |
Bromazepam | Cytochrome P450 2C19 | enzyme |
Bromazepam | Cytochrome P450 2E1 | enzyme |
Bromazepam | GABA(A) Receptor | target |
Bromazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Quazepam | Cytochrome P450 2C19 | enzyme |
Quazepam | Cytochrome P450 2C9 | enzyme |
Quazepam | Cytochrome P450 3A4 | enzyme |
Quazepam | GABA(A) Receptor | target |
Quazepam | Cytochrome P450 2B6 | enzyme |
Quazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Nitrazepam | Sodium channel protein type 1 subunit alpha | target |
Nitrazepam | Cytochrome P450 3A4 | enzyme |
Nitrazepam | Cytochrome P450 2E1 | enzyme |
Nitrazepam | GABA(A) Receptor | target |
Nitrazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Thiothixene | Cytochrome P450 1A2 | enzyme |
Thiothixene | Cytochrome P450 2D6 | enzyme |
Thiothixene | Dopamine D2 receptor | target |
Thiothixene | Dopamine D1 receptor | target |
Thiothixene | 5-hydroxytryptamine receptor 2A | target |
Thiothixene | Solute carrier family 22 member 1 | transporter |
Thiothixene | Serum albumin | carrier |
Zuclopenthixol | Dopamine D1 receptor | target |
Zuclopenthixol | Dopamine D5 receptor | target |
Zuclopenthixol | Dopamine D2 receptor | target |
Zuclopenthixol | Cytochrome P450 2D6 | enzyme |
Zuclopenthixol | Alpha-1A adrenergic receptor | target |
Zuclopenthixol | Alpha-2A adrenergic receptor | target |
Zuclopenthixol | 5-hydroxytryptamine receptor 2A | target |
Zuclopenthixol | Histamine H1 receptor | target |
Zuclopenthixol | Cytochrome P450 3A4 | enzyme |
Asenapine | 5-hydroxytryptamine receptor 1A | target |
Asenapine | 5-hydroxytryptamine receptor 1B | target |
Asenapine | 5-hydroxytryptamine receptor 2A | target |
Asenapine | 5-hydroxytryptamine receptor 2B | target |
Asenapine | 5-hydroxytryptamine receptor 2C | target |
Asenapine | 5-hydroxytryptamine receptor 6 | target |
Asenapine | 5-hydroxytryptamine receptor 7 | target |
Asenapine | Alpha-2A adrenergic receptor | target |
Asenapine | Alpha-2B adrenergic receptor | target |
Asenapine | Alpha-2C adrenergic receptor | target |
Asenapine | Alpha-1A adrenergic receptor | target |
Asenapine | Dopamine D1 receptor | target |
Asenapine | Dopamine D2 receptor | target |
Asenapine | Dopamine D3 receptor | target |
Asenapine | Dopamine D4 receptor | target |
Asenapine | Histamine H1 receptor | target |
Asenapine | Histamine H2 receptor | target |
Asenapine | Cytochrome P450 1A2 | enzyme |
Asenapine | Cytochrome P450 2D6 | enzyme |
Asenapine | 5-hydroxytryptamine receptor 5A | target |
Asenapine | UDP-glucuronosyltransferase 1-4 | enzyme |
Asenapine | Cytochrome P450 3A4 | enzyme |
Asenapine | Beta-1 adrenergic receptor | target |
Asenapine | Beta-2 adrenergic receptor | target |
Asenapine | Serum albumin | carrier |
Asenapine | alpha1-acid glycoprotein | carrier |
Lurasidone | Cytochrome P450 3A4 | enzyme |
Lurasidone | Dopamine D2 receptor | target |
Lurasidone | 5-hydroxytryptamine receptor 2A | target |
Lurasidone | 5-hydroxytryptamine receptor 7 | target |
Lurasidone | 5-hydroxytryptamine receptor 1A | target |
Lurasidone | Alpha-2C adrenergic receptor | target |
Lurasidone | Alpha-2A adrenergic receptor | target |
Paraldehyde | Aldehyde dehydrogenase, mitochondrial | enzyme |
Baclofen | Gamma-aminobutyric acid type B receptor subunit 1 | target |
Baclofen | Gamma-aminobutyric acid type B receptor subunit 2 | target |
Baclofen | C-X-C chemokine receptor type 4 | target |
Butalbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Butalbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Butalbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Butalbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Butalbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Butalbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Butalbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Butalbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Butalbital | Glutamate receptor 2 | target |
Butalbital | Glutamate receptor ionotropic, kainate 2 | target |
Butalbital | GABA(A) Receptor | target |
Phenytoin | Sodium channel protein type 5 subunit alpha | target |
Phenytoin | Sodium channel protein type 1 subunit alpha | target |
Phenytoin | Cytochrome P450 2C8 | enzyme |
Phenytoin | Cytochrome P450 2C19 | enzyme |
Phenytoin | Cytochrome P450 2C9 | enzyme |
Phenytoin | Cytochrome P450 2B6 | enzyme |
Phenytoin | Cytochrome P450 3A5 | enzyme |
Phenytoin | Serum albumin | carrier |
Phenytoin | Cytochrome P450 3A4 | enzyme |
Phenytoin | Solute carrier organic anion transporter family member 1C1 | transporter |
Phenytoin | P-glycoprotein 1 | transporter |
Phenytoin | Canalicular multispecific organic anion transporter 1 | transporter |
Phenytoin | Cytochrome P450 11B1, mitochondrial | enzyme |
Phenytoin | Cytochrome P450 3A7 | enzyme |
Phenytoin | Nuclear receptor subfamily 1 group I member 2 | target |
Phenytoin | Sodium channel subunit beta-1 | target |
Phenytoin | Sodium channel protein type 3 subunit alpha | target |
Phenytoin | UDP-glucuronosyltransferase 1-1 | enzyme |
Phenytoin | UDP-glucuronosyltransferase 1-6 | enzyme |
Phenytoin | UDP-glucuronosyltransferase 1-9 | enzyme |
Phenytoin | Thyroxine-binding globulin | carrier |
Phenytoin | Potassium voltage-gated channel subfamily H member 2 | target |
Phenytoin | Voltage-dependent L-type calcium channel | target |
Phenytoin | Sodium channel protein type 2 subunit alpha | target |
Phenytoin | Sodium channel protein type 8 subunit alpha | target |
Phenytoin | GABA(A) Receptor | target |
Phenytoin | Cytochrome P450 1A2 | enzyme |
Phenytoin | Cytochrome P450 2A6 | enzyme |
Phenytoin | Cytochrome P450 2D6 | enzyme |
Phenytoin | Cytochrome P450 2E1 | enzyme |
Phenytoin | Epoxide hydrolase 1 | enzyme |
Phenytoin | UDP-glucuronosyltransferase 1-4 | enzyme |
Phenytoin | Catechol O-methyltransferase | enzyme |
Phenytoin | NAD(P)H dehydrogenase [quinone] 1 | enzyme |
Phenytoin | Cytochrome P450 2C18 | enzyme |
Topiramate | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Topiramate | Voltage-gated sodium channel alpha subunit | target |
Topiramate | Carbonic anhydrase 2 | target |
Topiramate | Carbonic anhydrase 4 | target |
Topiramate | Kainate receptors | target |
Topiramate | Cytochrome P450 2C19 | enzyme |
Topiramate | Cytochrome P450 3A4 | enzyme |
Topiramate | Carbonic anhydrase 1 | target |
Topiramate | Carbonic anhydrase 3 | target |
Topiramate | Voltage gated L-type calcium channel | target |
Topiramate | Voltage-dependent R-type calcium channel | target |
Topiramate | Serum albumin | carrier |
Topiramate | P-glycoprotein 1 | transporter |
Topiramate | 5'-AMP-activated protein kinase | transporter |
Clemastine | Histamine H1 receptor | target |
Clemastine | Cytochrome P450 2D6 | enzyme |
Amitriptyline | Sodium-dependent serotonin transporter | target |
Amitriptyline | Sodium-dependent noradrenaline transporter | target |
Amitriptyline | Potassium voltage-gated channel subfamily KQT member 2 | target |
Amitriptyline | Alpha-2A adrenergic receptor | target |
Amitriptyline | Cytochrome P450 1A2 | enzyme |
Amitriptyline | Cytochrome P450 2C19 | enzyme |
Amitriptyline | Cytochrome P450 2D6 | enzyme |
Amitriptyline | Serum albumin | carrier |
Amitriptyline | Alpha-1-acid glycoprotein 1 | carrier |
Amitriptyline | Histamine H1 receptor | target |
Amitriptyline | 5-hydroxytryptamine receptor 2A | target |
Amitriptyline | 5-hydroxytryptamine receptor 1A | target |
Amitriptyline | Alpha-1A adrenergic receptor | target |
Amitriptyline | Cytochrome P450 3A4 | enzyme |
Amitriptyline | Cytochrome P450 3A5 | enzyme |
Amitriptyline | Potassium voltage-gated channel subfamily A member 1 | target |
Amitriptyline | Alpha-1D adrenergic receptor | target |
Amitriptyline | Delta-type opioid receptor | target |
Amitriptyline | Kappa-type opioid receptor | target |
Amitriptyline | High affinity nerve growth factor receptor | target |
Amitriptyline | BDNF/NT-3 growth factors receptor | target |
Amitriptyline | Cytochrome P450 2C9 | enzyme |
Amitriptyline | Cytochrome P450 2B6 | enzyme |
Amitriptyline | Cytochrome P450 2C8 | enzyme |
Amitriptyline | Histamine H2 receptor | target |
Amitriptyline | Histamine H4 receptor | target |
Amitriptyline | Sigma non-opioid intracellular receptor 1 | target |
Amitriptyline | 5-hydroxytryptamine receptor 2C | target |
Amitriptyline | Alpha-1B adrenergic receptor | target |
Amitriptyline | 5-hydroxytryptamine receptor 7 | target |
Amitriptyline | 5-hydroxytryptamine receptor 1D | target |
Amitriptyline | Mu-type opioid receptor | target |
Amitriptyline | 5-hydroxytryptamine receptor 1B | target |
Amitriptyline | 5-hydroxytryptamine receptor 6 | target |
Amitriptyline | Potassium voltage-gated channel subfamily KQT member 3 | target |
Amitriptyline | UDP-glucuronosyltransferase 2B10 | enzyme |
Amitriptyline | 5-hydroxytryptamine receptor 1C | target |
Amitriptyline | Muscarinic acetylcholine receptor | target |
Amitriptyline | HERG human cardiac K+ channel | target |
Amitriptyline | P-glycoprotein 1 | transporter |
Amitriptyline | UDP-glucuronosyltransferase 1-4 | enzyme |
Amitriptyline | Glutathione S-transferases (Cytosolic) | enzyme |
Tolcapone | Catechol O-methyltransferase | target |
Tolcapone | Cytochrome P450 2C9 | enzyme |
Cetirizine | Histamine H1 receptor | target |
Cetirizine | P-glycoprotein 1 | transporter |
Protriptyline | Sodium-dependent noradrenaline transporter | target |
Protriptyline | Sodium-dependent serotonin transporter | target |
Protriptyline | P-glycoprotein 1 | transporter |
Clobazam | Cytochrome P450 2C19 | enzyme |
Clobazam | Cytochrome P450 3A4 | enzyme |
Clobazam | Cytochrome P450 2B6 | enzyme |
Clobazam | Cytochrome P450 2C18 | enzyme |
Clobazam | P-glycoprotein 1 | transporter |
Clobazam | GABA(A) Receptor | target |
Clobazam | Cytochrome P450 2D6 | enzyme |
Clobazam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Chlorzoxazone | Calcium-activated potassium channel subunit alpha-1 | target |
Chlorzoxazone | Cytochrome P450 2E1 | enzyme |
Chlorzoxazone | Cytochrome P450 1A2 | enzyme |
Chlorzoxazone | Cytochrome P450 2A6 | enzyme |
Chlorzoxazone | Cytochrome P450 1A1 | enzyme |
Chlorzoxazone | Cytochrome P450 2D6 | enzyme |
Chlorzoxazone | Cytochrome P450 3A4 | enzyme |
Doxylamine | Histamine H1 receptor | target |
Doxylamine | Muscarinic acetylcholine receptor | target |
Doxylamine | CYP2B protein | enzyme |
Doxylamine | Nuclear receptor subfamily 1 group I member 3 | target |
Doxylamine | Serum albumin | carrier |
Mirtazapine | 5-hydroxytryptamine receptor 2A | target |
Mirtazapine | 5HT3 serotonin receptor | target |
Mirtazapine | Alpha-2A adrenergic receptor | target |
Mirtazapine | 5-hydroxytryptamine receptor 2C | target |
Mirtazapine | Kappa-type opioid receptor | target |
Mirtazapine | Histamine H1 receptor | target |
Mirtazapine | Cytochrome P450 1A2 | enzyme |
Mirtazapine | Cytochrome P450 3A4 | enzyme |
Mirtazapine | Cytochrome P450 2D6 | enzyme |
Mirtazapine | Alpha-1 adrenergic receptors | target |
Mirtazapine | Sodium-dependent serotonin transporter | transporter |
Carisoprodol | Cytochrome P450 2C19 | enzyme |
Carisoprodol | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Carisoprodol | Gamma-aminobutyric acid receptor subunit beta-2 | target |
Carisoprodol | Gamma-aminobutyric acid receptor subunit gamma-2 | target |
Carisoprodol | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Carisoprodol | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Dexbrompheniramine | Histamine H1 receptor | target |
Methocarbamol | Carbonic anhydrase 1 | target |
Triprolidine | Histamine H1 receptor | target |
Triprolidine | Serum albumin | carrier |
Cyproheptadine | 5-hydroxytryptamine receptor 2A | target |
Cyproheptadine | Histamine H1 receptor | target |
Cyproheptadine | Muscarinic acetylcholine receptor M1 | target |
Cyproheptadine | Muscarinic acetylcholine receptor M2 | target |
Cyproheptadine | Muscarinic acetylcholine receptor M3 | target |
Cyproheptadine | 5-hydroxytryptamine receptor 2C | target |
Cyproheptadine | UDP-glucuronosyltransferase 1-3 | enzyme |
Cyproheptadine | 5-hydroxytryptamine receptor 7 | target |
Cyproheptadine | UDP-glucuronosyltransferase 2B10 | enzyme |
Cyproheptadine | UDP-glucuronosyltransferase 1-4 | enzyme |
Cyproheptadine | 5-hydroxytryptamine receptor 2B | target |
Cyproheptadine | Histamine H2 receptor | target |
Cyproheptadine | Solute carrier family 22 member 1 | transporter |
Cyproheptadine | Serum albumin | carrier |
Imipramine | Sodium-dependent noradrenaline transporter | target |
Imipramine | Sodium-dependent serotonin transporter | target |
Imipramine | Cytochrome P450 1A2 | enzyme |
Imipramine | Cytochrome P450 2C19 | enzyme |
Imipramine | Cytochrome P450 2D6 | enzyme |
Imipramine | Histamine H1 receptor | target |
Imipramine | Alpha-1A adrenergic receptor | target |
Imipramine | 5-hydroxytryptamine receptor 2A | target |
Imipramine | Muscarinic acetylcholine receptor M1 | target |
Imipramine | Muscarinic acetylcholine receptor M2 | target |
Imipramine | Muscarinic acetylcholine receptor M3 | target |
Imipramine | Muscarinic acetylcholine receptor M4 | target |
Imipramine | Muscarinic acetylcholine receptor M5 | target |
Imipramine | Potassium voltage-gated channel subfamily D member 2 | target |
Imipramine | Potassium voltage-gated channel subfamily D member 3 | target |
Imipramine | Alpha-1D adrenergic receptor | target |
Imipramine | Alpha-1-acid glycoprotein 1 | carrier |
Imipramine | Solute carrier family 22 member 2 | transporter |
Imipramine | Solute carrier family 22 member 3 | transporter |
Imipramine | P-glycoprotein 1 | transporter |
Imipramine | Solute carrier family 22 member 4 | transporter |
Imipramine | Cytochrome P450 3A4 | enzyme |
Imipramine | Cytochrome P450 2B6 | enzyme |
Imipramine | Cytochrome P450 2C18 | enzyme |
Imipramine | Cytochrome P450 2E1 | enzyme |
Imipramine | Cytochrome P450 3A7 | enzyme |
Imipramine | 5-hydroxytryptamine receptor 2C | target |
Imipramine | Alpha-1B adrenergic receptor | target |
Imipramine | 5-hydroxytryptamine receptor 7 | target |
Imipramine | D(1) dopamine receptor | target |
Imipramine | Dopamine D2 receptor | target |
Imipramine | Potassium voltage-gated channel subfamily H member 2 | target |
Imipramine | Sodium-dependent dopamine transporter | target |
Imipramine | 5-hydroxytryptamine receptor 1A | target |
Imipramine | 5-hydroxytryptamine receptor 6 | target |
Imipramine | Potassium voltage-gated channel subfamily H member 1 | target |
Imipramine | Serum albumin | carrier |
Imipramine | Alpha-1-acid glycoprotein 2 | target |
Brimonidine | Alpha-2A adrenergic receptor | target |
Brimonidine | Alpha-2B adrenergic receptor | target |
Brimonidine | Alpha-2C adrenergic receptor | target |
Brimonidine | Aldehyde oxidase | enzyme |
Entacapone | Catechol O-methyltransferase | target |
Entacapone | Catechol O-methyltransferase | enzyme |
Entacapone | UDP-glucuronosyltransferase 1-9 | enzyme |
Entacapone | Cytochrome P450 2D6 | enzyme |
Nortriptyline | Sodium-dependent serotonin transporter | target |
Nortriptyline | Sodium-dependent noradrenaline transporter | target |
Nortriptyline | Cytochrome P450 1A2 | enzyme |
Nortriptyline | Cytochrome P450 2D6 | enzyme |
Nortriptyline | Serum albumin | carrier |
Nortriptyline | Alpha-1-acid glycoprotein 1 | carrier |
Nortriptyline | Histamine H1 receptor | target |
Nortriptyline | 5-hydroxytryptamine receptor 2A | target |
Nortriptyline | Alpha-1A adrenergic receptor | target |
Nortriptyline | 5-hydroxytryptamine receptor 1A | target |
Nortriptyline | Cytochrome P450 3A4 | enzyme |
Nortriptyline | Cytochrome P450 3A5 | enzyme |
Nortriptyline | Alpha-1D adrenergic receptor | target |
Nortriptyline | Cytochrome P450 2C19 | enzyme |
Nortriptyline | Cytochrome P450 2E1 | enzyme |
Nortriptyline | 5-hydroxytryptamine receptor 2C | target |
Nortriptyline | Alpha-1B adrenergic receptor | target |
Nortriptyline | Alpha-2 adrenergic receptors | target |
Nortriptyline | Beta adrenergic receptor | target |
Nortriptyline | Dopamine D2 receptor | target |
Nortriptyline | Sigma receptor | target |
Nortriptyline | 5-hydroxytryptamine receptor 1C | target |
Nortriptyline | Sodium-dependent noradrenaline transporter | transporter |
Nortriptyline | Muscarinic acetylcholine receptor | target |
Nortriptyline | P-glycoprotein 1 | transporter |
Amoxapine | Sodium-dependent serotonin transporter | target |
Amoxapine | Sodium-dependent noradrenaline transporter | target |
Amoxapine | Alpha-2A adrenergic receptor | target |
Amoxapine | Dopamine D2 receptor | target |
Amoxapine | Alpha-1A adrenergic receptor | target |
Amoxapine | Dopamine D1 receptor | target |
Amoxapine | Muscarinic acetylcholine receptor M1 | target |
Amoxapine | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Amoxapine | Alpha-1-acid glycoprotein 1 | carrier |
Amoxapine | Cytochrome P450 2D6 | enzyme |
Amoxapine | 5-hydroxytryptamine receptor 2A | target |
Amoxapine | 5-hydroxytryptamine receptor 2C | target |
Amoxapine | 5-hydroxytryptamine receptor 6 | target |
Amoxapine | 5-hydroxytryptamine receptor 7 | target |
Amoxapine | Dopamine D3 receptor | target |
Amoxapine | Dopamine D4 receptor | target |
Amoxapine | Histamine H1 receptor | target |
Amoxapine | Alpha-1 adrenergic receptors | target |
Amoxapine | Muscarinic acetylcholine receptor | target |
Amoxapine | 5-hydroxytryptamine receptor 2B | target |
Amoxapine | 5-hydroxytryptamine receptor 3A | target |
Amoxapine | 5-hydroxytryptamine receptor 1A | target |
Amoxapine | 5-hydroxytryptamine receptor 1B | target |
Amoxapine | Alpha-2 adrenergic receptors | target |
Amoxapine | Histamine H4 receptor | target |
Amoxapine | GABA(A) Receptor | target |
Amoxapine | Sodium-dependent dopamine transporter | target |
Lamotrigine | Voltage-gated sodium channel alpha subunit | target |
Lamotrigine | UDP-glucuronosyltransferases (UGTs) | enzyme |
Lamotrigine | P-glycoprotein 1 | transporter |
Lamotrigine | Dihydrofolate reductase | enzyme |
Lamotrigine | 5-hydroxytryptamine receptor 3A | target |
Lamotrigine | Voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E) | target |
Lamotrigine | Adenosine receptor A1 | target |
Lamotrigine | Adenosine receptor A2a | target |
Lamotrigine | Alpha-1A adrenergic receptor | target |
Lamotrigine | Alpha-2A adrenergic receptor | target |
Lamotrigine | Beta-1 adrenergic receptor | target |
Lamotrigine | D(1) dopamine receptor | target |
Lamotrigine | Dopamine D2 receptor | target |
Lamotrigine | GABA(A) Receptor | target |
Lamotrigine | GABA(A) Receptor Benzodiazepine Binding Site | target |
Lamotrigine | Histamine H1 receptor | target |
Lamotrigine | Kappa-type opioid receptor | target |
Lamotrigine | Acetylcholine receptor subunit alpha | target |
Lamotrigine | 5-hydroxytryptamine receptor 2A | target |
Lamotrigine | Solute carrier family 22 member 2 | transporter |
Lamotrigine | Serum albumin | carrier |
Lamotrigine | Solute carrier family 22 member 1 | transporter |
Lamotrigine | Glutamate receptor 1 | target |
Hydroxyzine | Histamine H1 receptor | target |
Hydroxyzine | Cytochrome P450 2D6 | enzyme |
Hydroxyzine | Cytochrome P450 3A4 | enzyme |
Hydroxyzine | Cytochrome P450 3A5 | enzyme |
Hydroxyzine | Potassium voltage-gated channel subfamily H member 2 | target |
Hydroxyzine | P-glycoprotein 1 | transporter |
Hydroxyzine | Serum albumin | carrier |
Clonidine | Alpha-2A adrenergic receptor | target |
Clonidine | Cytochrome P450 2D6 | enzyme |
Clonidine | Alpha-2B adrenergic receptor | target |
Clonidine | Alpha-2C adrenergic receptor | target |
Clonidine | Solute carrier family 22 member 3 | transporter |
Clonidine | Solute carrier family 22 member 5 | transporter |
Clonidine | Solute carrier family 22 member 4 | transporter |
Clonidine | Cytochrome P450 1A2 | enzyme |
Clonidine | Cytochrome P450 3A4 | enzyme |
Clonidine | Cytochrome P450 1A1 | enzyme |
Clonidine | Cytochrome P450 3A5 | enzyme |
Clonidine | Alpha-1A adrenergic receptor | target |
Clonidine | Alpha-1B adrenergic receptor | target |
Clonidine | Alpha-1D adrenergic receptor | target |
Clonidine | Serum albumin | carrier |
Fluticasone propionate | Corticosteroid-binding globulin | carrier |
Fluticasone propionate | Cytosolic phospholipase A2 | target |
Fluticasone propionate | Glucocorticoid receptor | target |
Fluticasone propionate | Cytochrome P450 3A4 | enzyme |
Fluticasone propionate | Progesterone receptor | target |
Fluticasone propionate | Mineralocorticoid receptor | target |
Fluticasone propionate | Cytochrome P450 3A5 | enzyme |
Fluticasone propionate | Cytochrome P450 3A7 | enzyme |
Fluticasone propionate | Cytochrome P450 2C8 | enzyme |
Fluticasone propionate | Solute carrier organic anion transporter family member 1B1 | carrier |
Fluticasone propionate | P-glycoprotein 1 | transporter |
Fluticasone propionate | Solute carrier organic anion transporter family member 1B1 | transporter |
Ethosuximide | Voltage-dependent T-type calcium channel subunit alpha-1G | target |
Ethosuximide | Cytochrome P450 3A4 | enzyme |
Ethosuximide | Cytochrome P450 2E1 | enzyme |
Ethosuximide | Cytochrome P450 3A Subfamily | enzyme |
Efavirenz | Cytochrome P450 2B6 | enzyme |
Efavirenz | Cytochrome P450 3A4 | enzyme |
Efavirenz | Cytochrome P450 2C19 | enzyme |
Efavirenz | Cytochrome P450 2C9 | enzyme |
Efavirenz | Cytochrome P450 1A2 | enzyme |
Efavirenz | Cytochrome P450 2D6 | enzyme |
Efavirenz | Reverse transcriptase/RNaseH | target |
Efavirenz | Cytochrome P450 2C8 | enzyme |
Efavirenz | Serum albumin | carrier |
Efavirenz | Cytochrome P450 3A5 | enzyme |
Efavirenz | Cytochrome P450 3A7 | enzyme |
Efavirenz | UDP-glucuronosyltransferase 1-1 | enzyme |
Efavirenz | Bile salt export pump | transporter |
Efavirenz | Solute carrier family 22 member 1 | transporter |
Tizanidine | Alpha-2 adrenergic receptors | target |
Tizanidine | Cytochrome P450 1A2 | enzyme |
Tizanidine | Nischarin | target |
Tizanidine | Alpha-1 adrenergic receptors | target |
Trimipramine | Sodium-dependent serotonin transporter | target |
Trimipramine | Sodium-dependent noradrenaline transporter | target |
Trimipramine | Cytochrome P450 2D6 | enzyme |
Trimipramine | Sodium-dependent dopamine transporter | target |
Trimipramine | 5-hydroxytryptamine receptor 2A | target |
Trimipramine | 5-hydroxytryptamine receptor 1A | target |
Trimipramine | Alpha-1A adrenergic receptor | target |
Trimipramine | Alpha-1B adrenergic receptor | target |
Trimipramine | Dopamine D2 receptor | target |
Trimipramine | Alpha-2B adrenergic receptor | target |
Trimipramine | Histamine H1 receptor | target |
Trimipramine | Cytochrome P450 2C19 | enzyme |
Trimipramine | P-glycoprotein 1 | transporter |
Trimipramine | Cytochrome P450 2C9 | enzyme |
Trimipramine | 5-hydroxytryptamine receptor 2C | target |
Trimipramine | 5-hydroxytryptamine receptor 3A | target |
Trimipramine | 5-hydroxytryptamine receptor 1D | target |
Trimipramine | Alpha-2A adrenergic receptor | target |
Trimipramine | D(1) dopamine receptor | target |
Trimipramine | Beta adrenergic receptor | target |
Trimipramine | Muscarinic acetylcholine receptor | target |
Trimipramine | 5-hydroxytryptamine receptor 1C | target |
Meclizine | Histamine H1 receptor | target |
Meclizine | Nuclear receptor subfamily 1 group I member 3 | target |
Meclizine | Cytochrome P450 2D6 | enzyme |
Meclizine | Serum albumin | carrier |
Scopolamine | Muscarinic acetylcholine receptor M1 | target |
Scopolamine | Sucrase-isomaltase, intestinal | target |
Scopolamine | Muscarinic acetylcholine receptor M2 | target |
Scopolamine | Muscarinic acetylcholine receptor M3 | target |
Scopolamine | Muscarinic acetylcholine receptor M4 | target |
Scopolamine | Muscarinic acetylcholine receptor M5 | target |
Scopolamine | Neuronal acetylcholine receptor subunit alpha-4 | target |
Scopolamine | Neuronal acetylcholine receptor subunit beta-2 | target |
Scopolamine | Cytochrome P450 3A4 | enzyme |
Carbinoxamine | Histamine H1 receptor | target |
Carbinoxamine | alpha1-acid glycoprotein | carrier |
Ethotoin | Sodium channel protein type 5 subunit alpha | target |
Ethotoin | Nuclear receptor subfamily 1 group I member 2 | target |
Ethotoin | Thyroxine-binding globulin | carrier |
Olopatadine | Histamine H1 receptor | target |
Olopatadine | Protein S100-A1 | target |
Olopatadine | Protein S100-A12 | target |
Olopatadine | Protein S100-B | target |
Olopatadine | Protein S100-A13 | target |
Olopatadine | Protein S100-A2 | target |
Olopatadine | Cytochrome P450 3A4 | enzyme |
Olopatadine | Serum albumin | carrier |
Olopatadine | Dimethylaniline monooxygenase [N-oxide-forming] 1 | enzyme |
Olopatadine | Dimethylaniline monooxygenase [N-oxide-forming] 3 | enzyme |
Olopatadine | P-glycoprotein 1 | transporter |
Olopatadine | Histamine H2 receptor | target |
Olopatadine | Histamine H3 receptor | target |
Clidinium | Muscarinic acetylcholine receptor M1 | target |
Primidone | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Primidone | Cytochrome P450 2C19 | enzyme |
Primidone | Cytochrome P450 2C9 | enzyme |
Primidone | Cytochrome P450 3A4 | enzyme |
Primidone | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Primidone | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Primidone | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Primidone | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Primidone | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Primidone | Neuronal acetylcholine receptor subunit alpha-4 | target |
Primidone | Neuronal acetylcholine receptor subunit alpha-7 | target |
Primidone | Glutamate receptor 2 | target |
Primidone | Glutamate receptor ionotropic, kainate 2 | target |
Primidone | GABA(A) Receptor | target |
Primidone | Transient receptor potential cation channel subfamily M member 3 | transporter |
Primidone | Cytochrome P450 2E1 | enzyme |
Primidone | Cytochrome P450 1A2 | enzyme |
Primidone | UDP-glucuronosyltransferases (UGTs) | enzyme |
Brompheniramine | Histamine H1 receptor | target |
Brompheniramine | Muscarinic acetylcholine receptor M1 | target |
Brompheniramine | Muscarinic acetylcholine receptor M2 | target |
Brompheniramine | Muscarinic acetylcholine receptor M3 | target |
Brompheniramine | Muscarinic acetylcholine receptor M4 | target |
Brompheniramine | Muscarinic acetylcholine receptor M5 | target |
Tiagabine | Sodium- and chloride-dependent GABA transporter 1 | target |
Tiagabine | Cytochrome P450 3A4 | enzyme |
Tiagabine | UDP-glucuronosyltransferase 1-1 | enzyme |
Zonisamide | Sodium channel protein type 1 subunit alpha | target |
Zonisamide | Carbonic anhydrase 1 | target |
Zonisamide | Voltage-dependent T-type calcium channel subunit alpha-1G | target |
Zonisamide | Cytochrome P450 3A4 | enzyme |
Zonisamide | Aldehyde oxidase | enzyme |
Zonisamide | Amine oxidase [flavin-containing] B | target |
Zonisamide | Carbonic anhydrase 2 | target |
Zonisamide | Carbonic anhydrase 3 | target |
Zonisamide | Carbonic anhydrase 4 | target |
Zonisamide | Carbonic anhydrase 5A, mitochondrial | target |
Zonisamide | Carbonic anhydrase 5B, mitochondrial | target |
Zonisamide | Carbonic anhydrase 6 | target |
Zonisamide | Carbonic anhydrase 7 | target |
Zonisamide | Carbonic anhydrase-related protein | target |
Zonisamide | Carbonic anhydrase 9 | target |
Zonisamide | Carbonic anhydrase-related protein 10 | target |
Zonisamide | Carbonic anhydrase-related protein 11 | target |
Zonisamide | Carbonic anhydrase 12 | target |
Zonisamide | Carbonic anhydrase 13 | target |
Zonisamide | Carbonic anhydrase 14 | target |
Zonisamide | Voltage-dependent T-type calcium channel subunit alpha-1H | target |
Zonisamide | Voltage-dependent T-type calcium channel subunit alpha-1I | target |
Zonisamide | Sodium channel protein type 2 subunit alpha | target |
Zonisamide | Sodium channel protein type 3 subunit alpha | target |
Zonisamide | Sodium channel protein type 4 subunit alpha | target |
Zonisamide | Sodium channel protein type 5 subunit alpha | target |
Zonisamide | Sodium channel protein type 9 subunit alpha | target |
Zonisamide | Sodium channel protein type 11 subunit alpha | target |
Zonisamide | Sodium channel subunit beta-1 | target |
Zonisamide | Sodium channel subunit beta-2 | target |
Zonisamide | Sodium channel subunit beta-3 | target |
Zonisamide | Sodium channel subunit beta-4 | target |
Zonisamide | Amine oxidase [flavin-containing] A | target |
Zonisamide | Cytochrome P450 2C19 | enzyme |
Zonisamide | UDP-glucuronosyltransferase 1-1 | enzyme |
Zonisamide | Cytochrome P450 3A5 | enzyme |
Zonisamide | P-glycoprotein 1 | transporter |
Zonisamide | GABA(A) Receptor Benzodiazepine Binding Site | target |
Maprotiline | Histamine H1 receptor | target |
Maprotiline | Sodium-dependent noradrenaline transporter | target |
Maprotiline | Alpha-1 adrenergic receptors | target |
Maprotiline | Cytochrome P450 2D6 | enzyme |
Maprotiline | Alpha-1-acid glycoprotein 1 | carrier |
Maprotiline | Muscarinic acetylcholine receptor M1 | target |
Maprotiline | Muscarinic acetylcholine receptor M2 | target |
Maprotiline | Muscarinic acetylcholine receptor M3 | target |
Maprotiline | Muscarinic acetylcholine receptor M4 | target |
Maprotiline | Muscarinic acetylcholine receptor M5 | target |
Maprotiline | Cytochrome P450 1A2 | enzyme |
Maprotiline | 5-hydroxytryptamine receptor 2A | target |
Maprotiline | 5-hydroxytryptamine receptor 2C | target |
Maprotiline | 5-hydroxytryptamine receptor 7 | target |
Maprotiline | Dopamine D2 receptor | target |
Maprotiline | Alpha-2 adrenergic receptors | target |
Felbamate | Glutamate receptor ionotropic, NMDA 2B | target |
Felbamate | Glutamate receptor ionotropic, NMDA 2A | target |
Felbamate | Cytochrome P450 2C19 | enzyme |
Felbamate | Cytochrome P450 3A4 | enzyme |
Felbamate | Cytochrome P450 2E1 | enzyme |
Felbamate | Cytochrome P450 2C9 | enzyme |
Desloratadine | Histamine H1 receptor | target |
Desloratadine | P-glycoprotein 1 | transporter |
Azelastine | Histamine H1 receptor | target |
Azelastine | Cytochrome P450 1A2 | enzyme |
Azelastine | Cytochrome P450 2D6 | enzyme |
Azelastine | Cytochrome P450 3A4 | enzyme |
Azelastine | Cytochrome P450 2C19 | enzyme |
Azelastine | Cytochrome P450 1A1 | enzyme |
Azelastine | Cytochrome P450 3A5 | enzyme |
Azelastine | Cytochrome P450 2C9 | enzyme |
Azelastine | Cytochrome P450 2C8 | enzyme |
Azelastine | P-glycoprotein 1 | transporter |
Azelastine | Cytochrome P450 2A6 | enzyme |
Azelastine | Cytochrome P450 2E1 | enzyme |
Azelastine | Histamine H2 receptor | target |
Azelastine | Phospholipase A2 | target |
Azelastine | Leukotriene C4 synthase | target |
Azelastine | Cytochrome P450 2B6 | enzyme |
Dimenhydrinate | Histamine H1 receptor | target |
Guanfacine | Alpha-2A adrenergic receptor | target |
Guanfacine | Cytochrome P450 2C19 | enzyme |
Guanfacine | Cytochrome P450 3A4 | enzyme |
Guanfacine | Alpha-2B adrenergic receptor | target |
Guanfacine | Multidrug and toxin extrusion protein 1 | transporter |
Guanfacine | Solute carrier family 22 member 1 | transporter |
Guanfacine | Solute carrier family 22 member 2 | transporter |
Thalidomide | Cytochrome P450 2C19 | enzyme |
Thalidomide | Cytochrome P450 2C9 | enzyme |
Thalidomide | Prostaglandin G/H synthase 1 | enzyme |
Thalidomide | Prostaglandin G/H synthase 2 | enzyme |
Thalidomide | Cytochrome P450 3A5 | enzyme |
Thalidomide | DNA | target |
Thalidomide | Protein cereblon | target |
Thalidomide | alpha1-acid glycoprotein | target |
Thalidomide | Cytochrome P450 3A4 | enzyme |
Thalidomide | Cytochrome P450 1A1 | enzyme |
Thalidomide | Cytochrome P450 2B6 | enzyme |
Clonazepam | Cytochrome P450 3A4 | enzyme |
Clonazepam | Serum albumin | carrier |
Clonazepam | Cytochrome P450 2E1 | enzyme |
Clonazepam | Arylamine N-acetyltransferase 2 | enzyme |
Clonazepam | GABA(A) Receptor | target |
Clonazepam | Nuclear receptor subfamily 1 group I member 2 | target |
Clonazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Promethazine | Dopamine D2 receptor | target |
Promethazine | Histamine H1 receptor | target |
Promethazine | Muscarinic acetylcholine receptor M4 | target |
Promethazine | Muscarinic acetylcholine receptor M1 | target |
Promethazine | Muscarinic acetylcholine receptor M5 | target |
Promethazine | Muscarinic acetylcholine receptor M2 | target |
Promethazine | Muscarinic acetylcholine receptor M3 | target |
Promethazine | Calmodulin | target |
Promethazine | Cytochrome P450 2D6 | enzyme |
Promethazine | Cytochrome P450 2B6 | enzyme |
Promethazine | P-glycoprotein 1 | transporter |
Promethazine | Cytochrome P450 2C9 | enzyme |
Promethazine | Histamine H2 receptor | target |
Promethazine | Alpha adrenergic receptor | target |
Promethazine | P2 Purinoceptors | target |
Promethazine | Voltage-gated sodium channel alpha subunit | target |
Promethazine | Voltage-gated Potassium Channels | target |
Promethazine | Canalicular multispecific organic anion transporter 2 | transporter |
Promethazine | Multidrug resistance-associated protein 4 | transporter |
Promethazine | Serum albumin | carrier |
Vigabatrin | 4-aminobutyrate aminotransferase, mitochondrial | target |
Vigabatrin | Proton-coupled amino acid transporter 1 | transporter |
Vigabatrin | Cytochrome P450 2C9 | enzyme |
Levocabastine | Neurotensin receptor type 2 | target |
Levocabastine | Histamine H1 receptor | target |
Chlorpheniramine | Histamine H1 receptor | target |
Chlorpheniramine | Cytochrome P450 3A4 | enzyme |
Chlorpheniramine | Cytochrome P450 2D6 | enzyme |
Chlorpheniramine | Sodium-dependent serotonin transporter | target |
Chlorpheniramine | Sodium-dependent noradrenaline transporter | target |
Chlorpheniramine | Sodium-dependent dopamine transporter | target |
Chlorpheniramine | Cytochrome P450 3A5 | enzyme |
Chlorpheniramine | Cytochrome P450 3A7 | enzyme |
Chlorpheniramine | Solute carrier family 22 member 2 | transporter |
Chlorpheniramine | Solute carrier family 22 member 1 | transporter |
Doxepin | Sodium-dependent serotonin transporter | target |
Doxepin | Sodium-dependent noradrenaline transporter | target |
Doxepin | Histamine H1 receptor | target |
Doxepin | Histamine H2 receptor | target |
Doxepin | Cytochrome P450 2D6 | enzyme |
Doxepin | Muscarinic acetylcholine receptor M1 | target |
Doxepin | Muscarinic acetylcholine receptor M2 | target |
Doxepin | Muscarinic acetylcholine receptor M3 | target |
Doxepin | Muscarinic acetylcholine receptor M4 | target |
Doxepin | Muscarinic acetylcholine receptor M5 | target |
Doxepin | Alpha-1A adrenergic receptor | target |
Doxepin | 5-hydroxytryptamine receptor 1A | target |
Doxepin | 5-hydroxytryptamine receptor 2A | target |
Doxepin | Cytochrome P450 2C19 | enzyme |
Doxepin | Cytochrome P450 2C9 | enzyme |
Doxepin | Cytochrome P450 1A2 | enzyme |
Doxepin | P-glycoprotein 1 | transporter |
Doxepin | 5-hydroxytryptamine receptor 2B | target |
Doxepin | 5-hydroxytryptamine receptor 2C | target |
Doxepin | Alpha-1B adrenergic receptor | target |
Doxepin | Alpha-1D adrenergic receptor | target |
Doxepin | Cytochrome P450 3A4 | enzyme |
Doxepin | 5-hydroxytryptamine receptor 6 | target |
Doxepin | Histamine H4 receptor | target |
Doxepin | Potassium voltage-gated channel subfamily H member 2 | target |
Doxepin | Serum albumin | carrier |
Doxepin | Alpha-1-acid glycoprotein 1 | carrier |
Desipramine | Muscarinic acetylcholine receptor M1 | target |
Desipramine | Sodium-dependent noradrenaline transporter | target |
Desipramine | Beta-2 adrenergic receptor | target |
Desipramine | Muscarinic acetylcholine receptor M2 | target |
Desipramine | Sodium-dependent serotonin transporter | target |
Desipramine | Histamine H1 receptor | target |
Desipramine | Beta-1 adrenergic receptor | target |
Desipramine | Cytochrome P450 2D6 | enzyme |
Desipramine | Muscarinic acetylcholine receptor M3 | target |
Desipramine | Muscarinic acetylcholine receptor M4 | target |
Desipramine | Muscarinic acetylcholine receptor M5 | target |
Desipramine | Alpha-1 adrenergic receptors | target |
Desipramine | 5-hydroxytryptamine receptor 2A | target |
Desipramine | Alpha-1-acid glycoprotein 1 | carrier |
Desipramine | Cytochrome P450 2B6 | enzyme |
Desipramine | Cytochrome P450 3A4 | enzyme |
Desipramine | Solute carrier family 22 member 2 | transporter |
Desipramine | Solute carrier family 22 member 1 | transporter |
Desipramine | Solute carrier family 22 member 3 | transporter |
Desipramine | Solute carrier family 22 member 5 | transporter |
Desipramine | P-glycoprotein 1 | transporter |
Desipramine | Solute carrier family 22 member 4 | transporter |
Desipramine | Cytochrome P450 1A2 | enzyme |
Desipramine | Cytochrome P450 2E1 | enzyme |
Desipramine | Sphingomyelin phosphodiesterase | target |
Desipramine | 5-hydroxytryptamine receptor 1A | target |
Desipramine | 5-hydroxytryptamine receptor 2C | target |
Desipramine | Dopamine D2 receptor | target |
Desipramine | Alpha-2 adrenergic receptors | target |
Orphenadrine | Glutamate receptor ionotropic, NMDA 1 | target |
Orphenadrine | Glutamate receptor ionotropic, NMDA 2D | target |
Orphenadrine | Glutamate receptor ionotropic, NMDA 3B | target |
Orphenadrine | Glutamate receptor ionotropic, NMDA 3A | target |
Orphenadrine | Histamine H1 receptor | target |
Orphenadrine | Cytochrome P450 2B6 | enzyme |
Orphenadrine | Cytochrome P450 2E1 | enzyme |
Orphenadrine | Cytochrome P450 3A4 | enzyme |
Orphenadrine | Sodium-dependent noradrenaline transporter | target |
Orphenadrine | Sodium channel protein type 10 subunit alpha | target |
Orphenadrine | Cytochrome P450 1A2 | enzyme |
Orphenadrine | Cytochrome P450 2D6 | enzyme |
Orphenadrine | Serum albumin | carrier |
Cyclizine | Histamine H1 receptor | target |
Cyclizine | Estrogen sulfotransferase | target |
Cyclizine | Cytochrome P450 2C9 | enzyme |
Cyclizine | Serum albumin | carrier |
Levetiracetam | Synaptic vesicle glycoprotein 2A | target |
Levetiracetam | P-glycoprotein 1 | transporter |
Levetiracetam | Voltage-dependent N-type calcium channel subunit alpha-1B | target |
Dantrolene | Ryanodine receptor 1 | target |
Dantrolene | Thyroxine-binding globulin | carrier |
Levodopa | Dopamine D1 receptor | target |
Levodopa | Dopamine D2 receptor | target |
Levodopa | Aromatic-L-amino-acid decarboxylase | enzyme |
Levodopa | Solute carrier family 15 member 1 | transporter |
Levodopa | Monocarboxylate transporter 10 | transporter |
Levodopa | Dopamine D3 receptor | target |
Levodopa | Dopamine D4 receptor | target |
Levodopa | Dopamine D5 receptor | target |
Levodopa | Large neutral amino acids transporter small subunit 1 | transporter |
Levodopa | Large neutral amino acids transporter small subunit 2 | transporter |
Levodopa | Serum albumin | carrier |
Clomipramine | Sodium-dependent serotonin transporter | target |
Clomipramine | Sodium-dependent noradrenaline transporter | target |
Clomipramine | Glutathione S-transferase P | target |
Clomipramine | 5-hydroxytryptamine receptor 2A | target |
Clomipramine | Cytochrome P450 1A2 | enzyme |
Clomipramine | Cytochrome P450 2D6 | enzyme |
Clomipramine | Cytochrome P450 2C19 | enzyme |
Clomipramine | P-glycoprotein 1 | transporter |
Clomipramine | Cytochrome P450 3A4 | enzyme |
Clomipramine | 5-hydroxytryptamine receptor 2B | target |
Clomipramine | 5-hydroxytryptamine receptor 2C | target |
Clomipramine | Serum albumin | carrier |
Fosphenytoin | Sodium channel protein type 5 subunit alpha | target |
Fosphenytoin | Cytochrome P450 2C19 | enzyme |
Fosphenytoin | Cytochrome P450 2B6 | enzyme |
Fosphenytoin | Cytochrome P450 2C9 | enzyme |
Fosphenytoin | Cytochrome P450 3A4 | enzyme |
Fosphenytoin | Serum albumin | carrier |
Fosphenytoin | Cytochrome P450 1A2 | enzyme |
Fosphenytoin | UDP-glucuronosyltransferase 1-6 | enzyme |
Fosphenytoin | UDP-glucuronosyltransferase 1-9 | enzyme |
Fosphenytoin | Thyroxine-binding globulin | carrier |
Pipotiazine | Cytochrome P450 2D6 | enzyme |
Pipotiazine | Cytochrome P450 3A4 | enzyme |
Pipotiazine | Dopamine D2 receptor | target |
Pipotiazine | Dopamine D1 receptor | target |
Pipotiazine | 5-hydroxytryptamine receptor 2A | target |
Pipotiazine | 5-hydroxytryptamine receptor 1A | target |
Pipotiazine | Solute carrier family 22 member 1 | transporter |
Pipotiazine | Serum albumin | carrier |
Pipotiazine | Cytochrome P450 2C19 | enzyme |
Flunarizine | Histamine H1 receptor | target |
Flunarizine | Voltage-dependent T-type calcium channel subunit alpha-1G | target |
Flunarizine | Voltage-dependent T-type calcium channel subunit alpha-1H | target |
Flunarizine | Voltage-dependent T-type calcium channel subunit alpha-1I | target |
Flunarizine | Calmodulin | target |
Flunarizine | Cytochrome P450 2D6 | enzyme |
Flunarizine | Cytochrome P450 2C9 | enzyme |
Flunarizine | Cytochrome P450 1A1 | enzyme |
Flunarizine | Cytochrome P450 1A2 | enzyme |
Flunarizine | Cytochrome P450 2A6 | enzyme |
Flunarizine | Cytochrome P450 3A4 | enzyme |
Flibanserin | 5-hydroxytryptamine receptor 1A | target |
Flibanserin | 5-hydroxytryptamine receptor 2A | target |
Flibanserin | Dopamine D4 receptor | target |
Flibanserin | Cytochrome P450 3A4 | enzyme |
Flibanserin | P-glycoprotein 1 | transporter |
Iloperidone | Dopamine D2 receptor | target |
Iloperidone | 5-hydroxytryptamine receptor 2A | target |
Iloperidone | Cytochrome P450 2D6 | enzyme |
Iloperidone | Cytochrome P450 3A4 | enzyme |
Iloperidone | Cytochrome P450 3A5 | enzyme |
Iloperidone | Cytochrome P450 3A7 | enzyme |
Iloperidone | Cytochrome P450 2E1 | enzyme |
Iloperidone | Dopamine D3 receptor | target |
Iloperidone | Alpha-1A adrenergic receptor | target |
Iloperidone | Dopamine D4 receptor | target |
Iloperidone | 5-hydroxytryptamine receptor 6 | target |
Iloperidone | 5-hydroxytryptamine receptor 7 | target |
Iloperidone | Histamine H1 receptor | target |
Iloperidone | Dopamine D1 receptor | target |
Iloperidone | 5-hydroxytryptamine receptor 1A | target |
Iloperidone | Alpha-2C adrenergic receptor | target |
Ezogabine | Potassium voltage-gated channel subfamily KQT member 2 | target |
Ezogabine | Potassium voltage-gated channel subfamily KQT member 3 | target |
Ezogabine | Potassium voltage-gated channel subfamily KQT member 4 | target |
Ezogabine | Potassium voltage-gated channel subfamily KQT member 5 | target |
Ezogabine | UDP-glucuronosyltransferase 1-1 | enzyme |
Ezogabine | UDP-glucuronosyltransferase 1-3 | enzyme |
Ezogabine | UDP-glucuronosyltransferase 1-4 | enzyme |
Ezogabine | UDP-glucuronosyltransferase 1-9 | enzyme |
Ezogabine | Arylamine N-acetyltransferase 2 | enzyme |
Methsuximide | Cytochrome P450 2C19 | enzyme |
Methsuximide | Voltage-dependent T-type calcium channel subunit alpha-1G | target |
Pizotifen | Muscarinic acetylcholine receptor M2 | target |
Pizotifen | Muscarinic acetylcholine receptor M1 | target |
Pizotifen | Muscarinic acetylcholine receptor M3 | target |
Pizotifen | 5-hydroxytryptamine receptor 2A | target |
Pizotifen | 5-hydroxytryptamine receptor 2B | target |
Pizotifen | 5-hydroxytryptamine receptor 2C | target |
Pizotifen | Histamine H1 receptor | target |
Pizotifen | 5-hydroxytryptamine receptor 1A | target |
Pizotifen | 5-hydroxytryptamine receptor 1B | target |
Pizotifen | Alpha-1A adrenergic receptor | target |
Pizotifen | Alpha-1B adrenergic receptor | target |
Pizotifen | Alpha-1D adrenergic receptor | target |
Pizotifen | Alpha-2A adrenergic receptor | target |
Pizotifen | Alpha-2B adrenergic receptor | target |
Pizotifen | Alpha-2C adrenergic receptor | target |
Pizotifen | UDP-glucuronosyltransferase 2B10 | enzyme |
Tapentadol | Mu-type opioid receptor | target |
Tapentadol | Kappa-type opioid receptor | target |
Tapentadol | Delta-type opioid receptor | target |
Tapentadol | Sodium-dependent noradrenaline transporter | target |
Tapentadol | 5-hydroxytryptamine receptor 3A | target |
Tapentadol | UDP-glucuronosyltransferase 1-9 | enzyme |
Tapentadol | UDP-glucuronosyltransferase 2B7 | enzyme |
Tapentadol | Cytochrome P450 2D6 | enzyme |
Tapentadol | Cytochrome P450 2C9 | enzyme |
Tapentadol | Cytochrome P450 2C19 | enzyme |
Tapentadol | Sodium-dependent serotonin transporter | target |
Levocetirizine | Histamine H1 receptor | target |
Levocetirizine | Solute carrier family 22 member 11 | transporter |
Levocetirizine | Cytochrome P450 3A4 | enzyme |
Levocetirizine | Serum albumin | carrier |
Ziconotide | Voltage-dependent N-type calcium channel subunit alpha-1B | target |
Ziconotide | Voltage-dependent P/Q-type calcium channel subunit alpha-1A | target |
Gabapentin enacarbil | Voltage-dependent calcium channel subunit alpha-2/delta-1 | target |
Gabapentin enacarbil | Voltage-dependent calcium channel subunit alpha-2/delta-2 | target |
Gabapentin enacarbil | Sodium-coupled monocarboxylate transporter 1 | transporter |
Gabapentin enacarbil | Sodium-dependent multivitamin transporter | transporter |
Perampanel | Glutamate receptor 1 | target |
Perampanel | Cytochrome P450 3A4 | enzyme |
Perampanel | Cytochrome P450 3A5 | enzyme |
Perampanel | Cytochrome P450 1A2 | enzyme |
Perampanel | Cytochrome P450 2B6 | enzyme |
Pomalidomide | Cytochrome P450 1A2 | enzyme |
Pomalidomide | Cytochrome P450 3A4 | enzyme |
Pomalidomide | P-glycoprotein 1 | transporter |
Pomalidomide | Protein cereblon | target |
Pomalidomide | Tumor necrosis factor | target |
Pomalidomide | Prostaglandin G/H synthase 2 | target |
Stiripentol | Cytochrome P450 2C19 | enzyme |
Stiripentol | Cytochrome P450 2D6 | enzyme |
Stiripentol | Cytochrome P450 3A4 | enzyme |
Stiripentol | Cytochrome P450 1A2 | enzyme |
Stiripentol | Cytochrome P450 2C9 | enzyme |
Stiripentol | GABA(A) Receptor | target |
Stiripentol | L-lactate dehydrogenase A chain | target |
Stiripentol | L-lactate dehydrogenase B chain | target |
Stiripentol | Cytochrome P450 2B6 | enzyme |
Stiripentol | Cytochrome P450 2C8 | enzyme |
Stiripentol | P-glycoprotein 1 | transporter |
Stiripentol | ATP-binding cassette sub-family G member 2 | transporter |
Brexpiprazole | Cytochrome P450 2D6 | enzyme |
Brexpiprazole | Cytochrome P450 3A4 | enzyme |
Brexpiprazole | 5-hydroxytryptamine receptor 1A | target |
Brexpiprazole | Dopamine D2 receptor | target |
Brexpiprazole | 5-hydroxytryptamine receptor 2A | target |
Brexpiprazole | Alpha-2C adrenergic receptor | target |
Brexpiprazole | Alpha-1B adrenergic receptor | target |
Fluvoxamine | Sodium-dependent serotonin transporter | target |
Fluvoxamine | Cytochrome P450 1A2 | enzyme |
Fluvoxamine | Cytochrome P450 2D6 | enzyme |
Fluvoxamine | Cytochrome P450 2C9 | enzyme |
Fluvoxamine | Cytochrome P450 2C19 | enzyme |
Fluvoxamine | Cytochrome P450 1A1 | enzyme |
Fluvoxamine | Cytochrome P450 3A4 | enzyme |
Fluvoxamine | Cytochrome P450 3A Subfamily | enzyme |
Fluvoxamine | P-glycoprotein 1 | transporter |
Fluvoxamine | Cytochrome P450 2B6 | enzyme |
Fluvoxamine | Potassium voltage-gated channel subfamily H member 2 | target |
Fluvoxamine | Bile salt export pump | transporter |
Ethchlorvynol | GABA(A) Receptor | target |
Enflurane | Calcium-transporting ATPase type 2C member 1 | target |
Enflurane | Glutamate (NMDA) receptor | target |
Enflurane | Voltage-gated Potassium Channels | target |
Enflurane | Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | target |
Enflurane | Cytochrome P450 2E1 | enzyme |
Enflurane | Serum albumin | carrier |
Enflurane | GABA(A) Receptor | target |
Enflurane | Voltage-dependent calcium channel | target |
Enflurane | Glycine receptor subunit alpha-1 | target |
Etomidate | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Etomidate | Alpha-2B adrenergic receptor | target |
Etomidate | Solute carrier family 2, facilitated glucose transporter member 1 | carrier |
Etomidate | Cytochrome P450 11B1, mitochondrial | enzyme |
Etomidate | Cytochrome P450 11B2, mitochondrial | enzyme |
Etomidate | GABA(A) Receptor | target |
Dapiprazole | Alpha-1A adrenergic receptor | target |
Dapiprazole | Alpha-1D adrenergic receptor | target |
Dapiprazole | Alpha-1B adrenergic receptor | target |
Valproic acid | Histone deacetylase 9 | target |
Valproic acid | Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial | target |
Valproic acid | Cytochrome P450 2A6 | enzyme |
Valproic acid | Cytochrome P450 2B6 | enzyme |
Valproic acid | Cytochrome P450 2C9 | enzyme |
Valproic acid | Solute carrier family 22 member 5 | transporter |
Valproic acid | Solute carrier family 22 member 6 | transporter |
Valproic acid | Solute carrier family 22 member 8 | transporter |
Valproic acid | Monocarboxylate transporter 1 | transporter |
Valproic acid | Solute carrier family 22 member 7 | transporter |
Valproic acid | Cytochrome P450 3A5 | enzyme |
Valproic acid | UDP-glucuronosyltransferase 1-9 | enzyme |
Valproic acid | Prostaglandin G/H synthase 1 | enzyme |
Valproic acid | Cytochrome P450 1A2 | enzyme |
Valproic acid | Cytochrome P450 2C19 | enzyme |
Valproic acid | Cytochrome P450 3A4 | enzyme |
Valproic acid | UDP-glucuronosyltransferase 1-4 | enzyme |
Valproic acid | UDP-glucuronosyltransferase 1-8 | enzyme |
Valproic acid | UDP-glucuronosyltransferase 1-10 | enzyme |
Valproic acid | UDP-glucuronosyltransferase 1-6 | enzyme |
Valproic acid | UDP-glucuronosyltransferase 1-3 | enzyme |
Valproic acid | UDP-glucuronosyltransferase 2B7 | enzyme |
Valproic acid | UDP-glucuronosyltransferase 2B15 | enzyme |
Valproic acid | 2-oxoglutarate dehydrogenase, mitochondrial | target |
Valproic acid | Succinate-semialdehyde dehydrogenase, mitochondrial | target |
Valproic acid | Sodium channel protein | target |
Valproic acid | Histone deacetylase 2 | target |
Valproic acid | Peroxisome proliferator-activated receptor alpha | target |
Valproic acid | Peroxisome proliferator-activated receptor delta | target |
Valproic acid | Peroxisome proliferator-activated receptor gamma | target |
Valproic acid | Serum albumin | carrier |
Valproic acid | UDP-glucuronosyltransferase 1-1 | enzyme |
Valproic acid | Solute carrier organic anion transporter family member 2B1 | transporter |
Valproic acid | Histone deacetylase | target |
Valproic acid | Cyclin-dependent kinase inhibitor 1 | target |
Valproic acid | Hepatocyte growth factor | target |
Valproic acid | Ornithine decarboxylase | target |
Valproic acid | Programmed cell death 1 ligand 1 | target |
Sulpiride | Dopamine D2 receptor | target |
Sulpiride | Dopamine D3 receptor | target |
Sulpiride | Cholinesterase | enzyme |
Sulpiride | Carbonic anhydrase 2 | target |
Sulpiride | Carbonic anhydrase 3 | target |
Sulpiride | Serum albumin | carrier |
Sulpiride | Solute carrier family 22 member 1 | transporter |
Sulpiride | Solute carrier family 22 member 2 | transporter |
Sulpiride | Multidrug and toxin extrusion protein 1 | transporter |
Sulpiride | Multidrug and toxin extrusion protein 2 | transporter |
Sulpiride | Dopamine D4 receptor | target |
Sulpiride | Solute carrier family 22 member 3 | transporter |
Sulpiride | P-glycoprotein 1 | transporter |
Sulpiride | ATP-binding cassette sub-family G member 2 | transporter |
Remoxipride | Dopamine D2 receptor | target |
Remoxipride | Dopamine D4 receptor | target |
Remoxipride | 5-hydroxytryptamine receptor 2A | target |
Remoxipride | Sigma non-opioid intracellular receptor 1 | target |
Remoxipride | Dopamine D3 receptor | target |
Remoxipride | Cytochrome P450 2D6 | enzyme |
Remoxipride | alpha1-acid glycoprotein | carrier |
Remoxipride | Cytochrome P450 1A2 | enzyme |
Remoxipride | Cytochrome P450 2B1 | enzyme |
Remoxipride | Cytochrome P450 3A Subfamily | enzyme |
Nabilone | Cannabinoid receptor 2 | target |
Nabilone | Cannabinoid receptor 1 | target |
Nabilone | Cytochrome P450 2E1 | enzyme |
Nabilone | Cytochrome P450 2C8 | enzyme |
Nabilone | Cytochrome P450 2C9 | enzyme |
Nabilone | Cytochrome P450 3A4 | enzyme |
Nabilone | Cytochrome P450 2J2 | enzyme |
Triflupromazine | Dopamine D1 receptor | target |
Triflupromazine | Dopamine D2 receptor | target |
Triflupromazine | Muscarinic acetylcholine receptor M1 | target |
Triflupromazine | Muscarinic acetylcholine receptor M2 | target |
Triflupromazine | 5-hydroxytryptamine receptor 2B | target |
Triflupromazine | P-glycoprotein 1 | transporter |
Triflupromazine | Cholinesterase | enzyme |
Thiopental | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Thiopental | Fatty-acid amide hydrolase 1 | target |
Thiopental | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Thiopental | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Thiopental | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Thiopental | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Thiopental | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Thiopental | Neuronal acetylcholine receptor subunit alpha-4 | target |
Thiopental | Neuronal acetylcholine receptor subunit alpha-7 | target |
Thiopental | Glutamate receptor 2 | target |
Thiopental | Glutamate receptor ionotropic, kainate 2 | target |
Thiopental | Cytochrome P450 3A Subfamily | enzyme |
Thiopental | Muscarinic acetylcholine receptor M3 | target |
Thiopental | Cytochrome P450 2C19 | enzyme |
Dexmedetomidine | Alpha-2A adrenergic receptor | target |
Dexmedetomidine | Cytochrome P450 2E1 | enzyme |
Dexmedetomidine | Cytochrome P450 1A2 | enzyme |
Dexmedetomidine | Cytochrome P450 1A1 | enzyme |
Dexmedetomidine | Cytochrome P450 2D6 | enzyme |
Dyclonine | Sodium channel protein type 10 subunit alpha | target |
Dextropropoxyphene | Mu-type opioid receptor | target |
Dextropropoxyphene | Delta-type opioid receptor | target |
Dextropropoxyphene | Kappa-type opioid receptor | target |
Dextropropoxyphene | Cytochrome P450 2D6 | enzyme |
Dextropropoxyphene | Cytochrome P450 3A4 | enzyme |
Dextropropoxyphene | Liver carboxylesterase 1 | target |
Dextropropoxyphene | Cytochrome P450 3A Subfamily | enzyme |
Dextropropoxyphene | UDP-glucuronosyltransferase 2B4 | enzyme |
Dextropropoxyphene | NMDA receptor | target |
Magnesium sulfate | Voltage-dependent L-type calcium channel | target |
Trazodone | 5-hydroxytryptamine receptor 2A | target |
Trazodone | Sodium-dependent serotonin transporter | target |
Trazodone | Alpha-1A adrenergic receptor | target |
Trazodone | Alpha-2A adrenergic receptor | target |
Trazodone | Histamine H1 receptor | target |
Trazodone | 5-hydroxytryptamine receptor 1A | target |
Trazodone | Cytochrome P450 2D6 | enzyme |
Trazodone | Cytochrome P450 3A4 | enzyme |
Trazodone | 5-hydroxytryptamine receptor 2C | target |
Trazodone | Cytochrome P450 3A5 | enzyme |
Trazodone | Cytochrome P450 3A7 | enzyme |
Trazodone | P-glycoprotein 1 | transporter |
Trazodone | 5-hydroxytryptamine receptor 1C | target |
Procaine | Sodium channel protein type 10 subunit alpha | target |
Procaine | Glutamate receptor ionotropic, NMDA 3A | target |
Procaine | 5-hydroxytryptamine receptor 3A | target |
Procaine | Sodium-dependent dopamine transporter | target |
Procaine | Neuronal acetylcholine receptor subunit alpha-2 | target |
Procaine | Cholinesterase | enzyme |
Procaine | DNA (cytosine-5)-methyltransferase 1 | target |
Procaine | Calcium-activated potassium channel | target |
Procaine | Cytosolic phospholipase A2 | target |
Procaine | 60 kDa lysophospholipase | target |
Procaine | Monoamine oxidase | target |
Procaine | Sodium-dependent dopamine transporter | transporter |
Procaine | Sodium-dependent noradrenaline transporter | transporter |
Procaine | Sodium-dependent serotonin transporter | transporter |
Procaine | DNA (cytosine-5)-methyltransferase 3A | target |
Tranylcypromine | Amine oxidase [flavin-containing] B | target |
Tranylcypromine | Amine oxidase [flavin-containing] A | target |
Tranylcypromine | Cytochrome P450 2C19 | enzyme |
Tranylcypromine | Cytochrome P450 2A6 | enzyme |
Tranylcypromine | Cytochrome P450 2D6 | enzyme |
Tranylcypromine | Cytochrome P450 1A2 | enzyme |
Tranylcypromine | Cytochrome P450 2C9 | enzyme |
Tranylcypromine | Cytochrome P450 3A4 | enzyme |
Halazepam | GABA(A) Receptor | target |
Halazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Methylphenobarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Methylphenobarbital | Cytochrome P450 2C19 | enzyme |
Methylphenobarbital | Cytochrome P450 2B6 | enzyme |
Methylphenobarbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Methylphenobarbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Methylphenobarbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Methylphenobarbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Methylphenobarbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Methylphenobarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Methylphenobarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Methylphenobarbital | Glutamate receptor 2 | target |
Methylphenobarbital | Glutamate receptor ionotropic, kainate 2 | target |
Methylphenobarbital | Nuclear receptor subfamily 1 group I member 2 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Ethanol | Glutamate receptor ionotropic, NMDA 3A | target |
Ethanol | Glycine receptor subunit alpha-1 | target |
Ethanol | Glycine receptor subunit alpha-2 | target |
Ethanol | Cytochrome P450 2E1 | enzyme |
Ethanol | Cytochrome P450 1A1 | enzyme |
Ethanol | Cytochrome P450 1A2 | enzyme |
Ethanol | Cytochrome P450 2B6 | enzyme |
Ethanol | Cytochrome P450 2C19 | enzyme |
Ethanol | Cytochrome P450 2C9 | enzyme |
Ethanol | Cytochrome P450 3A4 | enzyme |
Ethanol | Cytochrome P450 4A11 | enzyme |
Ethanol | Alcohol dehydrogenase 1A | enzyme |
Ethanol | Alcohol dehydrogenase 1B | enzyme |
Ethanol | Alcohol dehydrogenase 1C | enzyme |
Ethanol | Alcohol dehydrogenase class-3 | enzyme |
Ethanol | Voltage-dependent L-type calcium channel subunit beta-1 | target |
Ethanol | 5-hydroxytryptamine receptor 3A | target |
Ethanol | Alcohol dehydrogenase 4 | enzyme |
Ethanol | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Ethanol | Neuronal acetylcholine receptor subunit alpha-10 | target |
Ethanol | Voltage-dependent L-type calcium channel subunit alpha-1C | target |
Ethanol | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Ethanol | Alcohol dehydrogenase class 4 mu/sigma chain | enzyme |
Ethanol | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Ethanol | Glutamate receptor 1 | target |
Ethanol | Voltage-dependent calcium channel gamma-1 subunit | target |
Ethanol | Neuronal acetylcholine receptor subunit alpha-2 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Ethanol | Glutamate receptor 2 | target |
Ethanol | Glutamate receptor 4 | target |
Ethanol | Glutamate receptor 3 | target |
Ethanol | Neuronal acetylcholine receptor subunit alpha-4 | target |
Ethanol | Neuronal acetylcholine receptor subunit beta-2 | target |
Ethanol | G protein-activated inward rectifier potassium channel 1 | target |
Ethanol | G protein-activated inward rectifier potassium channel 2 | target |
Ethanol | Vascular cell adhesion protein 1 | target |
Ethanol | Equilibrative nucleoside transporter 1 | target |
Ethanol | G protein-activated inward rectifier potassium channel 4 | target |
Ethanol | Neuronal acetylcholine receptor subunit alpha-7 | target |
Ethanol | Neuronal acetylcholine receptor subunit alpha-9 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit beta-1 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit beta-3 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit beta-2 | target |
Ethanol | Voltage-dependent L-type calcium channel subunit alpha-1S | target |
Ethanol | Voltage-dependent L-type calcium channel subunit alpha-1D | target |
Ethanol | Alcohol dehydrogenase 6 | enzyme |
Ethanol | Neuronal acetylcholine receptor subunit beta-4 | target |
Ethanol | Neuronal acetylcholine receptor subunit alpha-3 | target |
Ethanol | Neuronal acetylcholine receptor subunit alpha-5 | target |
Ethanol | Neuronal acetylcholine receptor subunit alpha-6 | target |
Ethanol | Neuronal acetylcholine receptor subunit beta-3 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit gamma-1 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit gamma-3 | target |
Ethanol | Gamma-aminobutyric acid receptor subunit epsilon | target |
Ethanol | Gamma-aminobutyric acid receptor subunit pi | target |
Ethanol | Gamma-aminobutyric acid receptor subunit theta | target |
Ethanol | Gamma-aminobutyric acid receptor subunit delta | target |
Ethanol | Alcohol dehydrogenase [NADP(+)] | enzyme |
Ethanol | Equilibrative nucleoside transporter 2 | target |
Ethanol | 5-hydroxytryptamine receptor 3E | target |
Ethanol | 5-hydroxytryptamine receptor 3B | target |
Ethanol | 5-hydroxytryptamine receptor 3D | target |
Ethanol | 5-hydroxytryptamine receptor 3C | target |
Ethanol | Voltage-dependent calcium channel gamma-2 subunit | target |
Ethanol | G protein-activated inward rectifier potassium channel 3 | target |
Ethanol | Neural cell adhesion molecule L1 | target |
Ethanol | Acetylcholinesterase | target |
Ethanol | Alcohol dehydrogenase class 4 mu/sigma chain | target |
Ondansetron | 5-hydroxytryptamine receptor 3A | target |
Ondansetron | Cytochrome P450 3A4 | enzyme |
Ondansetron | Cytochrome P450 1A2 | enzyme |
Ondansetron | Cytochrome P450 2D6 | enzyme |
Ondansetron | Cytochrome P450 3A5 | enzyme |
Ondansetron | Cytochrome P450 3A7 | enzyme |
Ondansetron | 5-hydroxytryptamine receptor 4 | target |
Ondansetron | 5-hydroxytryptamine receptor 1A | target |
Ondansetron | 5-hydroxytryptamine receptor 1B | target |
Ondansetron | Mu-type opioid receptor | target |
Ondansetron | Cytochrome P450 2C9 | enzyme |
Ondansetron | Cytochrome P450 2E1 | enzyme |
Mesoridazine | Dopamine D2 receptor | target |
Mesoridazine | 5-hydroxytryptamine receptor 2A | target |
Mesoridazine | Cytochrome P450 2D6 | enzyme |
Methoxyflurane | Calcium-transporting ATPase type 2C member 1 | target |
Methoxyflurane | NADH-ubiquinone oxidoreductase chain 1 | target |
Methoxyflurane | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Methoxyflurane | Potassium voltage-gated channel subfamily A member 1 | target |
Methoxyflurane | Glutamate receptor 1 | target |
Methoxyflurane | Glycine receptor subunit alpha-1 | target |
Methoxyflurane | Cytochrome P450 2E1 | enzyme |
Methoxyflurane | Cytochrome P450 1A2 | enzyme |
Methoxyflurane | Cytochrome P450 2A6 | enzyme |
Methoxyflurane | Cytochrome P450 2B6 | enzyme |
Methoxyflurane | Cytochrome P450 2C9 | enzyme |
Methoxyflurane | Cytochrome P450 2D6 | enzyme |
Methoxyflurane | Cytochrome P450 3A4 | enzyme |
Methoxyflurane | GABA(A) Receptor | target |
Melatonin | Acetylserotonin O-methyltransferase | target |
Melatonin | Melatonin receptor type 1A | target |
Melatonin | Melatonin receptor type 1B | target |
Melatonin | Nuclear receptor ROR-beta | target |
Melatonin | Calmodulin | target |
Melatonin | Calreticulin | target |
Melatonin | Ribosyldihydronicotinamide dehydrogenase [quinone] | target |
Melatonin | Myeloperoxidase | target |
Melatonin | Estrogen receptor alpha | target |
Melatonin | Eosinophil peroxidase | target |
Melatonin | Cytochrome P450 1A1 | enzyme |
Melatonin | Cytochrome P450 1A2 | enzyme |
Melatonin | Cytochrome P450 2C19 | enzyme |
Melatonin | Cytochrome P450 2C9 | enzyme |
Melatonin | Acetylserotonin O-methyltransferase | enzyme |
Melatonin | Indoleamine 2,3-dioxygenase 1 | enzyme |
Melatonin | Myeloperoxidase | enzyme |
Melatonin | Cytochrome P450 1B1 | enzyme |
Melatonin | Solute carrier family 22 member 8 | transporter |
Melatonin | Cytochrome P450 19A1 | enzyme |
Thiamylal | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Thiamylal | ATP-sensitive inward rectifier potassium channel 8 | target |
Thiamylal | ATP-sensitive inward rectifier potassium channel 11 | target |
Thiamylal | Cytochrome P450 2C9 | enzyme |
Thiamylal | Cytochrome P450 3A4 | enzyme |
Thiamylal | Cytochrome P450 2E1 | enzyme |
Halothane | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Halothane | Glycine receptor subunit alpha-1 | target |
Halothane | Calcium-activated potassium channel subunit alpha-1 | target |
Halothane | NADH-ubiquinone oxidoreductase chain 1 | target |
Halothane | Intermediate conductance calcium-activated potassium channel protein 4 | target |
Halothane | Rhodopsin | target |
Halothane | G protein-activated inward rectifier potassium channel 2 | target |
Halothane | G protein-activated inward rectifier potassium channel 1 | target |
Halothane | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 | target |
Halothane | Neuropeptide S receptor | target |
Halothane | Cytochrome P450 2E1 | enzyme |
Halothane | Cytochrome P450 2A6 | enzyme |
Halothane | Cytochrome P450 3A4 | enzyme |
Halothane | Glutamate receptor ionotropic, NMDA 3A | target |
Halothane | Glutamate receptor ionotropic, NMDA 3B | target |
Halothane | Glutamate receptor ionotropic, NMDA 2A | target |
Halothane | Potassium channel subfamily K member 3 | target |
Halothane | Potassium channel subfamily K member 9 | target |
Halothane | Serum albumin | carrier |
Halothane | Cytochrome P450 2B6 | enzyme |
Halothane | Cytochrome P450 2C9 | enzyme |
Halothane | GABA(A) Receptor | target |
Halothane | Plasma membrane calcium-transporting ATPase | target |
Chlormezanone | Translocator protein | target |
Dezocine | Mu-type opioid receptor | target |
Dezocine | Kappa-type opioid receptor | target |
Levacetylmethadol | Mu-type opioid receptor | target |
Levacetylmethadol | Cytochrome P450 3A4 | enzyme |
Levacetylmethadol | Neuronal acetylcholine receptor subunit beta-4 | target |
Levacetylmethadol | Neuronal acetylcholine receptor subunit alpha-3 | target |
Levacetylmethadol | Cytochrome P450 3A7 | enzyme |
Chlorprothixene | Dopamine D1 receptor | target |
Chlorprothixene | Dopamine D2 receptor | target |
Chlorprothixene | Dopamine D3 receptor | target |
Chlorprothixene | 5-hydroxytryptamine receptor 2A | target |
Chlorprothixene | Histamine H1 receptor | target |
Chlorprothixene | Muscarinic acetylcholine receptor M1 | target |
Chlorprothixene | Muscarinic acetylcholine receptor M2 | target |
Chlorprothixene | Muscarinic acetylcholine receptor M3 | target |
Chlorprothixene | Muscarinic acetylcholine receptor M4 | target |
Chlorprothixene | Muscarinic acetylcholine receptor M5 | target |
Chlorprothixene | P-glycoprotein 1 | transporter |
Chlorprothixene | Serotonin Receptors | target |
Butobarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Butobarbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Butobarbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Butobarbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Butobarbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Butobarbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Butobarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Butobarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Butobarbital | Glutamate receptor 2 | target |
Butobarbital | Glutamate receptor ionotropic, kainate 2 | target |
Hexobarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Hexobarbital | Cytochrome P450 2C9 | enzyme |
Hexobarbital | Cytochrome P450 2C19 | enzyme |
Hexobarbital | Prostaglandin G/H synthase 1 | enzyme |
Hexobarbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Hexobarbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Hexobarbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Hexobarbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Hexobarbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Hexobarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Hexobarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Hexobarbital | Glutamate receptor 2 | target |
Hexobarbital | Glutamate receptor ionotropic, kainate 2 | target |
Lithium cation | Inositol monophosphatase 2 | target |
Lithium cation | Inositol monophosphatase 1 | target |
Lithium cation | Glycogen synthase kinase-3 beta | target |
Lithium cation | Glutamate receptor 3 | target |
Methadyl acetate | Mu-type opioid receptor | target |
Glutethimide | Cholesterol side-chain cleavage enzyme, mitochondrial | enzyme |
Glutethimide | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Glutethimide | GABA(A) Receptor | target |
Diamorphine | Mu-type opioid receptor | target |
Diamorphine | Kappa-type opioid receptor | target |
Diamorphine | Delta-type opioid receptor | target |
Diamorphine | Liver carboxylesterase 1 | target |
Diamorphine | Thyroxine-binding globulin | carrier |
Fencamfamin | Sodium-dependent dopamine transporter | target |
Ethylmorphine | Cytochrome P450 2D6 | enzyme |
Ethylmorphine | NADPH--cytochrome P450 reductase | enzyme |
Ethylmorphine | Mu-type opioid receptor | target |
Ethylmorphine | Cytochrome P450 2B6 | enzyme |
Ethylmorphine | Cytochrome P450 3A4 | enzyme |
Barbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Barbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Barbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Barbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Barbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Barbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Barbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Barbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Barbital | Glutamate receptor 2 | target |
Barbital | Glutamate receptor ionotropic, kainate 2 | target |
Barbital | Cytochrome P450 3A4 | enzyme |
Barbital | Cytochrome P450 2C19 | enzyme |
Carfentanil | Mu-type opioid receptor | target |
Carfentanil | Kappa-type opioid receptor | target |
Carfentanil | Delta-type opioid receptor | target |
Flunitrazepam | Cytochrome P450 2C19 | enzyme |
Flunitrazepam | UDP-glucuronosyltransferase 2B7 | enzyme |
Flunitrazepam | Cytochrome P450 2A6 | enzyme |
Flunitrazepam | Cytochrome P450 2B6 | enzyme |
Flunitrazepam | Cytochrome P450 2C9 | enzyme |
Flunitrazepam | Cytochrome P450 3A4 | enzyme |
Flunitrazepam | Cytochrome P450 2E1 | enzyme |
Flunitrazepam | UDP-glucuronosyltransferase 1-1 | enzyme |
Flunitrazepam | UDP-glucuronosyltransferase 1-3 | enzyme |
Flunitrazepam | GABA(A) Receptor | target |
Flunitrazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Ethyl loflazepate | GABA(A) Receptor | target |
Ethyl loflazepate | GABA(A) Receptor Benzodiazepine Binding Site | target |
Dihydromorphine | E3 ubiquitin-protein ligase TRIM13 | target |
Dihydromorphine | Pro-opiomelanocortin | target |
Dihydromorphine | Mu-type opioid receptor | target |
Dihydromorphine | Delta-type opioid receptor | target |
Dihydromorphine | Kappa-type opioid receptor | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit gamma-1 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit gamma-2 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit gamma-3 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit beta-1 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit beta-2 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit beta-3 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit delta | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit epsilon | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit pi | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit rho-1 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit rho-2 | target |
Fludiazepam | Gamma-aminobutyric acid receptor subunit rho-3 | target |
Oxprenolol | Beta-1 adrenergic receptor | target |
Oxprenolol | Beta-2 adrenergic receptor | target |
Oxprenolol | Solute carrier family 22 member 2 | transporter |
Oxprenolol | Cytochrome P450 2D6 | enzyme |
Oxprenolol | Beta-3 adrenergic receptor | target |
Ketazolam | Cytochrome P450 3A4 | enzyme |
Ketazolam | P-glycoprotein 1 | transporter |
Ketazolam | Serum albumin | carrier |
Ketazolam | GABA(A) Receptor | target |
Ketazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Prazepam | Cytochrome P450 3A4 | enzyme |
Prazepam | GABA(A) Receptor | target |
Prazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Acepromazine | Dopamine D2 receptor | target |
Acepromazine | Dopamine D1 receptor | target |
Acepromazine | 5-hydroxytryptamine receptor 2A | target |
Acepromazine | 5-hydroxytryptamine receptor 1A | target |
Acepromazine | Alpha-1A adrenergic receptor | target |
Acepromazine | Alpha-1B adrenergic receptor | target |
Acepromazine | Serum albumin | carrier |
Aceprometazine | Histamine H1 receptor | target |
Molindone | Dopamine D2 receptor | target |
Molindone | 5-hydroxytryptamine receptor 1A | target |
Molindone | 5-hydroxytryptamine receptor 2A | target |
Molindone | Muscarinic acetylcholine receptor M1 | target |
7-Nitroindazole | Nitric oxide synthase, endothelial | target |
7-Nitroindazole | Nitric oxide synthase, inducible | target |
7-Nitroindazole | Nitric oxide synthase, brain | target |
Urethane | Cytosolic phospholipase A2 | enzyme |
Urethane | Myeloperoxidase | enzyme |
Urethane | Aldehyde oxidase | enzyme |
Methaqualone | Cytochrome P450 3A4 | enzyme |
Fluspirilene | Dopamine D2 receptor | target |
Fluspirilene | 5-hydroxytryptamine receptor 2A | target |
Fluspirilene | Voltage-dependent calcium channel gamma-1 subunit | target |
Fluspirilene | Cytochrome P450 3A4 | enzyme |
Osanetant | Neuromedin-K receptor | target |
Tetrodotoxin | Sodium channel protein type 1 subunit alpha | target |
Tetrodotoxin | Sodium channel protein type 2 subunit alpha | target |
Tetrodotoxin | Sodium channel protein type 3 subunit alpha | target |
Tetrodotoxin | Sodium channel protein type 8 subunit alpha | target |
Sertindole | 5-hydroxytryptamine receptor 2A | target |
Sertindole | 5-hydroxytryptamine receptor 2C | target |
Sertindole | Dopamine D2 receptor | target |
Sertindole | Alpha-1A adrenergic receptor | target |
Sertindole | Alpha-1B adrenergic receptor | target |
Sertindole | Alpha-1D adrenergic receptor | target |
Sertindole | Potassium voltage-gated channel subfamily H member 2 | target |
Sertindole | 5-hydroxytryptamine receptor 6 | target |
Sertindole | Cytochrome P450 2D6 | enzyme |
Sertindole | Cytochrome P450 3A4 | enzyme |
Amisulpride | Dopamine D2 receptor | target |
Amisulpride | Dopamine D3 receptor | target |
Amisulpride | 5-hydroxytryptamine receptor 7 | target |
Amisulpride | 5-hydroxytryptamine receptor 2A | target |
Amisulpride | Erythrocyte | carrier |
Amisulpride | Multidrug and toxin extrusion protein 1 | transporter |
Amisulpride | Multidrug and toxin extrusion protein 2 | transporter |
Amisulpride | P-glycoprotein 1 | transporter |
Amisulpride | ATP-binding cassette sub-family G member 2 | transporter |
Amisulpride | Solute carrier family 22 member 1 | transporter |
Amisulpride | Mu-type opioid receptor | target |
Amisulpride | Delta-type opioid receptor | target |
Amisulpride | Kappa-type opioid receptor | target |
Clomethiazole | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Clomethiazole | Cytochrome P450 2A6 | enzyme |
Clomethiazole | Cytochrome P450 2B6 | enzyme |
Clomethiazole | Cytochrome P450 2C19 | enzyme |
Clomethiazole | Cytochrome P450 3A4 | enzyme |
Deramciclane | 5-hydroxytryptamine receptor 2A | target |
Deramciclane | 5-hydroxytryptamine receptor 2C | target |
Deramciclane | Cytochrome P450 2D6 | enzyme |
Adipiplon | GABA(A) Receptor Benzodiazepine Binding Site | target |
Agomelatine | 5-hydroxytryptamine receptor 2C | target |
Agomelatine | Melatonin receptor type 1B | target |
Agomelatine | Melatonin receptor type 1A | target |
Agomelatine | Cytochrome P450 2C9 | enzyme |
Agomelatine | Cytochrome P450 1A2 | enzyme |
Fospropofol | Gamma-aminobutyric acid receptor subunit beta-2 | target |
Fospropofol | Gamma-aminobutyric acid receptor subunit beta-3 | target |
Fospropofol | Serum albumin | carrier |
Ketobemidone | Prostaglandin G/H synthase 1 | enzyme |
Ketobemidone | Cytochrome P450 2C9 | enzyme |
Ketobemidone | Cytochrome P450 3A4 | enzyme |
Ketobemidone | UDP-glucuronosyltransferase 1-9 | enzyme |
Ketobemidone | Cytochrome P450 2B6 | enzyme |
Ketobemidone | Cytochrome P450 2C19 | enzyme |
Ketobemidone | Cytochrome P450 2C8 | enzyme |
Ketobemidone | Mu-type opioid receptor | target |
Ketobemidone | Kappa-type opioid receptor | target |
Ketobemidone | Delta-type opioid receptor | target |
Ketobemidone | NMDA receptor | target |
Benzyl alcohol | Cytochrome P450 2C8 | enzyme |
Benzyl alcohol | Cytochrome P450 1A1 | enzyme |
Benzyl alcohol | Aldehyde dehydrogenase, mitochondrial | enzyme |
Benzyl alcohol | Cytochrome P450 1A2 | enzyme |
Benzyl alcohol | Cytochrome P450 2E1 | enzyme |
Benzyl alcohol | Cytochrome P450 2D6 | enzyme |
DPDPE | Solute carrier organic anion transporter family member 1B3 | transporter |
Perospirone | 5-hydroxytryptamine receptor 2A | target |
Perospirone | Dopamine D2 receptor | target |
Perospirone | 5-hydroxytryptamine receptor 1A | target |
Perospirone | Cytochrome P450 3A4 | enzyme |
Perospirone | Cytochrome P450 2D6 | enzyme |
Perospirone | Cytochrome P450 2C8 | enzyme |
Perospirone | Cytochrome P450 1A1 | enzyme |
Perospirone | Histamine H1 receptor | target |
Perospirone | Dopamine D4 receptor | target |
Perospirone | Alpha-1 adrenergic receptors | target |
Amperozide | 5-hydroxytryptamine receptor 2A | target |
Brotizolam | Cytochrome P450 3A4 | enzyme |
Brotizolam | GABA(A) Receptor | target |
Brotizolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Vortioxetine | Sodium-dependent serotonin transporter | target |
Vortioxetine | 5-hydroxytryptamine receptor 3A | target |
Vortioxetine | 5-hydroxytryptamine receptor 7 | target |
Vortioxetine | 5-hydroxytryptamine receptor 1B | target |
Vortioxetine | 5-hydroxytryptamine receptor 1A | target |
Vortioxetine | Beta-1 adrenergic receptor | target |
Vortioxetine | Sodium-dependent noradrenaline transporter | target |
Vortioxetine | Cytochrome P450 2D6 | enzyme |
Vortioxetine | Cytochrome P450 3A4 | enzyme |
Vortioxetine | Cytochrome P450 3A5 | enzyme |
Vortioxetine | Cytochrome P450 2C19 | enzyme |
Vortioxetine | Cytochrome P450 2C9 | enzyme |
Vortioxetine | Cytochrome P450 2A6 | enzyme |
Vortioxetine | Cytochrome P450 2C8 | enzyme |
Vortioxetine | Cytochrome P450 2B6 | enzyme |
Etizolam | Cytochrome P450 3A4 | enzyme |
Etizolam | Cytochrome P450 2C18 | enzyme |
Etizolam | Cytochrome P450 2C19 | enzyme |
Etizolam | Platelet-activating factor receptor | target |
Etizolam | GABA(A) Receptor | target |
Etizolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Melperone | Dopamine D2 receptor | target |
Melperone | Cytochrome P450 2D6 | enzyme |
Zotepine | D(1) dopamine receptor | target |
Zotepine | Dopamine D2 receptor | target |
Zotepine | 5-hydroxytryptamine receptor 2A | target |
Zotepine | 5-hydroxytryptamine receptor 6 | target |
Zotepine | 5-hydroxytryptamine receptor 7 | target |
Zotepine | Sodium-dependent noradrenaline transporter | target |
Zotepine | Sodium-dependent serotonin transporter | target |
Zotepine | Cytochrome P450 1A2 | enzyme |
Zotepine | Cytochrome P450 3A4 | enzyme |
Pipamperone | Dopamine D2 receptor | target |
Pipamperone | 5-hydroxytryptamine receptor 2A | target |
Pipamperone | Alpha-1 adrenergic receptors | target |
Pipamperone | Dopamine D4 receptor | target |
Pipamperone | Dopamine D1 receptor | target |
Pipamperone | Dopamine D3 receptor | target |
Pipamperone | 5-hydroxytryptamine receptor 2B | target |
Pipamperone | Alpha-2A adrenergic receptor | target |
Opium | Delta-type opioid receptor | target |
Opium | Kappa-type opioid receptor | target |
Opium | Mu-type opioid receptor | target |
Opium | Serum albumin | carrier |
Opium | Beta-2-microglobulin | carrier |
Opium | Cytochrome P450 2D6 | enzyme |
Opium | Cytochrome P450 3A4 | enzyme |
Doramectin | Cytochrome P450 3A4 | enzyme |
Xylazine | Alpha-2 adrenergic receptors | target |
Brexanolone | GABA(A) Receptor | target |
Brexanolone | Aldose reductase | enzyme |
Tetrahydropalmatine | Dopamine D1 receptor | target |
Tetrahydropalmatine | Dopamine D2 receptor | target |
Tetrahydropalmatine | Cytochrome P450 3A4 | enzyme |
Raclopride | Dopamine D2 receptor | target |
Ritanserin | 5-hydroxytryptamine receptor 2A | target |
Ritanserin | Cytochrome P450 2D6 | enzyme |
Tiapride | Dopamine D2 receptor | target |
Tiapride | Dopamine D3 receptor | target |
Tiapride | Serotonin Receptors | target |
Tiapride | Alpha-1 adrenergic receptors | target |
Tiapride | Alpha-2 adrenergic receptors | target |
Medazepam | GABA(A) Receptor | target |
Medazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Loprazolam | GABA(A) Receptor | target |
Loprazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Penfluridol | Cytochrome P450 3A4 | enzyme |
Lormetazepam | GABA(A) Receptor | target |
Lormetazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Nordazepam | GABA(A) Receptor | target |
Nordazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Tryptophan | Tryptophan--tRNA ligase, cytoplasmic | target |
Tryptophan | Tryptophan--tRNA ligase | target |
Tryptophan | Tryptophan--tRNA ligase, mitochondrial | target |
Tryptophan | Tryptophan 2,3-dioxygenase | enzyme |
Tryptophan | Aromatic-L-amino-acid decarboxylase | enzyme |
Tryptophan | Monocarboxylate transporter 8 | transporter |
Tryptophan | Monocarboxylate transporter 10 | transporter |
Tryptophan | Tryptophan--tRNA ligase | enzyme |
Tryptophan | Tryptophan--tRNA ligase, mitochondrial | enzyme |
Tryptophan | Tryptophan 5-hydroxylase 1 | enzyme |
Tryptophan | Tryptophan 5-hydroxylase 2 | enzyme |
Tryptophan | Tryptophan--tRNA ligase, cytoplasmic | enzyme |
Tryptophan | Indoleamine 2,3-dioxygenase 1 | enzyme |
Citalopram | Sodium-dependent serotonin transporter | target |
Citalopram | Cytochrome P450 2C19 | enzyme |
Citalopram | Cytochrome P450 2D6 | enzyme |
Citalopram | Cytochrome P450 3A4 | enzyme |
Citalopram | P-glycoprotein 1 | transporter |
Citalopram | Cytochrome P450 1A2 | enzyme |
Citalopram | Histamine H1 receptor | target |
Reboxetine | Sodium-dependent noradrenaline transporter | target |
Reboxetine | Cytochrome P450 3A4 | enzyme |
Reboxetine | Cytochrome P450 2D6 | enzyme |
Reboxetine | P-glycoprotein 1 | transporter |
Venlafaxine | Sodium-dependent serotonin transporter | target |
Venlafaxine | Sodium-dependent noradrenaline transporter | target |
Venlafaxine | Cytochrome P450 2D6 | enzyme |
Venlafaxine | Cytochrome P450 3A4 | enzyme |
Venlafaxine | Sodium-dependent dopamine transporter | target |
Venlafaxine | P-glycoprotein 1 | transporter |
Venlafaxine | ATP-binding cassette sub-family G member 2 | transporter |
Venlafaxine | Cytochrome P450 2C9 | enzyme |
Venlafaxine | Cytochrome P450 2C19 | enzyme |
Fluoxetine | Sodium-dependent serotonin transporter | target |
Fluoxetine | Cytochrome P450 2C9 | enzyme |
Fluoxetine | Cytochrome P450 2D6 | enzyme |
Fluoxetine | CYP2B protein | enzyme |
Fluoxetine | Cytochrome P450 1A2 | enzyme |
Fluoxetine | Cytochrome P450 3A4 | enzyme |
Fluoxetine | Cytochrome P450 2C19 | enzyme |
Fluoxetine | P-glycoprotein 1 | transporter |
Fluoxetine | Cytochrome P450 2B6 | enzyme |
Fluoxetine | Cytochrome P450 3A5 | enzyme |
Fluoxetine | Serum albumin | carrier |
Fluoxetine | Alpha-1-acid glycoprotein 1 | carrier |
Fluoxetine | Potassium voltage-gated channel subfamily H member 2 | target |
Fluoxetine | 5-hydroxytryptamine receptor 2C | target |
Fluoxetine | Cyclin-dependent kinases regulatory subunit 1 | target |
Fluoxetine | Neuronal acetylcholine receptor subunit alpha-2 | target |
Fluoxetine | Neuronal acetylcholine receptor subunit alpha-3 | target |
Fluoxetine | Neuronal acetylcholine receptor subunit beta-4 | target |
Duloxetine | Sodium-dependent serotonin transporter | target |
Duloxetine | Sodium-dependent dopamine transporter | target |
Duloxetine | Sodium-dependent noradrenaline transporter | target |
Duloxetine | Cytochrome P450 1A2 | enzyme |
Duloxetine | Cytochrome P450 2D6 | enzyme |
Duloxetine | Cytochrome P450 2C9 | enzyme |
Duloxetine | Serum albumin | carrier |
Duloxetine | alpha1-acid glycoprotein | carrier |
Duloxetine | P-glycoprotein 1 | transporter |
Duloxetine | Cytochrome P450 3A4 | enzyme |
Duloxetine | Cytochrome P450 2B6 | enzyme |
Duloxetine | Cytochrome P450 2C19 | enzyme |
Paroxetine | Sodium-dependent serotonin transporter | target |
Paroxetine | Sodium-dependent noradrenaline transporter | target |
Paroxetine | 5-hydroxytryptamine receptor 2A | target |
Paroxetine | Cytochrome P450 2D6 | enzyme |
Paroxetine | Cytochrome P450 2C9 | enzyme |
Paroxetine | P-glycoprotein 1 | transporter |
Paroxetine | Cytochrome P450 2B6 | enzyme |
Paroxetine | Cytochrome P450 1A2 | enzyme |
Paroxetine | Cytochrome P450 3A4 | enzyme |
Paroxetine | Alpha-1 adrenergic receptors | target |
Paroxetine | Alpha-2 adrenergic receptors | target |
Paroxetine | Beta adrenergic receptor | target |
Paroxetine | Dopamine D2 receptor | target |
Paroxetine | Histamine H1 receptor | target |
Paroxetine | Serotonin Receptors | target |
Paroxetine | Muscarinic acetylcholine receptor | target |
Paroxetine | 5-hydroxytryptamine receptor 2B | target |
Paroxetine | D(1) dopamine receptor | target |
Paroxetine | Cytochrome P450 2C19 | enzyme |
Phenelzine | Membrane primary amine oxidase | target |
Phenelzine | Amine oxidase [flavin-containing] B | target |
Phenelzine | Amine oxidase [flavin-containing] A | target |
Phenelzine | Amine oxidase [flavin-containing] A | enzyme |
Phenelzine | Amine oxidase [flavin-containing] B | enzyme |
Phenelzine | Cytochrome P450 2E1 | enzyme |
Phenelzine | 4-aminobutyrate aminotransferase, mitochondrial | target |
Phenelzine | Glutamic acid decarboxylase | target |
Phenelzine | Alanine aminotransferase 1 | target |
Phenelzine | Alanine aminotransferase 2 | target |
Phenelzine | Cytochrome P450 2C19 | enzyme |
Phenelzine | Cytochrome P450 2C8 | enzyme |
Phenelzine | Cytochrome P450 3A4 | enzyme |
Phenelzine | Cytochrome P450 3A5 | enzyme |
Phenelzine | Cytochrome P450 3A7 | enzyme |
Phenelzine | Cytochrome P450 2D6 | enzyme |
Phenelzine | Cytochrome P450 3A Subfamily | enzyme |
Sertraline | Sodium-dependent serotonin transporter | target |
Sertraline | Cytochrome P450 2B6 | enzyme |
Sertraline | Cytochrome P450 2C19 | enzyme |
Sertraline | Cytochrome P450 2C9 | enzyme |
Sertraline | Cytochrome P450 2D6 | enzyme |
Sertraline | Sodium-dependent dopamine transporter | target |
Sertraline | CYP2B protein | enzyme |
Sertraline | Cytochrome P450 3A4 | enzyme |
Sertraline | Amine oxidase [flavin-containing] B | enzyme |
Sertraline | Amine oxidase [flavin-containing] A | enzyme |
Sertraline | P-glycoprotein 1 | transporter |
Sertraline | Serum albumin | carrier |
Sertraline | Sigma receptor | target |
Sertraline | Sodium-dependent noradrenaline transporter | target |
Sertraline | Equilibrative nucleoside transporter 4 | target |
Sertraline | Cytochrome P450 2E1 | enzyme |
Nefazodone | 5-hydroxytryptamine receptor 2A | target |
Nefazodone | Sodium-dependent serotonin transporter | target |
Nefazodone | Sodium-dependent noradrenaline transporter | target |
Nefazodone | Alpha-1A adrenergic receptor | target |
Nefazodone | Alpha-1B adrenergic receptor | target |
Nefazodone | Cytochrome P450 3A4 | enzyme |
Nefazodone | Cytochrome P450 2D6 | enzyme |
Nefazodone | Sodium-dependent dopamine transporter | target |
Nefazodone | Alpha-2A adrenergic receptor | target |
Nefazodone | 5-hydroxytryptamine receptor 1A | target |
Nefazodone | CYP2B protein | enzyme |
Nefazodone | P-glycoprotein 1 | transporter |
Nefazodone | 5-hydroxytryptamine receptor 2C | target |
Nefazodone | Potassium voltage-gated channel subfamily H member 2 | target |
Nefazodone | Cytochrome P450 3A Subfamily | enzyme |
Nefazodone | Solute carrier organic anion transporter family member 1B3 | transporter |
Nefazodone | Solute carrier organic anion transporter family member 2B1 | transporter |
Nefazodone | Bile salt export pump | transporter |
Bupropion | Sodium-dependent dopamine transporter | target |
Bupropion | Sodium-dependent noradrenaline transporter | target |
Bupropion | Cytochrome P450 2B6 | enzyme |
Bupropion | Cytochrome P450 2D6 | enzyme |
Bupropion | Alpha-1-acid glycoprotein 1 | carrier |
Bupropion | Neuronal acetylcholine receptor subunit alpha-3 | target |
Bupropion | Cytochrome P450 2C9 | enzyme |
Bupropion | Cytochrome P450 2E1 | enzyme |
Bupropion | Solute carrier family 22 member 2 | transporter |
Bupropion | 5-hydroxytryptamine receptor 3A | target |
Moclobemide | Amine oxidase [flavin-containing] A | target |
Moclobemide | Cytochrome P450 2C19 | enzyme |
Moclobemide | Cytochrome P450 2D6 | enzyme |
Moclobemide | Amine oxidase [flavin-containing] A | enzyme |
Moclobemide | Amine oxidase [flavin-containing] B | enzyme |
Moclobemide | Cytochrome P450 2C9 | enzyme |
Moclobemide | Monoamine oxidase | target |
Moclobemide | Amine oxidase [flavin-containing] B | target |
Escitalopram | Sodium-dependent serotonin transporter | target |
Escitalopram | Cytochrome P450 3A4 | enzyme |
Escitalopram | Cytochrome P450 2D6 | enzyme |
Escitalopram | Sodium-dependent dopamine transporter | target |
Escitalopram | Sodium-dependent noradrenaline transporter | target |
Escitalopram | Muscarinic acetylcholine receptor M1 | target |
Escitalopram | Histamine H1 receptor | target |
Escitalopram | Cytochrome P450 2C19 | enzyme |
Escitalopram | Monoamine oxidase | enzyme |
Escitalopram | P-glycoprotein 1 | transporter |
Escitalopram | 5-hydroxytryptamine receptor 1A | target |
Escitalopram | 5-hydroxytryptamine receptor 2A | target |
Escitalopram | 5-hydroxytryptamine receptor 2C | target |
Escitalopram | Alpha-1 adrenergic receptors | target |
Escitalopram | Alpha-2 adrenergic receptors | target |
Escitalopram | Dopamine D2 receptor | target |
Isocarboxazid | Amine oxidase [flavin-containing] A | target |
Isocarboxazid | Amine oxidase [flavin-containing] B | target |
Oxitriptan | Tryptophan--tRNA ligase 2 | target |
Nialamide | Amine oxidase [flavin-containing] B | target |
Nialamide | Amine oxidase [flavin-containing] A | target |
Nialamide | Catechol O-methyltransferase | target |
Amineptine | Sodium-dependent noradrenaline transporter | target |
Amineptine | Sodium-dependent serotonin transporter | target |
Milnacipran | Sodium-dependent serotonin transporter | target |
Milnacipran | Sodium-dependent noradrenaline transporter | target |
Milnacipran | NMDA receptor | target |
Milnacipran | Cytochrome P450 3A4 | enzyme |
Mianserin | Histamine H1 receptor | target |
Mianserin | Alpha-2A adrenergic receptor | target |
Mianserin | 5-hydroxytryptamine receptor 2A | target |
Mianserin | 5-hydroxytryptamine receptor 2C | target |
Mianserin | Cytochrome P450 2D6 | enzyme |
Mianserin | Sodium-dependent serotonin transporter | target |
Mianserin | Cytochrome P450 3A4 | enzyme |
Mianserin | Cytochrome P450 1A2 | enzyme |
Mianserin | Cytochrome P450 2B6 | enzyme |
Mianserin | Sodium-dependent noradrenaline transporter | target |
Mianserin | Histamine H4 receptor | target |
Mianserin | 5-hydroxytryptamine receptor 1A | target |
Mianserin | Alpha-2C adrenergic receptor | target |
Mianserin | 5-hydroxytryptamine receptor 2B | target |
Mianserin | 5-hydroxytryptamine receptor 1F | target |
Mianserin | Alpha-2B adrenergic receptor | target |
Mianserin | Dopamine D3 receptor | target |
Mianserin | Kappa-type opioid receptor | target |
Mianserin | Sodium-dependent dopamine transporter | target |
Mianserin | 5-hydroxytryptamine receptor 7 | target |
Mianserin | Dopamine D2 receptor | target |
Mianserin | 5-hydroxytryptamine receptor 6 | target |
Mianserin | Alpha-1 adrenergic receptors | target |
Mianserin | D(1) dopamine receptor | target |
Vilazodone | 5-hydroxytryptamine receptor 1A | target |
Vilazodone | Cytochrome P450 3A4 | enzyme |
Vilazodone | Cytochrome P450 2D6 | enzyme |
Vilazodone | Sodium-dependent serotonin transporter | target |
Vilazodone | Cytochrome P450 2C19 | enzyme |
Desvenlafaxine | Cytochrome P450 3A4 | enzyme |
Desvenlafaxine | Sodium-dependent serotonin transporter | target |
Desvenlafaxine | Sodium-dependent noradrenaline transporter | target |
Desvenlafaxine | Cytochrome P450 2D6 | enzyme |
Desvenlafaxine | Sodium-dependent dopamine transporter | target |
Viloxazine | Sodium-dependent noradrenaline transporter | target |
Viloxazine | Cytochrome P450 1A2 | enzyme |
Viloxazine | Cytochrome P450 2D6 | enzyme |
Viloxazine | UDP-glucuronosyltransferase 1-9 | enzyme |
Viloxazine | UDP-glucuronosyltransferase 2B15 | enzyme |
Viloxazine | Cytochrome P450 2B6 | enzyme |
Viloxazine | Cytochrome P450 3A4 | enzyme |
Viloxazine | Cytochrome P450 3A5 | enzyme |
Viloxazine | Multidrug and toxin extrusion protein 1 | transporter |
Viloxazine | 5-hydroxytryptamine receptor 2B | target |
Viloxazine | 5-hydroxytryptamine receptor 2C | target |
Viloxazine | Alpha-1B adrenergic receptor | target |
Viloxazine | Beta-2 adrenergic receptor | target |
Viloxazine | Amine oxidase [flavin-containing] A | target |
Viloxazine | Amine oxidase [flavin-containing] B | target |
Viloxazine | Histamine H1 receptor | target |
Viloxazine | Histamine H2 receptor | target |
Viloxazine | Muscarinic acetylcholine receptor M1 | target |
Viloxazine | Muscarinic acetylcholine receptor M2 | target |
Viloxazine | Muscarinic acetylcholine receptor M3 | target |
Viloxazine | Muscarinic acetylcholine receptor M4 | target |
Toloxatone | Amine oxidase [flavin-containing] A | target |
Toloxatone | Amine oxidase [flavin-containing] A | enzyme |
Tianeptine | Glutamate receptor 1 | target |
Tianeptine | Mu-type opioid receptor | target |
Tianeptine | 5-hydroxytryptamine receptor 1A | target |
Tianeptine | Dopamine D3 receptor | target |
Tianeptine | Cytochrome P450 3A4 | enzyme |
Adinazolam | Cytochrome P450 2C19 | enzyme |
Adinazolam | Cytochrome P450 3A4 | enzyme |
Adinazolam | GABA(A) Receptor | target |
Adinazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Progabide | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Progabide | Gamma-aminobutyric acid type B receptor subunit 1 | target |
Sibutramine | Sodium-dependent serotonin transporter | target |
Sibutramine | Sodium-dependent noradrenaline transporter | target |
Sibutramine | Cytochrome P450 3A4 | enzyme |
Sibutramine | Sodium-dependent dopamine transporter | target |
Rolipram | cAMP-specific 3',5'-cyclic phosphodiesterase 4D | target |
Rolipram | cAMP-specific 3',5'-cyclic phosphodiesterase 4B | target |
Rolipram | cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4) | target |
Aniracetam | 5-hydroxytryptamine receptor 2A | target |
Aniracetam | Dopamine D2 receptor | target |
Aniracetam | Glutamate receptor 2 | target |
Aniracetam | Glutamate receptor 3 | target |
Iproniazid | Amine oxidase [flavin-containing] B | enzyme |
Iproniazid | Cytochrome P450 2D6 | enzyme |
Iproniazid | Cytochrome P450 2C9 | enzyme |
Iproniazid | Amine oxidase [flavin-containing] A | enzyme |
Saredutant | Substance-K receptor | target |
Esmirtazapine | Cytochrome P450 2D6 | enzyme |
Esmirtazapine | Histamine H1 receptor | target |
Esmirtazapine | 5-hydroxytryptamine receptor 2 | target |
Esmirtazapine | Alpha-2 adrenergic receptors | target |
Tofisopam | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | target |
Tofisopam | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | target |
Tofisopam | cGMP-inhibited 3',5'-cyclic phosphodiesterase A | target |
Tofisopam | cGMP-dependent 3',5'-cyclic phosphodiesterase | target |
Tofisopam | Cytochrome P450 3A4 | enzyme |
Levomilnacipran | Cytochrome P450 3A4 | enzyme |
Levomilnacipran | Cytochrome P450 2C8 | enzyme |
Levomilnacipran | Cytochrome P450 2C19 | enzyme |
Levomilnacipran | Cytochrome P450 2D6 | enzyme |
Levomilnacipran | Cytochrome P450 2J2 | enzyme |
Levomilnacipran | Sodium-dependent serotonin transporter | target |
Levomilnacipran | Sodium-dependent noradrenaline transporter | target |
Levomilnacipran | P-glycoprotein 1 | transporter |
Indalpine | Cytochrome P450 3A4 | enzyme |
Pirlindole | Amine oxidase [flavin-containing] A | target |
Pirlindole | 5-hydroxytryptamine receptor 1A | target |
Pirlindole | Alpha-2A adrenergic receptor | target |
Pirlindole | Amine oxidase [flavin-containing] A | enzyme |
Hypericin | Serum albumin | carrier |
Hypericin | Glutathione S-transferase A1 | target |
Hypericin | Glutathione S-transferase P | target |
St. John's Wort | P-glycoprotein 1 | transporter |
St. John's Wort | Cytochrome P450 3A4 | enzyme |
St. John's Wort | Cytochrome P450 2D6 | enzyme |
St. John's Wort | Cytochrome P450 2C19 | enzyme |
Nomifensine | Sodium-dependent noradrenaline transporter | target |
Nomifensine | Sodium-dependent dopamine transporter | target |
Nomifensine | Alpha-1-acid glycoprotein 1 | carrier |
Nomifensine | Amine oxidase [flavin-containing] B | target |
Nomifensine | Amine oxidase [flavin-containing] A | target |
Nomifensine | Myeloperoxidase | target |
Nomifensine | Sodium-dependent serotonin transporter | target |
Nomifensine | Synaptic vesicular amine transporter | target |
Zimelidine | Sodium-dependent serotonin transporter | target |
Zimelidine | P-glycoprotein 1 | transporter |
Zimelidine | Amine oxidase [flavin-containing] B | target |
Zimelidine | Amine oxidase [flavin-containing] A | target |
Zimelidine | Cytochrome P450 3A4 | enzyme |
Dimetacrine | Acetylcholinesterase | target |
Butriptyline | Sodium-dependent serotonin transporter | target |
Butriptyline | Histamine H1 receptor | target |
Butriptyline | 5-hydroxytryptamine receptor 2A | target |
Etoperidone | Alpha-1 adrenergic receptors | target |
Etoperidone | Alpha-2 adrenergic receptors | target |
Etoperidone | Dopamine D2 receptor | target |
Etoperidone | Muscarinic acetylcholine receptor | target |
Etoperidone | 5-hydroxytryptamine receptor 2A | target |
Etoperidone | Sodium-dependent serotonin transporter | transporter |
Etoperidone | Sodium-dependent noradrenaline transporter | transporter |
Etoperidone | Sodium-dependent dopamine transporter | transporter |
Etoperidone | 5-hydroxytryptamine receptor 2C | target |
Dapoxetine | 5-hydroxytryptamine receptor 1A | target |
Dapoxetine | 5-hydroxytryptamine receptor 1B | target |
Dapoxetine | 5-hydroxytryptamine receptor 2C | target |
Dapoxetine | Cytochrome P450 3A4 | enzyme |
Dapoxetine | Cytochrome P450 2D6 | enzyme |
Mazindol | Sodium-dependent noradrenaline transporter | target |
Mazindol | Sodium-dependent dopamine transporter | target |
Mazindol | Sodium-dependent serotonin transporter | target |
Mazindol | Synaptic vesicular amine transporter | target |
Benzphetamine | Alpha-2A adrenergic receptor | target |
Benzphetamine | Alpha-1A adrenergic receptor | target |
Benzphetamine | Cytochrome P450 3A4 | enzyme |
Benzphetamine | Cytochrome P450 2B6 | enzyme |
Benzphetamine | NADPH--cytochrome P450 reductase | enzyme |
Benzphetamine | Synaptic vesicular amine transporter | target |
Benzphetamine | Sodium-dependent dopamine transporter | target |
Midomafetamine | Sodium-dependent serotonin transporter | target |
Midomafetamine | Synaptic vesicular amine transporter | target |
Midomafetamine | Sodium-dependent dopamine transporter | target |
Midomafetamine | 5-hydroxytryptamine receptor 2A | target |
Midomafetamine | 5-hydroxytryptamine receptor 2B | target |
Midomafetamine | 5-hydroxytryptamine receptor 2C | target |
Midomafetamine | Sodium-dependent noradrenaline transporter | target |
Midomafetamine | Sodium-dependent noradrenaline transporter | transporter |
Midomafetamine | Sodium-dependent dopamine transporter | transporter |
Midomafetamine | Sodium-dependent serotonin transporter | transporter |
Midomafetamine | Cytochrome P450 2D6 | enzyme |
Metamfetamine | Cytochrome P450 2D6 | enzyme |
Metamfetamine | Solute carrier family 22 member 3 | transporter |
Metamfetamine | Solute carrier family 22 member 5 | transporter |
Metamfetamine | Sodium-dependent dopamine transporter | target |
Metamfetamine | Synaptic vesicular amine transporter | target |
Metamfetamine | Trace amine-associated receptor 1 | target |
Metamfetamine | Sodium-dependent serotonin transporter | target |
Metamfetamine | Sodium-dependent noradrenaline transporter | target |
Metamfetamine | Chromaffin granule amine transporter | target |
Metamfetamine | Amine oxidase [flavin-containing] A | target |
Metamfetamine | Amine oxidase [flavin-containing] B | target |
Metamfetamine | Alpha-2A adrenergic receptor | target |
Metamfetamine | Alpha-2B adrenergic receptor | target |
Metamfetamine | Alpha-2C adrenergic receptor | target |
Selegiline | Amine oxidase [flavin-containing] B | target |
Selegiline | Cytochrome P450 2B6 | enzyme |
Selegiline | Amine oxidase [flavin-containing] A | target |
Selegiline | Cytochrome P450 2A6 | enzyme |
Selegiline | Cytochrome P450 3A4 | enzyme |
Selegiline | P-glycoprotein 1 | transporter |
Selegiline | Cytochrome P450 1A2 | enzyme |
Selegiline | Cytochrome P450 2C19 | enzyme |
Selegiline | Cytochrome P450 2C8 | enzyme |
Selegiline | Cytochrome P450 2C9 | enzyme |
Selegiline | Cytochrome P450 2D6 | enzyme |
Rasagiline | Apoptosis regulator Bcl-2 | target |
Rasagiline | Amine oxidase [flavin-containing] B | target |
Rasagiline | Cytochrome P450 1A2 | enzyme |
Pargyline | Amine oxidase [flavin-containing] B | target |
Pargyline | Amine oxidase [flavin-containing] A | target |
Methylene blue | Guanylate cyclase soluble subunit alpha-2 | target |
Methylene blue | Nitric oxide synthase, brain | target |
Methylene blue | UDP-glucuronosyltransferase 1-4 | enzyme |
Methylene blue | UDP-glucuronosyltransferase 1-9 | enzyme |
Methylene blue | Cytochrome P450 1A2 | enzyme |
Methylene blue | Cytochrome P450 2B6 | enzyme |
Methylene blue | Cytochrome P450 2C8 | enzyme |
Methylene blue | Cytochrome P450 2C9 | enzyme |
Methylene blue | Cytochrome P450 2C19 | enzyme |
Methylene blue | Cytochrome P450 3A4 | enzyme |
Methylene blue | Cytochrome P450 3A5 | enzyme |
Methylene blue | Serum albumin | carrier |
Methylene blue | P-glycoprotein 1 | transporter |
Methylene blue | Solute carrier family 22 member 2 | transporter |
Methylene blue | Multidrug and toxin extrusion protein 2 | transporter |
Methylene blue | Multidrug and toxin extrusion protein 1 | transporter |
Methylene blue | Flavin reductase (NADPH) | enzyme |
Methylene blue | Cytochrome P450 2D6 | enzyme |
Furazolidone | DNA | target |
Furazolidone | Amine oxidase [flavin-containing] B | enzyme |
Furazolidone | Amine oxidase [flavin-containing] A | enzyme |
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | Phenylethanolamine N-methyltransferase | target |
Harmaline | Histamine N-methyltransferase | target |
Brofaromine | Amine oxidase [flavin-containing] A | target |
Procarbazine | DNA | target |
Procarbazine | Xanthine dehydrogenase/oxidase | enzyme |
Procarbazine | Monoamine oxidase | target |
Dronabinol | Cannabinoid receptor 1 | target |
Dronabinol | Cytochrome P450 3A4 | enzyme |
Dronabinol | Cytochrome P450 2C9 | enzyme |
Dronabinol | Cannabinoid receptor 2 | target |
Dronabinol | P-glycoprotein 1 | transporter |
Dronabinol | ATP-binding cassette sub-family G member 2 | transporter |
Dronabinol | Prostaglandin G/H synthase 1 | enzyme |
Dronabinol | Cytochrome P450 2C19 | enzyme |
Dronabinol | Cytochrome P450 1A1 | enzyme |
Dronabinol | Cytochrome P450 1A2 | enzyme |
Dronabinol | Cytochrome P450 1B1 | enzyme |
Dronabinol | Cytochrome P450 2A6 | enzyme |
Dronabinol | Cytochrome P450 2B6 | enzyme |
Dronabinol | Cytochrome P450 2D6 | enzyme |
Dronabinol | Cytochrome P450 2J2 | enzyme |
Dronabinol | Cytochrome P450 3A5 | enzyme |
Dronabinol | Cytochrome P450 3A7 | enzyme |
Dronabinol | Multidrug resistance-associated protein 1 | transporter |
Dronabinol | Liver carboxylesterase 1 | enzyme |
Bufotenine | Amine oxidase [flavin-containing] A | enzyme |
4-Methoxyamphetamine | Alpha-1A adrenergic receptor | target |
4-Methoxyamphetamine | Alpha-2A adrenergic receptor | target |
4-Methoxyamphetamine | Cytochrome P450 2D6 | enzyme |
4-Methoxyamphetamine | Sodium-dependent dopamine transporter | target |
4-Methoxyamphetamine | Sodium-dependent serotonin transporter | target |
4-Methoxyamphetamine | Amine oxidase [flavin-containing] A | target |
4-Methoxyamphetamine | Amine oxidase [flavin-containing] B | target |
4-Methoxyamphetamine | Synaptic vesicular amine transporter | target |
Dimethyltryptamine | 5-hydroxytryptamine receptor 6 | target |
Dimethyltryptamine | 5-hydroxytryptamine receptor 2A | target |
Dimethyltryptamine | Sigma non-opioid intracellular receptor 1 | target |
Phencyclidine | Glutamate receptor ionotropic, NMDA 3A | target |
Phencyclidine | Sigma non-opioid intracellular receptor 1 | target |
Phencyclidine | Cytochrome P450 2B6 | enzyme |
Phenethylamine | Trypsin-1 | target |
Phenethylamine | Primary amine oxidase | target |
Phenethylamine | Trypsin-2 | target |
Lysergic acid diethylamide | 5-hydroxytryptamine receptor 1A | target |
Lysergic acid diethylamide | 5-hydroxytryptamine receptor 2B | target |
Lysergic acid diethylamide | 5-hydroxytryptamine receptor 6 | target |
Lysergic acid diethylamide | Cytochrome P450 3A4 | enzyme |
Lysergic acid diethylamide | Cytochrome P450 2D6 | enzyme |
Camazepam | GABA(A) Receptor | target |
Camazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Cloxazolam | GABA(A) Receptor | target |
Cloxazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Clotiazepam | Cytochrome P450 2B6 | enzyme |
Clotiazepam | Cytochrome P450 2C18 | enzyme |
Clotiazepam | Cytochrome P450 2C19 | enzyme |
Clotiazepam | Cytochrome P450 3A4 | enzyme |
Clotiazepam | GABA(A) Receptor | target |
Clotiazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Captodiame | 5-hydroxytryptamine receptor 2C | target |
Captodiame | Sigma non-opioid intracellular receptor 1 | target |
Captodiame | Dopamine D3 receptor | target |
Pinazepam | GABA(A) Receptor | target |
Pinazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Delorazepam | GABA(A) Receptor | target |
Delorazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Doxefazepam | GABA(A) Receptor | target |
Doxefazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Cinolazepam | GABA(A) Receptor | target |
Cinolazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Talbutal | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Talbutal | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Talbutal | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Talbutal | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Talbutal | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Talbutal | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Talbutal | Neuronal acetylcholine receptor subunit alpha-4 | target |
Talbutal | Neuronal acetylcholine receptor subunit alpha-7 | target |
Talbutal | Glutamate receptor 2 | target |
Talbutal | Glutamate receptor ionotropic, kainate 2 | target |
Talbutal | GABA(A) Receptor | target |
Propiomazine | 5-hydroxytryptamine receptor 2A | target |
Propiomazine | Dopamine D2 receptor | target |
Propiomazine | Histamine H1 receptor | target |
Propiomazine | 5-hydroxytryptamine receptor 2C | target |
Propiomazine | Alpha-1A adrenergic receptor | target |
Propiomazine | Muscarinic acetylcholine receptor | target |
Methyprylon | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Methyprylon | GABA(A) Receptor | target |
Aprobarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Aprobarbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Aprobarbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Aprobarbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Aprobarbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Aprobarbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Aprobarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Aprobarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Aprobarbital | Glutamate receptor 2 | target |
Aprobarbital | Glutamate receptor ionotropic, kainate 2 | target |
Aprobarbital | Cytochrome P450 3A4 | enzyme |
Heptabarbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Heptabarbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Heptabarbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Heptabarbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Heptabarbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Heptabarbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Heptabarbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Heptabarbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Heptabarbital | Glutamate receptor 2 | target |
Heptabarbital | Glutamate receptor ionotropic, kainate 2 | target |
Trimethadione | Voltage-dependent T-type calcium channel subunit alpha-1G | target |
Trimethadione | Cytochrome P450 2C19 | enzyme |
Trimethadione | Cytochrome P450 2C8 | enzyme |
Trimethadione | Cytochrome P450 2C9 | enzyme |
Trimethadione | Cytochrome P450 2E1 | enzyme |
Trimethadione | Cytochrome P450 3A4 | enzyme |
Mephenytoin | Sodium channel protein type 5 subunit alpha | target |
Mephenytoin | Cytochrome P450 2B6 | enzyme |
Mephenytoin | Cytochrome P450 2C9 | enzyme |
Mephenytoin | Cytochrome P450 2C19 | enzyme |
Mephenytoin | Cytochrome P450 1A2 | enzyme |
Mephenytoin | Cytochrome P450 2D6 | enzyme |
Mephenytoin | Cytochrome P450 2C8 | enzyme |
Mephenytoin | Nuclear receptor subfamily 1 group I member 2 | target |
Mephenytoin | Thyroxine-binding globulin | carrier |
Oxcarbazepine | Cytochrome P450 2C19 | enzyme |
Oxcarbazepine | Cytochrome P450 3A4 | enzyme |
Oxcarbazepine | Cytochrome P450 3A5 | enzyme |
Oxcarbazepine | Serum albumin | carrier |
Oxcarbazepine | P-glycoprotein 1 | transporter |
Oxcarbazepine | Aldo-keto reductase family 1 member C1 | enzyme |
Oxcarbazepine | Aldo-keto reductase family 1 member C2 | enzyme |
Oxcarbazepine | Aldo-keto reductase family 1 member C3 | enzyme |
Oxcarbazepine | Aldo-keto reductase family 1 member C4 | enzyme |
Oxcarbazepine | Carbonyl reductase [NADPH] 1 | enzyme |
Oxcarbazepine | Carbonyl reductase [NADPH] 3 | enzyme |
Oxcarbazepine | Sodium channel protein | target |
Valpromide | Limonene-1,2-epoxide hydrolase | target |
Lacosamide | Sodium channel protein type 9 subunit alpha | target |
Lacosamide | Sodium channel protein type 3 subunit alpha | target |
Lacosamide | Sodium channel protein type 10 subunit alpha | target |
Lacosamide | Cytochrome P450 2C19 | enzyme |
Lacosamide | Cytochrome P450 2C9 | enzyme |
Lacosamide | Cytochrome P450 3A4 | enzyme |
Eslicarbazepine acetate | Cytochrome P450 2C19 | enzyme |
Eslicarbazepine acetate | Cytochrome P450 3A4 | enzyme |
Eslicarbazepine acetate | P2X purinoceptor 4 | target |
Eslicarbazepine acetate | UDP-glucuronosyltransferase 1-1 | enzyme |
Sulthiame | Carbonic anhydrase 2 | target |
Riluzole | Sodium channel protein type 5 subunit alpha | target |
Riluzole | Cytochrome P450 1A2 | enzyme |
Riluzole | Cystine/glutamate transporter | target |
Riluzole | ATP-binding cassette sub-family G member 2 | transporter |
Riluzole | Cytochrome P450 1A1 | enzyme |
Acetazolamide | Carbonic anhydrase 1 | target |
Acetazolamide | Aquaporin-1 | target |
Acetazolamide | Carbonic anhydrase 14 | target |
Acetazolamide | Solute carrier family 22 member 6 | transporter |
Acetazolamide | Carbonic anhydrase 2 | target |
Acetazolamide | Carbonic anhydrase 3 | target |
Acetazolamide | Carbonic anhydrase 4 | target |
Acetazolamide | Cytochrome P450 3A4 | enzyme |
Acetazolamide | Carbonic anhydrase 7 | target |
Acetazolamide | Carbonic anhydrase 12 | target |
Remacemide | Cytochrome P450 3A4 | enzyme |
Gaboxadol | Proton-coupled amino acid transporter 1 | transporter |
Ifenprodil | Glutamate receptor ionotropic, NMDA 1 | target |
Ifenprodil | Glutamate receptor ionotropic, NMDA 2B | target |
Ifenprodil | G protein-activated inward rectifier potassium channel 1 | target |
Ifenprodil | G protein-activated inward rectifier potassium channel 2 | target |
Ifenprodil | G protein-activated inward rectifier potassium channel 4 | target |
Eperisone | Cytochrome P450 3A4 | enzyme |
Vinpocetine | Cytochrome P450 3A4 | enzyme |
Metharbital | Gamma-aminobutyric acid receptor subunit alpha-1 | target |
Metharbital | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Metharbital | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Metharbital | Gamma-aminobutyric acid receptor subunit alpha-4 | target |
Metharbital | Gamma-aminobutyric acid receptor subunit alpha-5 | target |
Metharbital | Gamma-aminobutyric acid receptor subunit alpha-6 | target |
Metharbital | Neuronal acetylcholine receptor subunit alpha-4 | target |
Metharbital | Neuronal acetylcholine receptor subunit alpha-7 | target |
Metharbital | Glutamate receptor 2 | target |
Metharbital | Glutamate receptor ionotropic, kainate 2 | target |
Metharbital | GABA(A) Receptor | target |
Paramethadione | Voltage-dependent T-type calcium channel subunit alpha-1I | target |
Paramethadione | Cytochrome P450 2C9 | enzyme |
Paramethadione | Cytochrome P450 2C8 | enzyme |
Paramethadione | Cytochrome P450 2E1 | enzyme |
Paramethadione | Cytochrome P450 3A4 | enzyme |
Phenacemide | Sodium channel protein type 1 subunit alpha | target |
Brivaracetam | Synaptic vesicle glycoprotein 2A | target |
Brivaracetam | Sodium channel protein | target |
Brivaracetam | Cytochrome P450 3A4 | enzyme |
Brivaracetam | Cytochrome P450 2C19 | enzyme |
Brivaracetam | Cytochrome P450 2B6 | enzyme |
Brivaracetam | Cytochrome P450 2C9 | enzyme |
Rufinamide | Metabotropic glutamate receptor 5 | target |
Rufinamide | Liver carboxylesterase 1 | enzyme |
Rufinamide | Sodium channel protein type 9 subunit alpha | target |
Rufinamide | Serum albumin | carrier |
Rufinamide | Cytochrome P450 2E1 | enzyme |
Rufinamide | Cytochrome P450 3A4 | enzyme |
Neocitrullamon | Thyroxine-binding globulin | carrier |
Succinylcholine | Cholinesterase | enzyme |
Succinylcholine | Muscarinic acetylcholine receptor M2 | target |
Succinylcholine | Muscarinic acetylcholine receptor M3 | target |
Succinylcholine | Neuronal Acetylcholine (nACh) Receptor Subunits | target |
Cisatracurium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Rocuronium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Rocuronium | Muscarinic acetylcholine receptor M2 | target |
Rocuronium | 5-hydroxytryptamine receptor 3A | target |
Rocuronium | Solute carrier family 22 member 1 | transporter |
Rocuronium | Solute carrier organic anion transporter family member 1A2 | transporter |
Atracurium besylate | Neuronal acetylcholine receptor subunit alpha-2 | target |
Pancuronium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Pancuronium | Cholinesterase | enzyme |
Pancuronium | Muscarinic acetylcholine receptor M2 | target |
Pancuronium | Muscarinic acetylcholine receptor M3 | target |
Pancuronium | Solute carrier family 22 member 1 | transporter |
Pancuronium | Solute carrier family 22 member 2 | transporter |
Vecuronium | P-glycoprotein 1 | transporter |
Vecuronium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Metocurine iodide | Neuronal acetylcholine receptor subunit alpha-2 | target |
Gallamine triethiodide | Neuronal acetylcholine receptor subunit alpha-2 | target |
Gallamine triethiodide | Muscarinic acetylcholine receptor M2 | target |
Gallamine triethiodide | Acetylcholinesterase | target |
Gallamine triethiodide | Muscarinic acetylcholine receptor M1 | target |
Gallamine triethiodide | Muscarinic acetylcholine receptor M5 | target |
Doxacurium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Doxacurium | Muscarinic acetylcholine receptor M2 | target |
Doxacurium | Cholinesterase | enzyme |
Tubocurarine | Neuronal acetylcholine receptor subunit alpha-2 | target |
Tubocurarine | Acetylcholinesterase | target |
Tubocurarine | 5-hydroxytryptamine receptor 3A | target |
Tubocurarine | Solute carrier family 22 member 1 | transporter |
Tubocurarine | Solute carrier family 22 member 2 | transporter |
Tubocurarine | Neuronal acetylcholine receptor subunit alpha-7 | target |
Tubocurarine | Cholinesterase | enzyme |
Mivacurium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Mivacurium | Muscarinic acetylcholine receptor M2 | target |
Mivacurium | Muscarinic acetylcholine receptor M3 | target |
Mivacurium | Cholinesterase | target |
Mivacurium | Cholinesterase | enzyme |
Decamethonium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Decamethonium | Acetylcholinesterase | target |
Decamethonium | Cholinesterase | enzyme |
Decamethonium | Neuronal acetylcholine receptor subunit alpha-4 | target |
Decamethonium | Neuronal acetylcholine receptor subunit beta-2 | target |
Metocurine | Neuronal acetylcholine receptor subunit alpha-2 | target |
Metocurine | Muscarinic acetylcholine receptor M2 | target |
Pipecuronium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Pipecuronium | Muscarinic acetylcholine receptor M2 | target |
Pipecuronium | Muscarinic acetylcholine receptor M3 | target |
Pipecuronium | Cholinesterase | enzyme |
Rapacuronium | Muscarinic acetylcholine receptor M2 | target |
Pyrantel | G-protein coupled receptor 35 | target |
Pyrantel | Cytochrome P450 4A11 | enzyme |
Pyrantel | Muscarinic acetylcholine receptor M1 | target |
Bifeprunox | Dopamine D2 receptor | target |
Bifeprunox | 5-hydroxytryptamine receptor 1A | target |
Acetophenazine | Dopamine D2 receptor | target |
Acetophenazine | Androgen receptor | target |
Periciazine | Alpha-1B adrenergic receptor | target |
Periciazine | Alpha-2A adrenergic receptor | target |
Periciazine | Dopamine D1 receptor | target |
Periciazine | Androgen receptor | target |
Thioproperazine | Dopamine D2 receptor | target |
Thioproperazine | Dopamine D1 receptor | target |
Thioproperazine | Alpha-1A adrenergic receptor | target |
Thioproperazine | Alpha-1B adrenergic receptor | target |
Thioproperazine | Serum albumin | carrier |
Cariprazine | Cytochrome P450 3A4 | enzyme |
Cariprazine | Cytochrome P450 2D6 | enzyme |
Cariprazine | P-glycoprotein 1 | transporter |
Cariprazine | Cytochrome P450 3A5 | enzyme |
Cariprazine | Dopamine D3 receptor | target |
Cariprazine | Dopamine D2 receptor | target |
Cariprazine | 5-hydroxytryptamine receptor 1A | target |
Cariprazine | 5-hydroxytryptamine receptor 2B | target |
Cariprazine | 5-hydroxytryptamine receptor 2A | target |
Cariprazine | Histamine H1 receptor | target |
Cariprazine | 5-hydroxytryptamine receptor 2C | target |
Cariprazine | Alpha-1A adrenergic receptor | target |
Cariprazine | Cytochrome P450 1A2 | enzyme |
Cariprazine | Cytochrome P450 2C9 | enzyme |
Cariprazine | Cytochrome P450 2C19 | enzyme |
Cariprazine | Cytochrome P450 2E1 | enzyme |
Botulinum toxin type B | Vesicle-associated membrane protein 1 | target |
Botulinum toxin type B | Vesicle-associated membrane protein 2 | target |
Botulinum toxin type B | Synaptotagmin-2 | target |
Botulinum toxin type A | Synaptosomal-associated protein 25 | target |
Botulinum toxin type A | Rho-related GTP-binding protein RhoB | target |
Botulinum toxin type A | Serum albumin | carrier |
Hexafluronium | Cholinesterase | target |
Thiocolchicoside | GABA(A) Receptor | target |
Thiocolchicoside | Glycine receptor subunit alpha-1 | target |
Thiocolchicoside | Tumor necrosis factor ligand superfamily member 11 | target |
Tolperisone | Cytochrome P450 1A2 | enzyme |
Thiethylperazine | Dopamine D2 receptor | target |
Moricizine | Sodium channel protein type 5 subunit alpha | target |
Alimemazine | Histamine H1 receptor | target |
BL-1020 | Dopamine D2 receptor | target |
BL-1020 | 5-hydroxytryptamine receptor 2A | target |
Blonanserin | Cytochrome P450 3A4 | enzyme |
Blonanserin | Dopamine D2 receptor | target |
Blonanserin | Dopamine D3 receptor | target |
Blonanserin | 5-hydroxytryptamine receptor 2A | target |
Blonanserin | Serum albumin | carrier |
Lumateperone | 5-hydroxytryptamine receptor 2A | target |
Lumateperone | Dopamine D2 receptor | target |
Lumateperone | Dopamine D1 receptor | target |
Lumateperone | Sodium-dependent serotonin transporter | target |
Lumateperone | Glutamate receptor ionotropic, NMDA 2B | target |
Lumateperone | Aldo-keto reductase family | enzyme |
Lumateperone | Cytochrome P450 3A4 | enzyme |
Lumateperone | Cytochrome P450 2C8 | enzyme |
Lumateperone | Cytochrome P450 1A2 | enzyme |
Lumateperone | UDP-glucuronosyltransferase 1-1 | enzyme |
Lumateperone | UDP-glucuronosyltransferase 1-4 | enzyme |
Lumateperone | UDP-glucuronosyltransferase 2B15 | enzyme |
Lumateperone | Aldo-keto reductase family 1 member C1 | enzyme |
Lumateperone | Aldo-keto reductase family 1 member B10 | enzyme |
Lumateperone | Aldo-keto reductase family 1 member C4 | enzyme |
Cannabidivarin | Transient receptor potential cation channel subfamily V member 1 | target |
Cannabidivarin | Transient receptor potential cation channel subfamily V member 2 | target |
Cannabidivarin | Transient receptor potential cation channel subfamily A member 1 | target |
Cannabidivarin | Sn1-specific diacylglycerol lipase alpha | target |
Nisoxetine | Sodium-dependent serotonin transporter | target |
Arbaclofen Placarbil | Monocarboxylate transporter 1 | transporter |
Arbaclofen Placarbil | Gamma-aminobutyric acid type B receptor subunit 1 | target |
Arbaclofen Placarbil | Gamma-aminobutyric acid type B receptor subunit 2 | target |
Donepezil | Acetylcholinesterase | target |
Donepezil | 5-hydroxytryptamine receptor 2A | target |
Donepezil | Cytochrome P450 3A4 | enzyme |
Donepezil | Cytochrome P450 2D6 | enzyme |
Donepezil | Cytochrome P450 2C9 | enzyme |
Donepezil | Cholinesterase | target |
Donepezil | Nitric oxide synthase, brain | target |
Donepezil | Tumor necrosis factor-inducible gene 6 protein | target |
Donepezil | Interleukin-1 beta | target |
Donepezil | Nuclear factor NF-kappa-B | target |
Donepezil | ATP-binding cassette sub-family G member 2 | transporter |
Donepezil | NMDA receptor | target |
Quinine | Platelet glycoprotein IX | target |
Quinine | Intermediate conductance calcium-activated potassium channel protein 4 | target |
Quinine | Cytochrome P450 3A4 | enzyme |
Quinine | Cytochrome P450 3A5 | enzyme |
Quinine | Cytochrome P450 1A1 | enzyme |
Quinine | Cytochrome P450 2D6 | enzyme |
Quinine | Cytochrome P450 1A2 | enzyme |
Quinine | Cytochrome P450 2C8 | enzyme |
Quinine | Cytochrome P450 2C9 | enzyme |
Quinine | Cytochrome P450 2C19 | enzyme |
Quinine | Cytochrome P450 2E1 | enzyme |
Quinine | Cytochrome P450 3A7 | enzyme |
Quinine | Solute carrier family 22 member 2 | transporter |
Quinine | Solute carrier family 22 member 1 | transporter |
Quinine | Solute carrier family 22 member 5 | transporter |
Quinine | P-glycoprotein 1 | transporter |
Quinine | Solute carrier organic anion transporter family member 1A2 | transporter |
Quinine | Solute carrier family 22 member 4 | transporter |
Quinine | Fe(II)-protoporphyrin IX | target |
Quinine | Solute carrier organic anion transporter family member 1B1 | transporter |
Gantacurium | Neuronal acetylcholine receptor subunit alpha-3 | target |
Hexamethonium | Neuronal acetylcholine receptor subunit alpha-2 | target |
Etorphine | E3 ubiquitin-protein ligase TRIM13 | target |
Etorphine | Pro-opiomelanocortin | target |
Etorphine | Mu-type opioid receptor | target |
Etorphine | Delta-type opioid receptor | target |
Etorphine | Kappa-type opioid receptor | target |
Etorphine | Nociceptin receptor | target |
Ramelteon | Melatonin receptor type 1B | target |
Ramelteon | Melatonin receptor type 1A | target |
Ramelteon | Cytochrome P450 1A2 | enzyme |
Ramelteon | Cytochrome P450 2C19 | enzyme |
Ramelteon | Cytochrome P450 3A4 | enzyme |
Ramelteon | Cytochrome P450 2C9 | enzyme |
Tasimelteon | Melatonin receptor type 1A | target |
Tasimelteon | Melatonin receptor type 1B | target |
Tasimelteon | Cytochrome P450 3A4 | enzyme |
Tasimelteon | Cytochrome P450 1A2 | enzyme |
Aripiprazole lauroxil | Dopamine D2 receptor | target |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 1A | target |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 2A | target |
Aripiprazole lauroxil | Cytochrome P450 3A4 | enzyme |
Aripiprazole lauroxil | Cytochrome P450 2D6 | enzyme |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 1B | target |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 1D | target |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 1E | target |
Aripiprazole lauroxil | Dopamine D1 receptor | target |
Aripiprazole lauroxil | Dopamine D5 receptor | target |
Aripiprazole lauroxil | Dopamine D3 receptor | target |
Aripiprazole lauroxil | Dopamine D4 receptor | target |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 2C | target |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 3A | target |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 6 | target |
Aripiprazole lauroxil | 5-hydroxytryptamine receptor 7 | target |
Aripiprazole lauroxil | Histamine H1 receptor | target |
Aripiprazole lauroxil | Alpha-1A adrenergic receptor | target |
Aripiprazole lauroxil | Alpha-1B adrenergic receptor | target |
Aripiprazole lauroxil | Alpha-2A adrenergic receptor | target |
Aripiprazole lauroxil | Alpha-2B adrenergic receptor | target |
Aripiprazole lauroxil | Alpha-2C adrenergic receptor | target |
Aripiprazole lauroxil | Muscarinic acetylcholine receptor M1 | target |
Aripiprazole lauroxil | Muscarinic acetylcholine receptor M2 | target |
Aripiprazole lauroxil | Muscarinic acetylcholine receptor M3 | target |
Aripiprazole lauroxil | Muscarinic acetylcholine receptor M4 | target |
Aripiprazole lauroxil | Muscarinic acetylcholine receptor M5 | target |
Aripiprazole lauroxil | Cytochrome P450 3A5 | enzyme |
Aripiprazole lauroxil | Cytochrome P450 3A7 | enzyme |
Aripiprazole lauroxil | Serum albumin | carrier |
Chlorphenesin | Cytochrome P450 19A1 | enzyme |
Chlorphenesin | Cytochrome P450 3A4 | enzyme |
Chlorphenesin | Xanthine dehydrogenase/oxidase | enzyme |
Chlorphenesin | Prostaglandin G/H synthase 2 | enzyme |
Chlorphenesin | Cholinesterase | enzyme |
Domoic Acid | Glutamate receptor ionotropic, kainate 2 | target |
Lithium carbonate | Inositol monophosphatase 2 | target |
Lithium carbonate | Inositol monophosphatase 1 | target |
Lithium carbonate | Glycogen synthase kinase-3 beta | target |
Lithium carbonate | Glutamate receptor 3 | target |
Lithium carbonate | Amiloride-sensitive sodium channel subunit alpha | transporter |
Lithium carbonate | Amiloride-sensitive sodium channel subunit beta | transporter |
Lithium carbonate | Amiloride-sensitive sodium channel subunit gamma | transporter |
Linezolid | 23S ribosomal RNA | target |
Linezolid | Amine oxidase [flavin-containing] A | enzyme |
Linezolid | Amine oxidase [flavin-containing] B | enzyme |
Linezolid | Serum albumin | carrier |
Linezolid | Solute carrier family 22 member 6 | transporter |
Linezolid | Solute carrier family 22 member 8 | transporter |
Safinamide | Amine oxidase [flavin-containing] B | target |
Safinamide | Amine oxidase [flavin-containing] A | enzyme |
Safinamide | ATP-binding cassette sub-family G member 2 | transporter |
Safinamide | Solute carrier organic anion transporter family member 3A1 | transporter |
Safinamide | Cytochrome P450 3A4 | enzyme |
Safinamide | Cytochrome P450 1A1 | enzyme |
Safinamide | Cytochrome P450 1A2 | enzyme |
Safinamide | Cytochrome P450 2D6 | enzyme |
Safinamide | Cytochrome P450 2C19 | enzyme |
Safinamide | Cytochrome P450 3A5 | enzyme |
Eletriptan | 5-hydroxytryptamine receptor 1D | target |
Eletriptan | 5-hydroxytryptamine receptor 1A | target |
Eletriptan | 5-hydroxytryptamine receptor 1F | target |
Eletriptan | 5-hydroxytryptamine receptor 1B | target |
Eletriptan | Cytochrome P450 3A4 | enzyme |
Eletriptan | Cytochrome P450 2D6 | enzyme |
Eletriptan | Cytochrome P450 2C9 | enzyme |
Eletriptan | Cytochrome P450 2C19 | enzyme |
Eletriptan | Prostaglandin G/H synthase 1 | enzyme |
Eletriptan | Cytochrome P450 2A6 | enzyme |
Eletriptan | P-glycoprotein 1 | transporter |
Methysergide | 5-hydroxytryptamine receptor 2A | target |
Methysergide | 5-hydroxytryptamine receptor 1A | target |
Methysergide | 5-hydroxytryptamine receptor 7 | target |
Methysergide | 5-hydroxytryptamine receptor 2C | target |
Methysergide | 5-hydroxytryptamine receptor 2B | target |
Methysergide | 5-hydroxytryptamine receptor 1B | target |
Methysergide | 5-hydroxytryptamine receptor 1F | target |
Methysergide | 5-hydroxytryptamine receptor 1E | target |
Methysergide | Cytochrome P450 3A4 | enzyme |
Zolmitriptan | 5-hydroxytryptamine receptor 1D | target |
Zolmitriptan | 5-hydroxytryptamine receptor 1B | target |
Zolmitriptan | 5-hydroxytryptamine receptor 1F | target |
Zolmitriptan | Cytochrome P450 1A2 | enzyme |
Zolmitriptan | Amine oxidase [flavin-containing] A | enzyme |
Zolmitriptan | 5-hydroxytryptamine receptor 1A | target |
Zolmitriptan | P-glycoprotein 1 | transporter |
Zolmitriptan | 5-hydroxytryptamine receptor 7 | target |
Zolmitriptan | 5-hydroxytryptamine receptor 2A | target |
Zolmitriptan | 5-hydroxytryptamine receptor 2B | target |
Zolmitriptan | 5-hydroxytryptamine receptor 1E | target |
Palonosetron | 5-hydroxytryptamine receptor 3A | target |
Palonosetron | Cytochrome P450 2D6 | enzyme |
Palonosetron | Cytochrome P450 3A4 | enzyme |
Palonosetron | Cytochrome P450 1A2 | enzyme |
Fenfluramine | 5-hydroxytryptamine receptor 2C | target |
Fenfluramine | 5-hydroxytryptamine receptor 2B | target |
Fenfluramine | Cytochrome P450 2D6 | enzyme |
Fenfluramine | Sodium-dependent serotonin transporter | target |
Fenfluramine | 5-hydroxytryptamine receptor 2A | target |
Fenfluramine | Sodium-dependent serotonin transporter | transporter |
Fenfluramine | 5-hydroxytryptamine receptor 1D | target |
Fenfluramine | Sigma non-opioid intracellular receptor 1 | target |
Fenfluramine | 5-hydroxytryptamine receptor 1A | target |
Fenfluramine | Cytochrome P450 1A2 | enzyme |
Fenfluramine | Cytochrome P450 2B6 | enzyme |
Fenfluramine | Cytochrome P450 2C9 | enzyme |
Fenfluramine | Cytochrome P450 2C19 | enzyme |
Fenfluramine | Cytochrome P450 3A4 | enzyme |
Fenfluramine | Cytochrome P450 3A5 | enzyme |
Lisuride | Dopamine D1 receptor | target |
Lisuride | 5-hydroxytryptamine receptor 1A | target |
Lisuride | Dopamine D2 receptor | target |
Lisuride | Alpha-2A adrenergic receptor | target |
Lisuride | Alpha-2B adrenergic receptor | target |
Lisuride | Alpha-2C adrenergic receptor | target |
Lisuride | Dopamine D3 receptor | target |
Lisuride | 5-hydroxytryptamine receptor 1D | target |
Lisuride | 5-hydroxytryptamine receptor 2B | target |
Lisuride | 5-hydroxytryptamine receptor 2A | target |
Lisuride | Dopamine D4 receptor | target |
Lisuride | 5-hydroxytryptamine receptor 2C | target |
Lisuride | Dopamine D5 receptor | target |
Lisuride | 5-hydroxytryptamine receptor 1B | target |
Lisuride | Cytochrome P450 3A4 | enzyme |
Lisuride | 5-hydroxytryptamine receptor 7 | target |
Sumatriptan | 5-hydroxytryptamine receptor 1D | target |
Sumatriptan | 5-hydroxytryptamine receptor 1B | target |
Sumatriptan | 5-hydroxytryptamine receptor 1F | target |
Sumatriptan | Amine oxidase [flavin-containing] A | enzyme |
Sumatriptan | 5-hydroxytryptamine receptor 1A | target |
Sumatriptan | Solute carrier organic anion transporter family member 1A2 | transporter |
Sumatriptan | P-glycoprotein 1 | transporter |
Sumatriptan | ATP-binding cassette sub-family G member 2 | transporter |
Sumatriptan | Solute carrier organic anion transporter family member 1B1 | transporter |
Ergotamine | Alpha-1A adrenergic receptor | target |
Ergotamine | 5-hydroxytryptamine receptor 1D | target |
Ergotamine | 5-hydroxytryptamine receptor 1B | target |
Ergotamine | 5-hydroxytryptamine receptor 2A | target |
Ergotamine | Alpha-2A adrenergic receptor | target |
Ergotamine | Dopamine D2 receptor | target |
Ergotamine | Cytochrome P450 3A4 | enzyme |
Ergotamine | Alpha-1B adrenergic receptor | target |
Ergotamine | Alpha-1D adrenergic receptor | target |
Ergotamine | P-glycoprotein 1 | transporter |
Ergotamine | D(1) dopamine receptor | target |
Ergotamine | 5-hydroxytryptamine receptor 1A | target |
Ergotamine | 5-hydroxytryptamine receptor 1F | target |
Ergotamine | 5-hydroxytryptamine receptor 2C | target |
Ergotamine | 5-hydroxytryptamine receptor 2B | target |
Ergotamine | Alpha-2C adrenergic receptor | target |
Dolasetron | 5-hydroxytryptamine receptor 3A | target |
Dolasetron | Cytochrome P450 3A4 | enzyme |
Dolasetron | Cytochrome P450 2D6 | enzyme |
Dolasetron | Cytochrome P450 2C9 | enzyme |
Granisetron | 5-hydroxytryptamine receptor 3A | target |
Granisetron | Cytochrome P450 3A4 | enzyme |
Granisetron | Cytochrome P450 1A1 | enzyme |
Almotriptan | 5-hydroxytryptamine receptor 1D | target |
Almotriptan | 5-hydroxytryptamine receptor 1B | target |
Almotriptan | Cytochrome P450 3A4 | enzyme |
Almotriptan | Cytochrome P450 2D6 | enzyme |
Almotriptan | Amine oxidase [flavin-containing] A | enzyme |
Almotriptan | Dimethylaniline monooxygenase [N-oxide-forming] 3 | enzyme |
Almotriptan | Cytochrome P450 2C19 | enzyme |
Almotriptan | Cytochrome P450 2E1 | enzyme |
Almotriptan | Cytochrome P450 2C8 | enzyme |
Naratriptan | 5-hydroxytryptamine receptor 1D | target |
Naratriptan | 5-hydroxytryptamine receptor 1B | target |
Naratriptan | 5-hydroxytryptamine receptor 1F | target |
Naratriptan | 5-hydroxytryptamine receptor 1A | target |
Naratriptan | Amine oxidase [flavin-containing] A | enzyme |
Rizatriptan | 5-hydroxytryptamine receptor 1D | target |
Rizatriptan | 5-hydroxytryptamine receptor 1B | target |
Rizatriptan | 5-hydroxytryptamine receptor 1F | target |
Rizatriptan | Amine oxidase [flavin-containing] A | enzyme |
Pindolol | Beta-1 adrenergic receptor | target |
Pindolol | Beta-2 adrenergic receptor | target |
Pindolol | 5-hydroxytryptamine receptor 1A | target |
Pindolol | 5-hydroxytryptamine receptor 1B | target |
Pindolol | Cytochrome P450 2D6 | enzyme |
Pindolol | Beta-3 adrenergic receptor | target |
Pindolol | Beta adrenergic receptor | target |
Pindolol | UDP-glucuronosyltransferases (UGTs) | enzyme |
Pindolol | Sulfotransferase | enzyme |
Pindolol | Solute carrier family 22 member 2 | transporter |
Pindolol | alpha1-acid glycoprotein | carrier |
Alosetron | 5-hydroxytryptamine receptor 3A | target |
Alosetron | Cytochrome P450 1A2 | enzyme |
Alosetron | Cytochrome P450 2C9 | enzyme |
Alosetron | Cytochrome P450 3A4 | enzyme |
Alosetron | Cytochrome P450 2E1 | enzyme |
Frovatriptan | 5-hydroxytryptamine receptor 1D | target |
Frovatriptan | 5-hydroxytryptamine receptor 1B | target |
Frovatriptan | Cytochrome P450 1A2 | enzyme |
Renzapride | 5-hydroxytryptamine receptor 3A | target |
Renzapride | 5-hydroxytryptamine receptor 4 | target |
APD791 | 5-hydroxytryptamine receptor 2A | target |
Naronapride | 5-hydroxytryptamine receptor 4 | target |
Naluzotan | 5-hydroxytryptamine receptor 1A | target |
YKP-1358 | 5-hydroxytryptamine receptor 2A | target |
YKP-1358 | Dopamine D2 receptor | target |
Dotarizine | 5-hydroxytryptamine receptor 2A | target |
Dotarizine | 5-hydroxytryptamine receptor 1A | target |
Dotarizine | Voltage-dependent P/Q-type calcium channel subunit alpha-1A | target |
Dotarizine | 5-hydroxytryptamine receptor 2C | target |
Dotarizine | Cytochrome P450 3A4 | enzyme |
Serotonin | Solute carrier family 22 member 2 | transporter |
Serotonin | Sodium-dependent serotonin transporter | target |
Serotonin | 5-hydroxytryptamine receptor 2A | target |
Serotonin | 5-hydroxytryptamine receptor 3A | target |
Serotonin | 5-hydroxytryptamine receptor 3B | target |
Serotonin | Synaptic vesicular amine transporter | target |
Ramosetron | 5-hydroxytryptamine receptor 3A | target |
Ramosetron | Cytochrome P450 1A2 | enzyme |
Tropisetron | 5-hydroxytryptamine receptor 3A | target |
m-Chlorophenylpiperazine | 5-hydroxytryptamine receptor 2C | target |
Sarpogrelate | 5-hydroxytryptamine receptor 2C | target |
Sarpogrelate | 5-hydroxytryptamine receptor 2A | target |
Eplivanserin | 5-hydroxytryptamine receptor 2A | target |
Eplivanserin | 5-hydroxytryptamine receptor 2C | target |
Ketanserin | 5-hydroxytryptamine receptor 2A | target |
Metergoline | Sodium channel protein type 2 subunit alpha | target |
Wortmannin | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | target |
Wortmannin | Serine/threonine-protein kinase PLK1 | target |
Wortmannin | Phosphatidylinositol 3-kinase regulatory subunit alpha | target |
Wortmannin | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | target |
Dextromethorphan | Sigma non-opioid intracellular receptor 1 | target |
Dextromethorphan | Neuronal acetylcholine receptor subunit alpha-2 | target |
Dextromethorphan | Sodium-dependent serotonin transporter | target |
Dextromethorphan | Glutamate receptor ionotropic, NMDA 3A | target |
Dextromethorphan | Cytochrome P450 2D6 | enzyme |
Dextromethorphan | Cytochrome P450 3A4 | enzyme |
Dextromethorphan | Cytochrome P450 3A7 | enzyme |
Dextromethorphan | Cytochrome P450 2C9 | enzyme |
Dextromethorphan | Cytochrome P450 2B6 | enzyme |
Dextromethorphan | Cytochrome P450 2C19 | enzyme |
Dextromethorphan | Membrane-associated progesterone receptor component 1 | target |
Dextromethorphan | Neuronal acetylcholine receptor subunit alpha-3 | target |
Dextromethorphan | Neuronal acetylcholine receptor subunit alpha-4 | target |
Dextromethorphan | Neuronal acetylcholine receptor subunit beta-4 | target |
Dextromethorphan | Neuronal acetylcholine receptor subunit beta-2 | target |
Dextromethorphan | Neuronal acetylcholine receptor subunit alpha-7 | target |
Dextromethorphan | Mu-type opioid receptor | target |
Dextromethorphan | Delta-type opioid receptor | target |
Dextromethorphan | Kappa-type opioid receptor | target |
Dextromethorphan | NADPH oxidase | target |
Dextromethorphan | Sodium-dependent noradrenaline transporter | target |
Dextromethorphan | UDP-glucuronosyltransferase 2B4 | enzyme |
Dextromethorphan | UDP-glucuronosyltransferase 2B7 | enzyme |
Dextromethorphan | UDP-glucuronosyltransferase 2B15 | enzyme |
Dextromethorphan | UDP-glucuronosyltransferase 2B17 | enzyme |
Dihydroergotamine | 5-hydroxytryptamine receptor 1D | target |
Dihydroergotamine | 5-hydroxytryptamine receptor 1B | target |
Dihydroergotamine | Cytochrome P450 3A4 | enzyme |
Dihydroergotamine | Alpha-2A adrenergic receptor | target |
Dihydroergotamine | 5-hydroxytryptamine receptor 2B | target |
Dihydroergotamine | P-glycoprotein 1 | transporter |
Dihydroergotamine | 5-hydroxytryptamine receptor 1A | target |
Dihydroergotamine | 5-hydroxytryptamine receptor 1E | target |
Dihydroergotamine | 5-hydroxytryptamine receptor 2A | target |
Dihydroergotamine | 5-hydroxytryptamine receptor 2C | target |
Dihydroergotamine | Alpha-1 adrenergic receptors | target |
Dihydroergotamine | Alpha-2 adrenergic receptors | target |
Dihydroergotamine | Dopamine D2 receptor | target |
Dihydroergotamine | Dopamine D3 receptor | target |
Dihydroergotamine | Dopamine D4 receptor | target |
Dihydroergotamine | 5-hydroxytryptamine receptor 1F | target |
Dihydroergotamine | 5-hydroxytryptamine receptor 4 | target |
Dihydroergotamine | Beta-3 adrenergic receptor | target |
Cabergoline | Dopamine D2 receptor | target |
Cabergoline | 5-hydroxytryptamine receptor 2B | target |
Cabergoline | Dopamine D3 receptor | target |
Cabergoline | 5-hydroxytryptamine receptor 2A | target |
Cabergoline | Alpha-2B adrenergic receptor | target |
Cabergoline | 5-hydroxytryptamine receptor 1D | target |
Cabergoline | Dopamine D4 receptor | target |
Cabergoline | Alpha-2A adrenergic receptor | target |
Cabergoline | 5-hydroxytryptamine receptor 1A | target |
Cabergoline | Alpha-2C adrenergic receptor | target |
Cabergoline | Dopamine D5 receptor | target |
Cabergoline | Dopamine D1 receptor | target |
Cabergoline | 5-hydroxytryptamine receptor 1B | target |
Cabergoline | 5-hydroxytryptamine receptor 2C | target |
Cabergoline | Cytochrome P450 3A4 | enzyme |
Cabergoline | 5-hydroxytryptamine receptor 7 | target |
Cabergoline | Alpha-1A adrenergic receptor | target |
Cabergoline | Alpha-1B adrenergic receptor | target |
Cabergoline | Alpha-1D adrenergic receptor | target |
Cabergoline | Beta-1 adrenergic receptor | target |
Cabergoline | Beta-2 adrenergic receptor | target |
Cabergoline | D(1) dopamine receptor | target |
Cabergoline | P-glycoprotein 1 | transporter |
Rotigotine | Dopamine D3 receptor | target |
Rotigotine | Dopamine D5 receptor | target |
Rotigotine | Dopamine D4 receptor | target |
Rotigotine | Dopamine D2 receptor | target |
Rotigotine | 5-hydroxytryptamine receptor 1A | target |
Rotigotine | Dopamine D1 receptor | target |
Rotigotine | Cytochrome P450 2D6 | enzyme |
Rotigotine | Cytochrome P450 3A4 | enzyme |
Rotigotine | Alpha-2B adrenergic receptor | target |
Rotigotine | Cytochrome P450 2C19 | enzyme |
Cinitapride | 5-hydroxytryptamine receptor 1A | target |
Cinitapride | 5-hydroxytryptamine receptor 4 | target |
Cinitapride | 5-hydroxytryptamine receptor 2A | target |
5-methoxy-N,N-dimethyltryptamine | 5-hydroxytryptamine receptor 1A | target |
5-methoxy-N,N-dimethyltryptamine | 5-hydroxytryptamine receptor 2A | target |
5-methoxy-N,N-dimethyltryptamine | Cytochrome P450 2D6 | enzyme |
Tetrahydrocannabivarin | Cannabinoid receptor 1 | target |
Tetrahydrocannabivarin | Cannabinoid receptor 2 | target |
Tetrahydrocannabivarin | G-protein coupled receptor 55 | target |
Tetrahydrocannabivarin | 5-hydroxytryptamine receptor 1A | target |
Tetrahydrocannabivarin | Transient receptor potential cation channel subfamily V member 2 | target |
Tetrahydrocannabivarin | Transient receptor potential cation channel subfamily M member 8 | target |
Tetrahydrocannabivarin | Transient receptor potential cation channel subfamily A member 1 | target |
Pergolide | Dopamine D2 receptor | target |
Pergolide | Dopamine D1 receptor | target |
Pergolide | Dopamine D3 receptor | target |
Pergolide | 5-hydroxytryptamine receptor 1A | target |
Pergolide | Alpha-1A adrenergic receptor | target |
Pergolide | Alpha-2 adrenergic receptors | target |
Pergolide | Alpha-1B adrenergic receptor | target |
Pergolide | Alpha-1D adrenergic receptor | target |
Pergolide | Dopamine D4 receptor | target |
Pergolide | Dopamine D5 receptor | target |
Pergolide | 5-hydroxytryptamine receptor 1B | target |
Pergolide | 5-hydroxytryptamine receptor 1D | target |
Pergolide | 5-hydroxytryptamine receptor 2A | target |
Pergolide | 5-hydroxytryptamine receptor 2B | target |
Pergolide | 5-hydroxytryptamine receptor 2C | target |
Pergolide | Cytochrome P450 3A4 | enzyme |
Bromocriptine | Dopamine D2 receptor | target |
Bromocriptine | Cytochrome P450 3A4 | enzyme |
Bromocriptine | 5-hydroxytryptamine receptor 1D | target |
Bromocriptine | Alpha-2A adrenergic receptor | target |
Bromocriptine | Dopamine D3 receptor | target |
Bromocriptine | 5-hydroxytryptamine receptor 1A | target |
Bromocriptine | Alpha-2C adrenergic receptor | target |
Bromocriptine | Alpha-2B adrenergic receptor | target |
Bromocriptine | 5-hydroxytryptamine receptor 2B | target |
Bromocriptine | Dopamine D4 receptor | target |
Bromocriptine | 5-hydroxytryptamine receptor 2A | target |
Bromocriptine | 5-hydroxytryptamine receptor 1B | target |
Bromocriptine | 5-hydroxytryptamine receptor 2C | target |
Bromocriptine | Dopamine D5 receptor | target |
Bromocriptine | Dopamine D1 receptor | target |
Bromocriptine | Alpha-1A adrenergic receptor | target |
Bromocriptine | Alpha-1B adrenergic receptor | target |
Bromocriptine | Alpha-1D adrenergic receptor | target |
Bromocriptine | 5-hydroxytryptamine receptor 7 | target |
Bromocriptine | P-glycoprotein 1 | transporter |
MMDA | 5-hydroxytryptamine receptor 2A | target |
MMDA | Sodium-dependent serotonin transporter | target |
MMDA | Sodium-dependent dopamine transporter | target |
MMDA | Chromaffin granule amine transporter | target |
MMDA | Synaptic vesicular amine transporter | target |
MMDA | Amine oxidase [flavin-containing] A | target |
MMDA | Amine oxidase [flavin-containing] B | target |
MMDA | Sodium-dependent noradrenaline transporter | target |
2,5-Dimethoxy-4-ethylthioamphetamine | 5-hydroxytryptamine receptor 2A | target |
2,5-Dimethoxy-4-ethylthioamphetamine | 5-hydroxytryptamine receptor 2C | target |
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine | 5-hydroxytryptamine receptor 2A | target |
Lofexidine | Alpha-2A adrenergic receptor | target |
Lofexidine | Alpha-1A adrenergic receptor | target |
Lofexidine | 5-hydroxytryptamine receptor 1A | target |
Lofexidine | 5-hydroxytryptamine receptor 7 | target |
Lofexidine | 5-hydroxytryptamine receptor 2C | target |
Lofexidine | 5-hydroxytryptamine receptor 1D | target |
Lofexidine | Cytochrome P450 2D6 | enzyme |
Lofexidine | Cytochrome P450 1A2 | enzyme |
Lofexidine | Cytochrome P450 2C19 | enzyme |
Lofexidine | ATP-binding cassette sub-family B member 5 | transporter |
Lofexidine | Multidrug and toxin extrusion protein 1 | transporter |
Lorcaserin | 5-hydroxytryptamine receptor 2C | target |
Lorcaserin | Cytochrome P450 1A2 | enzyme |
Lorcaserin | Cytochrome P450 2A6 | enzyme |
Lorcaserin | Cytochrome P450 2B6 | enzyme |
Lorcaserin | Cytochrome P450 2C19 | enzyme |
Lorcaserin | Cytochrome P450 2D6 | enzyme |
Lorcaserin | Cytochrome P450 3A4 | enzyme |
Lorcaserin | Dimethylaniline monooxygenase [N-oxide-forming] 1 | enzyme |
Lorcaserin | Cytochrome P450 1A1 | enzyme |
Cannabidiol | Cytochrome P450 2C9 | enzyme |
Cannabidiol | Cytochrome P450 2C19 | enzyme |
Cannabidiol | Cytochrome P450 2D6 | enzyme |
Cannabidiol | Cytochrome P450 3A4 | enzyme |
Cannabidiol | Cannabinoid receptor 1 | target |
Cannabidiol | Cannabinoid receptor 2 | target |
Cannabidiol | G-protein coupled receptor 12 | target |
Cannabidiol | Glycine receptor subunit alpha-1 | target |
Cannabidiol | Glycine receptor (alpha-1/beta) | target |
Cannabidiol | Glycine receptor subunit alpha-3 | target |
Cannabidiol | N-arachidonyl glycine receptor | target |
Cannabidiol | G-protein coupled receptor 55 | target |
Cannabidiol | 5-hydroxytryptamine receptor 1A | target |
Cannabidiol | 5-hydroxytryptamine receptor 2A | target |
Cannabidiol | Neuronal acetylcholine receptor subunit alpha-7 | target |
Cannabidiol | Delta-type opioid receptor | target |
Cannabidiol | Mu-type opioid receptor | target |
Cannabidiol | Peroxisome proliferator-activated receptor gamma | target |
Cannabidiol | Cytochrome P450 3A5 | enzyme |
Cannabidiol | Arylalkylamine N-acetyltransferase | enzyme |
Cannabidiol | Cytochrome P450 1A1 | enzyme |
Cannabidiol | Fatty-acid amide hydrolase 1 | enzyme |
Cannabidiol | Arachidonate 5-lipoxygenase | enzyme |
Cannabidiol | Arachidonate 15-lipoxygenase | enzyme |
Cannabidiol | Quinone oxidoreductase | enzyme |
Cannabidiol | Multidrug resistance-associated protein 1 | transporter |
Cannabidiol | ATP-binding cassette sub-family G member 2 | transporter |
Cannabidiol | Equilibrative nucleoside transporter 1 | transporter |
Cannabidiol | Transient receptor potential cation channel subfamily V member 1 | target |
Cannabidiol | Voltage-dependent T-type calcium channel subunit alpha-1G | target |
Cannabidiol | Voltage-dependent T-type calcium channel subunit alpha-1H | target |
Cannabidiol | Voltage-dependent T-type calcium channel subunit alpha-1I | target |
Cannabidiol | Transient receptor potential cation channel subfamily A member 1 | target |
Cannabidiol | Transient receptor potential cation channel subfamily M member 8 | target |
Cannabidiol | Transient receptor potential cation channel subfamily V member 2 | target |
Cannabidiol | Transient receptor potential cation channel subfamily V member 3 | target |
Cannabidiol | Transient receptor potential cation channel subfamily V member 4 | target |
Cannabidiol | Voltage-dependent anion-selective channel protein 1 | target |
Cannabidiol | 5-hydroxytryptamine receptor 3A | target |
Cannabidiol | Adenosine receptor A1 | target |
Cannabidiol | Prostaglandin G/H synthase 1 | target |
Cannabidiol | Prostaglandin G/H synthase 2 | target |
Cannabidiol | Acetyl-CoA acetyltransferase, mitochondrial | target |
Cannabidiol | Steroid 17-alpha-hydroxylase/17,20 lyase | target |
Cannabidiol | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | target |
Cannabidiol | Glutathione reductase, mitochondrial | target |
Cannabidiol | Glutathione peroxidase 1 | target |
Cannabidiol | Indoleamine 2,3-dioxygenase 1 | target |
Cannabidiol | Cytochrome P450 1B1 | target |
Cannabidiol | NAD(P)H dehydrogenase [quinone] 1 | target |
Cannabidiol | Catalase | target |
Cannabidiol | Cytochrome P450 3A5 | target |
Cannabidiol | Cytochrome P450 2D6 | target |
Cannabidiol | Superoxide dismutase [Cu-Zn] | target |
Cannabidiol | Cytochrome P450 1A2 | target |
Cannabidiol | Cytochrome P450 3A7 | target |
Cannabidiol | Arylalkylamine N-acetyltransferase | target |
Cannabidiol | N-acylethanolamine-hydrolyzing acid amidase | target |
Cannabidiol | Cytochrome P450 1A2 | enzyme |
Cannabidiol | Cytochrome P450 1B1 | enzyme |
Cannabidiol | Cytochrome P450 2A6 | enzyme |
Cannabidiol | Cytochrome P450 2B6 | enzyme |
Cannabidiol | Cytochrome P450 2C8 | enzyme |
Cannabidiol | Cytochrome P450 2E1 | enzyme |
Cannabidiol | Cytochrome P450 3A7 | enzyme |
Cannabidiol | UDP-glucuronosyltransferase 1-7 | enzyme |
Cannabidiol | UDP-glucuronosyltransferase 1-9 | enzyme |
Cannabidiol | UDP-glucuronosyltransferase 2B7 | enzyme |
Cannabidiol | UDP-glucuronosyltransferase 2B17 | enzyme |
Cannabidiol | P-glycoprotein 1 | transporter |
Cannabidiol | Cytochrome P450 2J2 | enzyme |
Cannabidiol | Liver carboxylesterase 1 | enzyme |
Cilansetron | 5-hydroxytryptamine receptor 3A | target |
Yohimbine | Alpha-2A adrenergic receptor | target |
Yohimbine | Alpha-2B adrenergic receptor | target |
Yohimbine | Alpha-2C adrenergic receptor | target |
Yohimbine | 5-hydroxytryptamine receptor 1A | target |
Yohimbine | 5-hydroxytryptamine receptor 1B | target |
Yohimbine | 5-hydroxytryptamine receptor 1D | target |
Yohimbine | Dopamine D2 receptor | target |
Yohimbine | Dopamine D3 receptor | target |
Yohimbine | 5-hydroxytryptamine receptor 2A | target |
Yohimbine | 5-hydroxytryptamine receptor 2C | target |
Yohimbine | Cytochrome P450 2D6 | enzyme |
Yohimbine | Cytochrome P450 3A4 | enzyme |
Yohimbine | ATP-sensitive potassium channel | target |
Yohimbine | 5-hydroxytryptamine receptor 2B | target |
PRX-08066 | 5-hydroxytryptamine receptor 2B | target |
Epinastine | Histamine H1 receptor | target |
Epinastine | Histamine H2 receptor | target |
Epinastine | Alpha-1A adrenergic receptor | target |
Epinastine | Alpha-2A adrenergic receptor | target |
Epinastine | 5-hydroxytryptamine receptor 2A | target |
Epinastine | 5-hydroxytryptamine receptor 7 | target |
Epinastine | P-glycoprotein 1 | transporter |
Epinastine | Cytochrome P450 2B6 | enzyme |
Epinastine | Cytochrome P450 2D6 | enzyme |
Epinastine | Cytochrome P450 3A4 | enzyme |
Alprenolol | Beta-1 adrenergic receptor | target |
Alprenolol | Beta-2 adrenergic receptor | target |
Alprenolol | 5-hydroxytryptamine receptor 1A | target |
Alprenolol | Cytochrome P450 2D6 | enzyme |
Alprenolol | Beta-3 adrenergic receptor | target |
Alverine | 5-hydroxytryptamine receptor 1A | target |
Penbutolol | Alpha-1-acid glycoprotein 1 | carrier |
Penbutolol | Beta-1 adrenergic receptor | target |
Penbutolol | Beta-2 adrenergic receptor | target |
Penbutolol | 5-hydroxytryptamine receptor 1A | target |
Penbutolol | 5-hydroxytryptamine receptor 1B | target |
Penbutolol | Cytochrome P450 2D6 | enzyme |
Ergoloid mesylate | Dopamine receptor | target |
Ergoloid mesylate | Alpha adrenergic receptor | target |
Ergoloid mesylate | Beta adrenergic receptor | target |
Ergoloid mesylate | Serotonin Receptors | target |
Ergoloid mesylate | Cytochrome P450 3A4 | enzyme |
Ergometrine | Cytochrome P450 3A4 | enzyme |
Ergometrine | P-glycoprotein 1 | transporter |
Ergometrine | Alpha-1A adrenergic receptor | target |
Tedizolid phosphate | 23S ribosomal RNA | target |
Tedizolid phosphate | Amine oxidase [flavin-containing] A | enzyme |
Tedizolid phosphate | Amine oxidase [flavin-containing] B | enzyme |
Dexmethylphenidate | Sodium-dependent dopamine transporter | target |
Dexmethylphenidate | Sodium-dependent noradrenaline transporter | target |
Dexmethylphenidate | Sodium-dependent serotonin transporter | target |
Dexmethylphenidate | Carboxylesterase | enzyme |
Eslicarbazepine | UDP-glucuronosyltransferase 1-1 | enzyme |
Eslicarbazepine | Cytochrome P450 2C19 | enzyme |
Eslicarbazepine | P2X purinoceptor 4 | target |
Eslicarbazepine | Cytochrome P450 3A4 | enzyme |
Pagoclone | Gamma-aminobutyric acid receptor subunit alpha-2 | target |
Pagoclone | Gamma-aminobutyric acid receptor subunit alpha-3 | target |
Oxazepam acetate | GABA(A) Receptor | target |
Oxazepam acetate | GABA(A) Receptor Benzodiazepine Binding Site | target |
Minaprine | Dopamine D1 receptor | target |
Minaprine | Dopamine D2 receptor | target |
Minaprine | 5-hydroxytryptamine receptor 2A | target |
Minaprine | 5-hydroxytryptamine receptor 2B | target |
Minaprine | 5-hydroxytryptamine receptor 2C | target |
Minaprine | Sodium-dependent serotonin transporter | target |
Minaprine | Cytochrome P450 2D6 | enzyme |
Minaprine | Muscarinic acetylcholine receptor M1 | target |
Minaprine | Acetylcholinesterase | target |
Minaprine | Amine oxidase [flavin-containing] A | target |
Dosulepin | 5-hydroxytryptamine receptor 1A | target |
Dosulepin | 5-hydroxytryptamine receptor 2A | target |
Dosulepin | Cytochrome P450 2D6 | enzyme |
Dosulepin | Cytochrome P450 1A2 | enzyme |
Dosulepin | Cytochrome P450 2C19 | enzyme |
Dosulepin | Cytochrome P450 2C9 | enzyme |
Dosulepin | Histamine H1 receptor | target |
Dosulepin | Muscarinic acetylcholine receptor M1 | target |
Dosulepin | Muscarinic acetylcholine receptor M2 | target |
Dosulepin | Muscarinic acetylcholine receptor M3 | target |
Dosulepin | Muscarinic acetylcholine receptor M4 | target |
Dosulepin | Muscarinic acetylcholine receptor M5 | target |
Dosulepin | Sodium-dependent noradrenaline transporter | target |
Dosulepin | Sodium-dependent serotonin transporter | target |
Dosulepin | Alpha-1 adrenergic receptors | target |
Dosulepin | Alpha-2 adrenergic receptors | target |
Cisapride | 5-hydroxytryptamine receptor 4 | target |
Cisapride | 5-hydroxytryptamine receptor 3A | target |
Cisapride | Potassium voltage-gated channel subfamily H member 2 | target |
Cisapride | 5-hydroxytryptamine receptor 2A | target |
Cisapride | Cytochrome P450 3A4 | enzyme |
Cisapride | Cytochrome P450 3A5 | enzyme |
Cisapride | Cytochrome P450 3A7 | enzyme |
Cisapride | Cytochrome P450 2A6 | enzyme |
Cisapride | Cytochrome P450 2B6 | enzyme |
Cisapride | Cytochrome P450 2C19 | enzyme |
Cisapride | Cytochrome P450 2C8 | enzyme |
Cisapride | Cytochrome P450 2C9 | enzyme |
Cisapride | Cytochrome P450 2D6 | enzyme |
Apomorphine | Dopamine D2 receptor | target |
Apomorphine | Dopamine D1 receptor | target |
Apomorphine | Dopamine D4 receptor | target |
Apomorphine | Dopamine D3 receptor | target |
Apomorphine | Dopamine D5 receptor | target |
Apomorphine | Alpha-2C adrenergic receptor | target |
Apomorphine | Alpha-2B adrenergic receptor | target |
Apomorphine | 5-hydroxytryptamine receptor 2C | target |
Apomorphine | 5-hydroxytryptamine receptor 1A | target |
Apomorphine | 5-hydroxytryptamine receptor 2A | target |
Apomorphine | 5-hydroxytryptamine receptor 2B | target |
Apomorphine | Alpha-2A adrenergic receptor | target |
Apomorphine | 5-hydroxytryptamine receptor 1D | target |
Apomorphine | 5-hydroxytryptamine receptor 1B | target |
Apomorphine | Catechol O-methyltransferase | enzyme |
Apomorphine | Sulfotransferase 1A1 | enzyme |
Apomorphine | Sulfotransferase 1A2 | enzyme |
Apomorphine | Sulfotransferase 1A3/1A4 | enzyme |
Apomorphine | Estrogen sulfotransferase | enzyme |
Apomorphine | Sulfotransferase family cytosolic 1B member 1 | enzyme |
Apomorphine | Cytochrome P450 2B6 | enzyme |
Apomorphine | Cytochrome P450 2C8 | enzyme |
Apomorphine | Cytochrome P450 3A4 | enzyme |
Apomorphine | Cytochrome P450 3A5 | enzyme |
Apomorphine | UDP-glucuronosyltransferases (UGTs) | enzyme |
Apomorphine | Serum albumin | carrier |
Apomorphine | Synaptic vesicular amine transporter | transporter |
Cinazepam | GABA(A) Receptor | target |
Cinazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
1,2-Benzodiazepine | Cytochrome P450 3A4 | enzyme |
1,2-Benzodiazepine | GABA(A) Receptor | target |
1,2-Benzodiazepine | GABA(A) Receptor Benzodiazepine Binding Site | target |
Bentazepam | GABA(A) Receptor | target |
Bentazepam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Clorgiline | Amine oxidase [flavin-containing] A | target |
Seproxetine | Cytochrome P450 3A5 | enzyme |
Seproxetine | Cytochrome P450 3A7 | enzyme |
Seproxetine | Cytochrome P450 2C9 | enzyme |
Seproxetine | Cytochrome P450 2C19 | enzyme |
Seproxetine | Cytochrome P450 3A4 | enzyme |
S-Ethylisothiourea | Nitric oxide synthase oxygenase | target |
S-Ethylisothiourea | Nitric oxide synthase, inducible | target |
S-Ethylisothiourea | Nitric oxide synthase, endothelial | target |
Diethylpropion | Sodium-dependent noradrenaline transporter | target |
Diethylpropion | Sodium-dependent dopamine transporter | target |
Suvorexant | Orexin receptor type 1 | target |
Suvorexant | Orexin receptor type 2 | target |
Suvorexant | Cytochrome P450 3A4 | enzyme |
Suvorexant | P-glycoprotein 1 | transporter |
Esketamine | NMDA receptor | target |
Esketamine | Cytochrome P450 2B6 | enzyme |
Esketamine | Cytochrome P450 3A4 | enzyme |
Esketamine | Cytochrome P450 2C19 | enzyme |
Esketamine | Cytochrome P450 2C9 | enzyme |
Esketamine | Glutamate receptor ionotropic, NMDA 2B | target |
Esketamine | Elongation factor 2 | target |
Esketamine | Brain-derived neurotrophic factor | target |
Esketamine | BDNF/NT-3 growth factors receptor | target |
Solriamfetol | Solute carrier family 22 member 2 | transporter |
Solriamfetol | Solute carrier family 22 member 4 | transporter |
Solriamfetol | Solute carrier family 22 member 5 | transporter |
Solriamfetol | Sodium-dependent dopamine transporter | target |
Solriamfetol | Sodium-dependent noradrenaline transporter | target |
Mepyramine | Cytochrome P450 2D6 | enzyme |
Mepyramine | Histamine H1 receptor | target |
Mepyramine | Solute carrier family 22 member 4 | transporter |
Mepyramine | Solute carrier family 22 member 5 | transporter |
Lithium citrate | Inositol monophosphatase 2 | target |
Lithium citrate | Inositol monophosphatase 1 | target |
Lithium citrate | Glycogen synthase kinase-3 beta | target |
Lithium citrate | Glutamate receptor 3 | target |
Mexazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Mexazolam | Cytochrome P450 3A4 | enzyme |
Mexazolam | GABA(A) Receptor | target |
Metoclopramide | Muscarinic acetylcholine receptor M1 | target |
Metoclopramide | Dopamine D2 receptor | target |
Metoclopramide | Cytochrome P450 2D6 | enzyme |
Metoclopramide | 5-hydroxytryptamine receptor 4 | target |
Metoclopramide | 5-hydroxytryptamine receptor 3A | target |
Metoclopramide | Cytochrome P450 3A4 | enzyme |
Metoclopramide | Cytochrome P450 1A2 | enzyme |
Metoclopramide | P-glycoprotein 1 | transporter |
Metoclopramide | Alpha-1-acid glycoprotein 1 | carrier |
Lorpiprazole | 5-hydroxytryptamine receptor 2A | target |
Lorpiprazole | 5-hydroxytryptamine receptor 2C | target |
Lorpiprazole | Alpha-1 adrenergic receptors | target |
Lorpiprazole | Alpha-2 adrenergic receptors | target |
Lorpiprazole | Histamine H1 receptor | target |
Lorpiprazole | Sodium-dependent serotonin transporter | target |
Lorpiprazole | Cytochrome P450 2D6 | enzyme |
Lorpiprazole | Cytochrome P450 3A4 | enzyme |
Lorpiprazole | Serum albumin | carrier |
Cenobamate | UDP-glucuronosyltransferase 2B7 | enzyme |
Cenobamate | UDP-glucuronosyltransferase 2B4 | enzyme |
Cenobamate | Cytochrome P450 2E1 | enzyme |
Cenobamate | Cytochrome P450 2A6 | enzyme |
Cenobamate | Cytochrome P450 2B6 | enzyme |
Cenobamate | Cytochrome P450 2C19 | enzyme |
Cenobamate | Cytochrome P450 3A4 | enzyme |
Cenobamate | Cytochrome P450 3A5 | enzyme |
Cenobamate | Serum albumin | carrier |
Cenobamate | Cytochrome P450 2C8 | enzyme |
Lemborexant | Orexin receptor type 1 | target |
Lemborexant | Orexin receptor type 2 | target |
Lemborexant | Cytochrome P450 3A4 | enzyme |
Lemborexant | Cytochrome P450 3A5 | enzyme |
Lemborexant | Cytochrome P450 3A Subfamily | enzyme |
Lemborexant | Cytochrome P450 2B6 | enzyme |
Lemborexant | P-glycoprotein 1 | transporter |
Y-27632 | cAMP-dependent protein kinase catalytic subunit alpha | target |
Y-27632 | cAMP-dependent protein kinase inhibitor alpha | target |
Y-27632 | Rho-associated protein kinase 1 | target |
Y-27632 | Rho-associated protein kinase 2 | target |
Harmine | Amine oxidase [flavin-containing] A | target |
Amibegron | Beta-3 adrenergic receptor | target |
Tegaserod | 5-hydroxytryptamine receptor 4 | target |
Tegaserod | 5-hydroxytryptamine receptor 2B | target |
Tegaserod | 5-hydroxytryptamine receptor 2C | target |
Tegaserod | 5-hydroxytryptamine receptor 2A | target |
Tegaserod | Sodium-dependent serotonin transporter | transporter |
Tegaserod | Cytochrome P450 1A2 | enzyme |
Tegaserod | Cytochrome P450 2C8 | enzyme |
Tegaserod | Cytochrome P450 2D6 | enzyme |
Tegaserod | Cytochrome P450 2E1 | enzyme |
Tegaserod | ATP-binding cassette sub-family G member 2 | transporter |
Tegaserod | P-glycoprotein 1 | transporter |
Remimazolam | Liver carboxylesterase 1 | enzyme |
Remimazolam | GABA(A) Receptor Benzodiazepine Binding Site | target |
Remimazolam | GABA(A) Receptor | target |
Remimazolam | Serum albumin | carrier |
Lidocaine | Sodium channel protein type 5 subunit alpha | target |
Lidocaine | Sodium channel protein type 10 subunit alpha | target |
Lidocaine | Epidermal growth factor receptor | target |
Lidocaine | Sodium channel protein type 9 subunit alpha | target |
Lidocaine | Cytochrome P450 1A2 | enzyme |
Lidocaine | Cytochrome P450 2D6 | enzyme |
Lidocaine | Cytochrome P450 3A4 | enzyme |
Lidocaine | Cytochrome P450 3A5 | enzyme |
Lidocaine | Cytochrome P450 3A7 | enzyme |
Lidocaine | Solute carrier family 22 member 5 | transporter |
Lidocaine | P-glycoprotein 1 | transporter |
Lidocaine | Cytochrome P450 2A6 | enzyme |
Lidocaine | Cytochrome P450 2B6 | enzyme |
Lidocaine | Cytochrome P450 2C8 | enzyme |
Lidocaine | Cytochrome P450 2C9 | enzyme |
Lidocaine | Sodium channel protein type 4 subunit alpha | target |
Lidocaine | Alpha-1-acid glycoprotein 1 | target |
Lidocaine | Alpha-1-acid glycoprotein 2 | target |
Ropivacaine | Sodium channel protein type 10 subunit alpha | target |
Ropivacaine | Cytochrome P450 1A2 | enzyme |
Ropivacaine | Cytochrome P450 2B6 | enzyme |
Ropivacaine | Cytochrome P450 3A4 | enzyme |
Ropivacaine | Alpha-1-acid glycoprotein 1 | carrier |
Bupivacaine | Sodium channel protein type 10 subunit alpha | target |
Bupivacaine | Prostaglandin E2 receptor EP1 subtype | target |
Bupivacaine | Cytochrome P450 3A4 | enzyme |
Bupivacaine | Cytochrome P450 2C19 | enzyme |
Bupivacaine | Cytochrome P450 2D6 | enzyme |
Buspirone | 5-hydroxytryptamine receptor 1A | target |
Buspirone | Dopamine D2 receptor | target |
Buspirone | Cytochrome P450 3A4 | enzyme |
Buspirone | Cytochrome P450 3A5 | enzyme |
Buspirone | Cytochrome P450 3A7 | enzyme |
Buspirone | P-glycoprotein 1 | transporter |
Buspirone | Cytochrome P450 2D6 | enzyme |
Buspirone | Serum albumin | carrier |
Buspirone | Alpha-1-acid glycoprotein 1 | carrier |
Buspirone | Dopamine D3 receptor | target |
Buspirone | Dopamine D4 receptor | target |
Buspirone | Alpha-1 adrenergic receptors | target |
Cinchocaine | Sodium channel protein type 5 subunit alpha | target |
Cinchocaine | Sodium channel protein type 10 subunit alpha | target |
Cinchocaine | Calmodulin | target |
Cinchocaine | Cholinesterase | enzyme |
Prilocaine | Sodium channel protein type 5 subunit alpha | target |
Proparacaine | Sodium channel protein type 10 subunit alpha | target |
Oxybuprocaine | Sodium channel protein type 10 subunit alpha | target |
Oxybuprocaine | Cholinesterase | enzyme |
Mepivacaine | Sodium channel protein type 10 subunit alpha | target |
Levobupivacaine | Sodium channel protein type 10 subunit alpha | target |
Levobupivacaine | Cytochrome P450 3A4 | enzyme |
Levobupivacaine | Cytochrome P450 1A2 | enzyme |
Benzocaine | Sodium channel protein type 10 subunit alpha | target |
Benzocaine | P-glycoprotein 1 | transporter |
Benzocaine | Liver carboxylesterase 1 | enzyme |
Benzocaine | Cytochrome P450 1A2 | enzyme |
Benzocaine | Cytochrome P450 2B6 | enzyme |
Benzocaine | Cytochrome P450 2C19 | enzyme |
Benzocaine | Cytochrome P450 2D6 | enzyme |
Benzocaine | Cytochrome P450 2E1 | enzyme |
Benzocaine | Serum albumin | carrier |
Benzocaine | alpha1-acid glycoprotein | carrier |
Chloroprocaine | Sodium channel protein type 10 subunit alpha | target |
Chloroprocaine | Sodium-dependent dopamine transporter | target |
Chloroprocaine | Cholinesterase | enzyme |
Tetracaine | Ryanodine receptor 1 | target |
Tetracaine | Ryanodine receptor 2 | target |
Tetracaine | Voltage-gated sodium channel alpha subunit | target |
Pramocaine | Voltage-gated sodium channel alpha subunit | target |
Butamben | Voltage-dependent calcium channel | target |
Butamben | Cholinesterase | enzyme |
Butamben | Alpha-1-acid glycoprotein 1 | carrier |
Butamben | Serum albumin | carrier |
Butamben | ATP-sensitive potassium channel | target |
Butamben | Transient receptor potential cation channel subfamily A member 1 | target |
Butamben | Transient receptor potential cation channel subfamily V member 4 | target |
SUVN-502 | 5-hydroxytryptamine receptor 6 | target |
Oliceridine | Mu-type opioid receptor | target |
Oliceridine | Cytochrome P450 3A4 | enzyme |
Oliceridine | Cytochrome P450 2D6 | enzyme |
Oliceridine | Cytochrome P450 2C9 | enzyme |
Oliceridine | Cytochrome P450 2C19 | enzyme |
Volinanserin | 5-hydroxytryptamine receptor 2A | target |
Prucalopride | 5-hydroxytryptamine receptor 4 | target |
Prucalopride | Cytochrome P450 3A4 | enzyme |
Prucalopride | Serum albumin | carrier |
Prucalopride | P-glycoprotein 1 | transporter |
Pimavanserin | 5-hydroxytryptamine receptor 2A | target |
Pimavanserin | 5-hydroxytryptamine receptor 2C | target |
Pimavanserin | Sigma non-opioid intracellular receptor 1 | target |
Pimavanserin | Cytochrome P450 3A4 | enzyme |
Pimavanserin | Cytochrome P450 3A5 | enzyme |
Pimavanserin | Cytochrome P450 2J2 | enzyme |
Pimavanserin | Cytochrome P450 2D6 | enzyme |
Daridorexant | Cytochrome P450 3A4 | enzyme |
Daridorexant | Orexin receptor type 1 | target |
Daridorexant | Orexin receptor type 2 | target |
Methylecgonine | Ig gamma-2 chain C region | target |
Methylecgonine | Ig kappa chain C region | target |
Canertinib | Epidermal growth factor receptor | target |
Propoxycaine | Liver carboxylesterase 1 | enzyme |
Propoxycaine | Voltage-gated sodium channel alpha subunit | target |
Dexfenfluramine | Sodium-dependent serotonin transporter | target |
Dexfenfluramine | 5-hydroxytryptamine receptor 2C | target |
Dexfenfluramine | Cytochrome P450 2D6 | enzyme |
Dexfenfluramine | Cytochrome P450 1A2 | enzyme |
Dexfenfluramine | Cytochrome P450 2E1 | enzyme |
4-Bromo-2,5-dimethoxyphenethylamine | 5-hydroxytryptamine receptor 2C | target |
4-Bromo-2,5-dimethoxyphenethylamine | 5-hydroxytryptamine receptor 2A | target |
Xaliproden | 5-hydroxytryptamine receptor 1A | target |
Repinotan | 5-hydroxytryptamine receptor 1A | target |
Repinotan | Cytochrome P450 2D6 | enzyme |
Lasmiditan | 5-hydroxytryptamine receptor 1F | target |
Lasmiditan | P-glycoprotein 1 | transporter |
Lasmiditan | ATP-binding cassette sub-family G member 2 | transporter |
Lasmiditan | Solute carrier family 22 member 1 | transporter |
Lasmiditan | Multidrug and toxin extrusion protein 1 | transporter |
Lasmiditan | Multidrug and toxin extrusion protein 2 | transporter |
Lasmiditan | Cytochrome P450 2D6 | enzyme |
Norclozapine | Muscarinic acetylcholine receptor M1 | target |
Norclozapine | Dopamine D2 receptor | target |
Norclozapine | Dopamine D3 receptor | target |
Lecozotan | 5-hydroxytryptamine receptor 1 | target |
Lecozotan | 5-hydroxytryptamine receptor 1A | target |
Letibotulinumtoxina | Synaptosomal-associated protein 25 | target |
Ganaxolone | GABA(A) Receptor | target |
Ganaxolone | Cytochrome P450 3A4 | enzyme |
Ganaxolone | Cytochrome P450 3A5 | enzyme |
Ganaxolone | Cytochrome P450 2B6 | enzyme |
Ganaxolone | Cytochrome P450 2C19 | enzyme |
Ganaxolone | Cytochrome P450 2D6 | enzyme |